2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception by Weiner, Michael W. et al.
2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: 
A review of papers published since its inception
Michael W. Weinera,b,c,d,e,*, Dallas P. Veitcha, Paul S. Aisenf, Laurel A. Beckettg, Nigel J. 
Cairnsh,i, Jesse Cedarbaumj, Robert C. Greenk, Danielle Harveyg, Clifford R. Jackl, William 
Jagustm, Johan Luthmann, John C. Morrisf, Ronald C. Peterseno, Andrew J. Saykinp,q, 
Leslie Shawr, Li Shenp, Adam Schwarzs, Arthur W. Togat, John Q. Trojanowskiu,v,w,x, and 
Alzheimer’s Disease Neuroimaging Initiative
aDepartment of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative 
Diseases, San Francisco, CA, USA
bDepartment of Radiology, University of California, San Francisco, CA, USA
cDepartment of Medicine, University of California, San Francisco, CA, USA
dDepartment of Psychiatry, University of California, San Francisco, CA, USA
eDepartment of Neurology, University of California, San Francisco, CA, USA
fDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA
gDivision of Biostatistics, Department of Public Health Sciences, University of California, Davis, 
CA, USA
hKnight Alzheimer’s Disease Research Center, Washington University School of Medicine, Saint 
Louis, MO, USA
iDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO, USA
jNeurology Early Clinical Development, Biogen Idec, Cambridge, MA, USA
kDivision of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard 
Medical School, Boston, MA, USA
lDepartment of Radiology, Mayo Clinic, Rochester, MN, USA
mHelen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA
nNeuroscience Clinical Development, Neuroscience & General Medicine Product Creation Unit, 
Eisai Inc., Philadelphia, PA, USA
oDepartment of Neurology, Mayo Clinic, Rochester, MN, USA
*Corresponding author. Tel.: 415-221-4810 x3642; Fax: 415-668-2864. michael.weiner@ucsf.edu. 
Disclosures
Dallas P. Veitch has no conflicts to report.
Robert C. Green has no conflicts of interest to report.
Danielle Harvey has no conflicts of interest to report.
Judith A. Siuciak has no conflicts of interest to report.
Arthur W. Toga has no conflicts of interest to report.
HHS Public Access
Author manuscript
Alzheimers Dement. Author manuscript; available in PMC 2017 June 13.
Published in final edited form as:













pDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, 
Indianapolis, IN, USA
qDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, 
Indianapolis, IN, USA
rDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, PA, USA
sTailored Therapeutics, Eli Lilly and Company, Indianapolis, IN, USA
tLaboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine 
of University of Southern California, Los Angeles, CA, USA
uInstitute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 
USA
vAlzheimer’s Disease Core Center, Perelman School of Medicine, University of Pennsylvania, 
Philadelphia, PA, USA
wUdall Parkinson’s Research Center, Perelman School of Medicine, University of Pennsylvania, 
Philadelphia, PA, USA
xDepartment of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, 
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Abstract
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter 
study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early 
detection and tracking of Alzheimer’s disease (AD). The initial study, ADNI-1, enrolled 400 
subjects with early mild cognitive impairment (MCI), 200 with early AD, and 200 cognitively 
normal elderly controls. ADNI-1 was extended by a 2-year Grand Opportunities grant in 2009 and 
by a competitive renewal, ADNI-2, which enrolled an additional 550 participants and will run until 
2015. This article reviews all papers published since the inception of the initiative and summarizes 
the results to the end of 2013. The major accomplishments of ADNI have been as follows: (1) the 
development of standardized methods for clinical tests, magnetic resonance imaging (MRI), 
positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers in a multicenter 
setting; (2) elucidation of the patterns and rates of change of imaging and CSF biomarker 
measurements in control subjects, MCI patients, and AD patients. CSF biomarkers are largely 
consistent with disease trajectories predicted by β-amyloid cascade (Hardy, J Alzheimer’s Dis 
2006;9(Suppl 3):151–3) and tau-mediated neurodegeneration hypotheses for AD, whereas brain 
atrophy and hypometabolism levels show predicted patterns but exhibit differing rates of change 
depending on region and disease severity; (3) the assessment of alternative methods of diagnostic 
categorization. Currently, the best classifiers select and combine optimum features from multiple 
modalities, including MRI, [18F]-fluorodeoxyglucose-PET, amyloid PET, CSF biomarkers, and 
clinical tests; (4) the development of blood biomarkers for AD as potentially noninvasive and low-
cost alternatives to CSF biomarkers for AD diagnosis and the assessment of α-syn as an additional 
biomarker; (5) the development of methods for the early detection of AD. CSF biomarkers, β-
amyloid 42 and tau, as well as amyloid PET may reflect the earliest steps in AD pathology in 
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mildly symptomatic or even nonsymptomatic subjects and are leading candidates for the detection 
of AD in its preclinical stages; (6) the improvement of clinical trial efficiency through the 
identification of subjects most likely to undergo imminent future clinical decline and the use of 
more sensitive outcome measures to reduce sample sizes. Multimodal methods incorporating 
APOE status and longitudinal MRI proved most highly predictive of future decline. Refinements 
of clinical tests used as outcome measures such as clinical dementia rating-sum of boxes further 
reduced sample sizes; (7) the pioneering of genome-wide association studies that leverage 
quantitative imaging and biomarker phenotypes, including longitudinal data, to confirm recently 
identified loci, CR1, CLU, and PICALM and to identify novel AD risk loci; (8) worldwide impact 
through the establishment of ADNI-like programs in Japan, Australia, Argentina, Taiwan, China, 
Korea, Europe, and Italy; (9) understanding the biology and pathobiology of normal aging, MCI, 
and AD through integration of ADNI biomarker and clinical data to stimulate research that will 
resolve controversies about competing hypotheses on the etiopathogenesis of AD, thereby 
advancing efforts to find disease-modifying drugs for AD; and (10) the establishment of 
infrastructure to allow sharing of all raw and processed data without embargo to interested 
scientific investigators throughout the world.
Keywords
Alzheimer’s disease; Mild cognitive impairment; Amyloid; Tau; Biomarker
1. Introduction to Alzheimer’s Disease Neuroimaging Initiative: Goals, 
history, and organization
1.1. Background
Alzheimer’s disease (AD), the most common form of dementia, is a complex disease 
characterized by an accumulation of β-amyloid (Aβ) plaques and neurofibrillary tangles 
composed of tau amyloid fibrils [1] associated with synapse loss and neurodegeneration 
leading to memory impairment and other cognitive problems. There is currently no known 
treatment that slows the progression of this disorder. According to the 2014 World 
Alzheimer report, there are an estimated 44 million people worldwide living with dementia 
at a total cost of more than US$600 billion in 2010, and the incidence of AD throughout the 
world is expected to triple by 2050. There is a pressing need to find and validate biomarkers 
to both predict future clinical decline and for use as outcome measures in clinical trials of 
disease-modifying agents to facilitate phase II–III studies and foster the development of 
innovative drugs [2]. To this end, Alzheimer’s Disease Neuroimaging Initiative (ADNI) was 
conceived at the beginning of the millennium and began as a North American multicenter 
collaborative effort funded by public and private interests in October 2004. Although special 
issues focused on North American ADNI have been published in Alzheimer’s and Dementia 
[3] and Neurobiology of Aging [4] in addition to a number of other review articles [5–12], 
the purpose of this review is to provide a detailed and comprehensive overview of the 
approximately 500 papers that have been published as a direct result of ADNI to the end of 
2013. The original review [350] covered approximately 200 papers to the end of 2010. The 
first update [351] detailed an additional 150 papers published from 2011 to mid-2012, and 
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this material is highlighted in yellow. The current iteration adds around 200 more 
publications from mid-2012 to the end of 2013, and these are highlighted in green. To 
mid-2014, an additional 70 publications indicate the continuing impact of ADNI.
1.2. Disease model and progression
One approach toward a greater understanding of the events that occur in AD is the 
formulation of a disease model [3,12– 16]. According to the Aβ hypothesis, AD begins with 
the abnormal processing of the transmembrane Aβ precursor protein. Proteolysis of 
extracellular domains by sequential β and γ secretases result in a family of peptides that 
form predominantly β-sheets, the β-amyloids (Aβ) (Fig. 1). The more insoluble of these 
peptides, mostly Aβ42, have a propensity for self-aggregation into fibrils that form the senile 
plaques characteristic of AD pathology. Subsequently, it is thought that the microtubule-
associated tau protein in neurons becomes abnormally hyperphosphorylated and forms 
neurofibrillary tangles that disrupt neurons. However, although ADNI and other biomarker 
data support this sequence of events, by direct examination of postmortem human brains, 
Braak and Del Tredici have shown that tau pathology in the medial temporal limbic 
isocortex precedes the development of Aβ deposits with advancing age in the human brain 
[17]. Downstream processes such as oxidative and inflammatory stress contribute to loss of 
synaptic and neuronal integrity, and eventually, neuron loss results in brain atrophy. Jack et 
al [14,16] presented a hypothetical model for biomarker dynamics in AD pathogenesis. The 
model begins with the abnormal deposition of Aβ fibrils, as evidenced by a corresponding 
drop in the levels of soluble Aβ42 in cerebrospinal fluid (CSF) and increased retention of 
the positron emission tomography (PET) radioactive tracer [11C]-labeled Pittsburgh 
compound B (11C-PiB) in the cortex. Sometime later, neuronal damage begins to occur, as 
evidenced by increased levels of CSF tau protein. Synaptic dysfunction follows, resulting in 
decreased [18F]-fluorodeoxyglucose (FDG) uptake measured by PET. As neuronal 
degeneration progresses, atrophy in certain areas typical of AD becomes detectable by 
magnetic resonance imaging (MRI). The model provided by Jack et al [14] is highly relevant 
to many papers reviewed in section 4 (Studies of the ADNI cohort), which often provide 
empirical evidence to support it. An example of a model that proposes a series of 
pathological events leading to cognitive impairment and dementia is summarized in Fig. 2.
1.3. Mild cognitive impairment
Similar to many disease processes that originate in microscopic environments and are 
asymptomatic until the start of organ failure, the course of AD pathology is likely to be 20 to 
30 years. It is now generally accepted that the initial AD pathology develops in situ while 
the patient is cognitively normal, sometimes termed the “preclinical stage” [18,19]. At some 
point in time, sufficient brain damage accumulates to result in cognitive symptoms and 
impairment. Originally defined in 1999, this has been classified in a number of ways, 
including as predementia AD or as mild cognitive impairment (MCI), a condition in which 
subjects are usually only mildly impaired in memory with relative preservation of other 
cognitive domains and functional activities and do not meet the criteria for dementia [5], or 
as the prodromal state AD [18]. Epidemiological studies of participants aged 70 to 89 years 
who were nondemented found the prevalence of MCI in this population to be approximately 
15%, with an approximate 2:1 ratio of two identified phenotypes, amnestic and nonamnestic 
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[20,21]. Studies showed that MCI patients progressed to AD at a yearly rate of 10% to 15%, 
and that predictors of this conversion included whether the patient was a carrier of the ε4 
allele of the apolipoprotein E (APOE) gene, clinical severity, brain atrophy, certain patterns 
of CSF biomarkers and of cerebral glucose metabolism, and Aβ deposition [5]. The National 
Institute on Aging-Alzheimer’s Association (NIA-AA) has developed criteria for MCI due 
to AD that use biomarkers to determine the likelihood of AD pathology and classify patients 
accordingly [350]. The application of these criteria to ADNI is described later in this review 
[352–354].
1.4. History of biomarker development
Although the etiology of AD was not known, there was sufficient knowledge of the 
mechanisms of AD pathology at the beginning of the past decade to allow the development 
of new drugs. Once transgenic mice expressing Aβ in their brains were available [22], 
development of treatments to slow the progression of AD began in earnest. Although 
considerable work had been done to develop quantitative measurements of cognitive 
function and activities of daily living for clinical trials of symptomatic treatments such as 
acetylcholinesterase inhibitors, it was recognized that changes in cognition did not 
necessarily signify “disease modification.” Therefore, investigators from academia and the 
pharmaceutical industry became interested in how “disease modification” of AD could be 
detected using a variety of biomarkers, including brain MRI scanning, and blood and CSF 
analytes. This led to a decision by the National Institute on Aging (NIA) to fund the ADNI 
and to structure it as a public–private partnership.
The development of AD biomarkers for clinical trials, both for use in subject selection and 
as outcome measures, is paramount to the success of ADNI. During the genesis of the 
initiative, Frank et al [23] described the importance of biomarkers to ADNI and to clinical 
trials. In the first paper to come out of ADNI, Trojanowski [24] reviewed candidate AD 
biofluid biomarkers thought to be most promising at the time, homocysteine, isoprostanes, 
sulfatide, tau, and Aβ, and described how ADNI was poised, as a large public–private 
collaboration, to identify and validate the best candidate AD biomarkers. Mueller et al [25] 
reported on the scientific background at the beginning of ADNI and the limitations of the 
clinical and neuropsychological tests available for monitoring disease progression at that 
time. Principally, a definitive diagnosis of AD required severe cognitive deficits and autopsy 
confirmation, whereas the clinical criteria for the detection of the MCI transitional phase 
were much less certain. Accordingly, outcome measures for assessing the efficacy of new 
drugs relied primarily on neurocognitive tests such as ADAS-cog (cognitive subscale of the 
Alzheimer’s Disease Assessment Scale), the efficacy of which was limited by substantial 
ceiling effects and variability in subject performance over time. There was a clear need to 
develop biomarkers, biological tools that “mark” the presence of pathology, for the early 
diagnosis of AD and for measuring clinical drug trial outcomes [8].
Relatively early in the initiative, a major concern was developing an AD biomarker that 
distinguished AD from other dementias, such as Lewy body dementia, frontotemporal 
degeneration, and Parkinson disease with dementia [10]. Based on a model of AD 
pathogenesis fundamentally similar to that described in the paper by Jack et al [14], Shaw et 
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al [10] reviewed a number of potential biomarkers, including some, such as isoprostanes and 
total plasma homocysteine, that did not subsequently prove to be of use. Others, such as 
levels of soluble Aβ42 or tau protein in CSF, reflected the increase in deposition of Aβ in 
fibrillar plaques or the later release of tau protein as a result of neuronal damage. Neuronal 
metabolism and neuronal degeneration could be measured using FDG-PET and by 
examining the concentrations of total tau protein (t-tau) and tau phosphorylated at serine 181 
(p-tau181p) in CSF, respectively. Volumetric changes to brain structure could be assessed by 
MRI of specific regions such as the hippocampus, entorhinal cortex, temporal and parietal 
lobes, and ventricles. Additional potential risk biomarkers included genetic susceptibility 
factors, such as the APOE genotype, plasma homocysteine levels, and isoprostanes as non-
AD-specific indicators of oxidative stress. By the following year, the wide range of potential 
biomarkers had been substantially narrowed to include CSFAβ42, t-tau and p-tau181p 
hippocampal volume, voxel-based volumetry, deformation-based morphometry (DBM), 
functional MRI, and FDG-PET [26]. In tandem with the development of these biomarkers, a 
new imaging technology using 11C-PiB in PET scans was being developed [27,28], and the 
possibility of a diagnostic approach predicated on the concept of certain combinations of 
biomarkers providing complementary information was raised [8,26].
In 2008, twin reviews were published in Neurosignals [8,15] by members of the ADNI 
Biomarker Core at the University of Pennsylvania. The first paper reviewed potential 
biomarkers for the early detection of AD. In addition to the potential biomarkers described 
previously, these included MRI T1ρ relaxation times to image neuritic plaques and single-
photon emission computed tomography (SPECT) using a 125I-labeled imidazole derivative 
(6-iodo-2-(4’-dimethylamino-)phenyl-imidazo[1, 2]pyridine) as an alternative approach to 
amyloid PET imaging [29]. The second paper distinguished between diagnostic biomarkers 
and risk biomarkers, such as the APOE ε4 allele and plasma total homocysteine levels, 
suggesting that although they were not sufficiently sensitive for diagnostic purposes, they 
were indicative of increased risk for AD and were predictive of disease progression. Finally, 
in 2010, Hampel et al [7] presented a review that updated our current understanding of tau 
and Aβ biomarkers, including levels of Aβ42 and activity of BACE1 (the major amyloid 
precursor protein-cleaving β-secretase in the brain) in CSF, blood plasma levels of Aβ40 and 
Aβ42, and human antibodies against Aβ-related proteins. Thus, the search for biomarkers to 
fulfill a variety of niches is an ongoing quest and is without doubt set to evolve even further 
as research progresses.
1.5. Goals of ADNI
A comprehensive description of the goals of ADNI is given in papers by Mueller et al [2] 
and Weiner et al [3]. At initiation, ADNI had the overall objective of characterizing clinical, 
genetic, imaging, and biochemical biomarkers of AD and identifying the relationships 
between them over the course of disease progression from normal cognition to MCI to 
dementia. Specific goals of ADNI included the development of optimized and standardized 
methods for use across multiple centers, the enrollment of a large cohort (>800) of healthy 
elderly subjects, MCI patients, and AD patients for baseline characterization and 
longitudinal studies, and the establishment of repositories of data and biological samples, 
both of which were to be accessible to the wider scientific community without embargo. A 
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specific pre-specified goal was to identify those imaging (MRI and PET) and image analysis 
techniques and blood/CSF biomarkers that had the highest statistical power to measure 
change (defined as the sample size required to detect a 25% reduction of rate of change in 1 
year) and thus, it was hoped, detect effects of treatments that would slow the progression of 
AD. With these goals, ADNI hoped to identify a combination of biomarkers that could act as 
a signature for a more accurate and earlier diagnosis of AD, and that could be used to 
monitor the effects of AD treatment [2,3].
When originally conceived, ADNI had not included aims around genetic or proteomic 
analysis. Additional add-on studies supported the evolution of the Genetics Core (see later in 
the text) and the study of protein changes in plasma and CSF. Plasma proteomic data from a 
190-analyte multiplex panel have been posted to the ADNI Web site and are available for 
additional data mining.
1.6. The evolution of an idea: ADNI-1, ADNI Grand Opportunities, and ADNI-2
Drs. Neil Buckholz and William Potter had discussed the overall concept of a large 
biomarker project to study AD for many years. Dr. Buckholz convened an NIA meeting 
focused on AD biomarkers in 2000. In 2001, Drs. Michael Weiner and Leon Thal (since 
deceased) proposed a longitudinal MRI study of AD, MCI, and control subjects. 
Subsequently, Dr. Buckholz brought together a number of investigators from the field of AD 
as well as industry leaders, all of whom strongly supported the overall concept. The NIA 
published a Request for Applications, and ADNI was funded in 2004. The initial ADNI was 
projected to run for 5 years and to collect serial information, every 6 months, on cognitive 
performance; brain structural and metabolic changes; and biochemical changes in blood, 
CSF, and urine in a cohort of 200 elderly control subjects, 200 MCI patients, and 400 AD 
patients [2–4]. It was funded as a public–private partnership, with $40 million from the NIA 
and $27 million from 20 companies in the pharmaceutical industry and 2 foundations for a 
total of $67 million, with the funds from private partners provided through the Foundation 
for the National Institutes of Health. An interesting perspective of the process by which 
potential competitors in the race to develop new drugs for AD were brought together in a 
consortium under the auspices of the Foundation for the National Institutes of Health is 
given in the paper by Schmidt et al [30], who emphasize the importance of the cooperative, 
precompetitive nature of ADNI. When the ADNI grant was first submitted and funded, the 
significance and impact of 11C-PiB [27,28] studies were not fully appreciated, and there was 
no infrastructure to conduct multisite clinical trials with 11C-PiB. Therefore, Aβ imaging 
with 11C-PiB was not included in the application. However, after the first year of funding, 
Chet Mathis proposed adding an 11C-PiB substudy to ADNI, which was funded by the 
Alzheimer’s Association and General Electric. In addition, further industry and foundation 
funding was secured to allow supplemental or “add-on” genomewide association studies 
(GWAS), and for additional lumbar punctures to obtain CSF, as new technologies emerged 
to make these studies feasible in a large-scale initiative such as ADNI.
In 2009, toward the end of the ADNI study, a Grand Opportunities grant, ADNI-GO, was 
secured to extend the original ADNI-1 studies with both longitudinal studies of the existing 
cohort and the enrollment of a new cohort of early MCI patients to investigate the 
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relationship between biomarkers at an earlier stage of disease progression. Technical 
advances made it possible to add analyses of the new cohorts using AV45 (Florbetapir; Eli 
Lilly, Indianapolis, IN) amyloid imaging. Additional experimental MRI sequences included 
for evaluation ofADNI-GOandADNI-2 are arterial spin labeling perfusion imaging and 
diffusion tensor imaging. The development of the [18F]-labeled AV45 amyloid imaging 
agent with a substantially longer radioactive half-life than the 11C form made it practicable 
to extend amyloid imaging studies to additional sites beyond those undertaken in ADNI-1 
[7].
A competitive renewal of the ADNI-1 grant, ADNI-2, was awarded with total funding of 
$69 million on October 1, 2010, together with funding from the pharmaceutical industry in a 
cooperative agreement similar to the original initiative, to further extend these studies with 
additional cohorts [3,4,31]. It is anticipated that the study of very mild MCI patients in 
ADNI-GO and ADNI-2 will help identify subjects at risk who are candidates for 
preventative therapy when they are mildly symptomatic or asymptomatic [30]. Table 1 
summarizes details of the three initiatives.
1.7. Structure and organization of ADNI
A full description of ADNI structure is given in the paper by Weiner et al [3]. Briefly, ADNI 
is governed by a Steering Committee that includes representatives from all funding sources 
as well as principal investigators of the ADNI sites and is organized as eight cores, each with 
different responsibilities, under the direction of an Administrative Core, led by Dr. Weiner, 
as well as a Data and Publications Committee (DPC), led by Dr. Green (Fig. 3). The eight 
cores comprise (1) the Clinical Core, led by Drs. Aisen and Petersen, responsible for subject 
recruitment, collection and quality control of clinical and neuropsychological data, testing 
clinical hypotheses, and maintaining databases; (2) the MRI and (3) PET Cores, led by Drs. 
Jack and Jagust, respectively, responsible for developing imaging methods, ensuring quality 
control between neuroimaging centers, and testing imaging hypotheses; (4) the Biomarker 
Core, led by Drs. Shaw and Trojanowski, responsible for the receipt, storage, and analysis of 
biological samples; (5) the Genetics Core, led by Dr. Saykin, responsible for genetic 
characterization and analysis of participants as well as banking DNA, RNA, and 
immortalized cell lines at the National Cell Repository for Alzheimer’s Disease; (6) the 
Neuropathology Core, led by Drs. Morris and Cairn, responsible for analyzing brain 
pathology obtained at autopsies of ADNI participants; (7) the Biostatistics Core, led by Dr. 
Beckett, responsible for statistical analyses of ADNI data; and (8) the Informatics Core, led 
by Dr. Toga, responsible for managing data sharing functions [2,3]. Additionally, Dr. Robert 
Green directs a recently funded project involving whole genome sequencing of ADNI DNA. 
The Private Partner Scientific Board (PPSB), convened by the Foundation for the National 
Institutes of Health and chaired in 2013 by Dr. Adam Schwarz, provides an independent, 
precompetitive forum for study-related scientific exchange among industry partners. 
Representatives of the PPSB liaise with the Steering and Executive Committee and with the 
ADNI Cores. A schematic of ADNI structure is given in Fig. 3. In addition to the Core 
leaders, the NIA established a completely independent committee, chaired by Tom Montine 
(U. Washington), to review and make recommendations concerning requests for ADNI 
blood, CSF, or DNA samples. Instructions concerning the preparation of requests for 
Weiner et al. Page 8













samples can be found at www.ADNI-info.org. Since the founding of ADNI in 2004, 11 
batches of samples have been provided to requestors. The results of all sample analyses can 
be found in the ADNI data base at UCLA/LONI/ADNI.
1.8. Data sharing and informatics
An objective of ADNI, in addition to its scientific goals outlined in section 1.5, was to make 
data available to the scientific community, without embargo. To this end, the Informatics 
Core of ADNI at the Laboratory of Neuro Imaging (LONI) at the University of Southern 
California in conjunction with the DPC, has developed policies and procedures for 
immediate, open-access data sharing on a previously unprecedented scale. The principles for 
this data sharing were developed in the initial months of the ADNI project in consultation 
with the Executive Committee and presented to the Steering Committee for adoption in the 
first year. The infrastructure for implementing this policy is through the LONI data archive 
(LDA), enabling the widespread sharing of imaging, clinical, genetics, and proteomic ADNI 
results, while overcoming fundamental hurdles such as the question of ownership of the 
disseminated scientific data, and the collection of data from multiple sites in a form that 
supports data analysis [32]. Briefly, LONI has developed automated systems that deidentify 
and upload data from the 57 ADNI sites, ensure quality control of images before removing 
them from quarantine status and make them available for download, manage preprocessing 
and postprocessing of images and their linkage to associated metadata, support search 
functions, and manage user access and approval. Clinical data are collected by the 
Alzheimer’s Disease Cooperative Study through their online data capture system and 
transferred to the ADNI repository at LONI through nightly data transfers. After these data 
are received at LONI, portions of the clinical data are used to update data in the ADNI 
repository to ensure consistency of demographic and examination data and to update the 
status of image data based on quality assessment results. Additional nightly processes 
integrate other clinical data elements, so they may be used in querying the data in the 
repository. Any researcher who has been granted access to ADNI data is able to analyze any 
part of the available data and can post results to LONI. In addition to ADNI data, LDA also 
contains data from the parallel Australian Imaging Biomarkers and Lifestyle (AIBL) 
Flagship Study of Ageing, which were collected using protocols comparable with those of 
ADNI. To date, from 35 countries worldwide, more than 1300 investigators from academic 
and governmental institutions, the pharmaceutical and biotechnology industries, and the 
scanner manufacturing sector have accessed ADNI data through the LDA [32]. The number 
of downloads of ADNI data has increased yearly since 2006, and in 2014, more than 5.5 
million images, 322,000 sets of clinical data (including cognitive tests and levels of CSF 
biomarkers), and sets of genetic data were downloaded by more than 3000 distinct 
downloaders.
Recently, ADNI has been held up as an example of comprehensive and elegant data sharing 
in the clinical research community. It has been estimated that the costs of data sharing, 
which include infrastructure costs and administration, amount to approximately 10%to 
15%of the monetary cost of the initiative and that providing data in a standardized form with 
documentation takes approximately 15% of investigators’ time [355]. A considerable 
number of NIH grants have been funded to investigators not directly funded by ADNI for 
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analysis of ADNI data. A query of the NIH database indicates that a total of 23 separate NIH 
grants of this type have been funded. In 2014, there were 20 active grants of this sort, 
indicating the continued impact of ADNI-generated data throughout the research 
community.
To further enhance the utility of ADNI T1-weighted screening and baseline MR images to 
the scientific community, Heckemann et al[226] automatically segmented images of 816 
healthy elderly, MCI, and AD patients in the ADNI database. They used the MAPER 
approach to generate WM, GM and CSF labels in 83 regions from the raw ADNI data with 
the aim of reducing future computation times. The automatic segmentations were in strong 
agreement with independent atlas-subset based segmentations of the target images, making 
this work a highly significant contribution to the repository.
Although LONI acts as the ADNI data repository, the DPC is responsible for developing 
policy around publication, granting access to the data to investigators around the world, and 
reviewing publications that result from this data use. Briefly, members of the scientific 
community can apply for access to ADNI data for either research or teaching purposes and 
must submit a data use agreement (available at: http://adni.loni.usc.edu/wp-content/uploads/
how_to_apply/ADNI_Data_Use_Agreement.pdf) for approval. Several thousand data 
applications from across the world had been approved, predominantly from academia, but 
also from the biotechnology, pharmaceutical, and other industries. Part of the data use 
agreement requires applicants to include certain language in manuscripts prepared from 
ADNI data, including citing “for the Alzheimer’s Disease Neuroimaging Initiative” as an 
ADNI group acknowledgment, and the recognition of ADNI’s role in data gathering in the 
Methods section and of ADNI’s funding in the Acknowledgments. Manuscripts must be 
submitted for approval to the DPC before publication. The full publication policy can be 
found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_DSP_Policy.pdf. 
The role of the DPC in this step is primarily to check that manuscripts are compliant with 
ADNI publication policy, and not to provide a scientific peer review. Papers found to be 
noncompliant are returned to the authors for editing and can subsequently be resubmitted for 
approval. This process is primarily designed to track, tabulate, and standardize the 
publication of manuscripts using ADNI data.
The approval by the Food and Drug Administration (FDA) of Florbetapir for clinical use 
brought into question the ADNI policy of nondisclosure of research results to study 
participants. Shulman et al [356] surveyed ADNI investigators about their willingness to 
disclose amyloid imaging results to different clinical groups and found that a majority were 
in favor of releasing results to MCI patients, whereas fewer supported data release to 
cognitively normal controls. The study also reported a desire for guidance on this issue from 
investigators and may reflect a need for ADNI to respond to a changing research/clinical 
environment with a review of disclosure policy.
1.9. The ADNI special issue of Alzheimer’s and Dementia
Weiner et al [3] introduced the special ADNI issue of Alzheimer’s and Dementia in 2010 
with an overview of ADNI’s background, rationale, goals, structure, methods, impact, and 
future directions. A set of papers followed highlighting the achievements of individual 
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ADNI cores and perspectives of the Industry Scientific Advisory Board (or ISAB), which is 
now referred to as the Private Partner Scientific Board (or PPSB). Jack et al [33] described 
the achievements of the MRI Core of ADNI in areas ranging from the development of MRI 
technology to the elucidation of AD biology, and concluded that this Core had succeeded in 
demonstrating the feasibility of multicenter MRI studies in ADNI and validity of this 
method as a biomarker in clinical trials. The progress of the PET Core of ADNI in 
developing FDG-PET and 11C-PiB PET protocols, ensuring quality control, and acquiring 
and analyzing longitudinal data was reviewed by Jagust et al [34], who similarly concluded 
that the Core had successfully demonstrated both the feasibility of this technology in a 
multicenter setting and the potential of FDG-PET to reduce sample sizes in clinical trials. 
Trojanowski et al [12] reviewed progress by the Biomarker Core of ADNI in developing 
profiles of CSF or plasma biomarkers that would act as a “signature” of mild AD or predict 
future MCI to AD conversion. Moreover, the review described studies in support of a 
temporal sequence of changes in individual biomarkers that reflected proposed trajectories 
of Aβ deposition and the formation of neurofibrillary tangles in AD progression [14]. The 
accomplishments of the Clinical Core of ADNI were reviewed by Aisen et al [35], who 
reported that the Core had successfully recruited a cohort of >800 subjects, characterizing 
them both clinically and cognitively at baseline and following them longitudinally over the 
course of the study. As the Clinical Core provided data management support to ADNI, this 
review also reported on the contribution of ADNI biomarker and MRI findings to improving 
clinical trial design by determining the most powerful outcome measures and reducing 
sample size using subject selection strategies. The contribution of the Genetics Core of 
ADNI to untangling the apparently complex genetic contributions to AD was reviewed by 
Saykin et al [6], who reported considerable progress in the identification of novel AD 
susceptibility loci and of candidate loci worthy of further investigation, often using AD 
biomarkers as quantitative traits (QTs) in imaging genetics and GWAS. The role of the 
Neuropathology Core in developing procedures to improve the autopsy rate of ADNI 
patients and to standardize neuropathological assessment was reviewed by Cairns et al [36]. 
Finally, Schmidt et al [30] discussed the contributions of the Industry Scientific Advisory 
Board, including acting as a conduit of information to and from sponsoring companies and 
foundations, supporting add-on studies, and contributing to the scientific review of protocols 
and procedures.
2. Development and assessment of treatments for AD: Perspectives of 
academia and the pharmaceutical industry
Given that the ultimate goal of ADNI is to develop biomarkers to facilitate clinical trials of 
AD therapeutics, it is germane to consider the perspective of investigators from academia 
and the pharmaceutical industry on the development of these biomarkers. The aim of this 
section is to review those papers that focus on this issue.
Although ADNI is a natural history study, and it is not known whether its biomarkers can 
measure the effect of candidate treatments in drug trials, the primary focus of ADNI has 
been the development of diagnostic biomarkers for the early detection of AD and 
development of prognostic biomarkers that would be used to monitor disease progression 
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[37]. Mueller et al [38] and Weiner et al [3] reaffirmed the definition of an ideal biomarker 
formulated at the first meeting of the NIA working group on AD biomarkers, which 
proposed that an ideal AD biomarker should detect a fundamental feature of AD pathology; 
be minimally invasive, simple to analyze, and inexpensive; and meet criteria with regard to 
specificity and sensitivity outlined in Table 2. Prognostic biomarkers should be 
representative of a stage of AD at which the treatment has maximal effect, and also be 
representative of the proposed mechanism of action of the treatment [3,38].
Both diagnostic and prognostic biomarkers are required for clinical trials. To date, such 
clinical trials have been frustratingly unsuccessful. It was thought that the failures of phase 
III clinical trials of high-profile putative antiamyloid therapies, flurizan and Alzhemed, were 
in part due to methodological difficulties, such as the initial subject selection, and the 
statistical comparison of results from multiple centers [7,9,39]. In the case of the first 
generation of clinical trials focusing on patients with MCI, there was a lack of consistency in 
numbers of patients progressing to AD over a certain period, likely due to the heterogeneous 
nature of MCI; it is possible that one-half of study participants did not have underlying AD 
pathology [7,11,40]. Correctly distinguishing patients with AD pathology is critical, 
especially considering the overlap that exists between various late-life neurodegenerative 
pathologies. For example, the Lewy bodies that characterize Parkinson’s disease are found in 
>50% of patients with AD, in addition to neuritic plaques and tangles. Therefore, there is a 
real need for biomarkers that reliably distinguish between different types of dementias 
[8,10].
Diagnostic biomarkers that meet the criteria outlined previously are urgently needed for 
subject selection, thereby allowing the stratification and enrichment of clinical trials. There 
is a need to select subjects at an early stage of the Alzheimer’s continuum who are likely to 
progress through MCI to dementia, and also to eliminate subjects with other pathologies. In 
phase I, II, and III trials, biomarkers that detect the earliest indications of AD pathology, Aβ 
deposition, such as CSF Aβ42, and 11C-PiB PET are most likely to be useful. FDG-PET as a 
measure of metabolism could also have potential [41].
The biomarkers used in a clinical trial will differ depending on the mechanism of action of 
the therapeutic, the goals of the trial, and questions at hand. In small, short phase I trials, 
CSF and plasma measures can be used to monitor Aβ turnover in healthy subjects. In phase 
II proof-of-principle or proof-of-concept trials, Aβ biomarkers in brain can be used to 
confirm the mechanism of action of a new treatment and “target engagement.” For phase II 
and III trials, CSF tau and phosphorylated tau, MRI, and Aβ PET can be used to determine 
whether there is evidence of an effect of treatment on disease progression. Clinical MRI is 
used routinely for subject selection, to exclude confounding medical conditions, and for 
detection of vasogenic edema as a safety end point of “immune”-based treatments [41]. 
Finally, Aβ PET imaging, MRI, CSF and plasma biomarkers, and FDG-PET are candidates 
as prognostic biomarkers in phase II trials for selection of nondemented subjects at risk for 
developing AD to test whether treatments have the potential of preventing or delaying the 
onset of AD. The predictive power of these biomarkers in isolation or in combination varies 
and will need to be factored into consideration. None of the current generation of treatments 
proposed to modify the progression of AD is free of safety concerns. Estimation of the 
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probability of developing AD will be required for assessing the risk versus possible benefit 
of participating in research trials [41]. Figure 4 shows ADNI biomarkers that could be used 
at different stages of the drug development process.
Looking at drug development as a whole, Cummings [37] saw a wide variety of roles for 
biomarkers, from identifying disease pathology and tracking disease progression, to 
demonstrating pharmacokinetic effects of the body on the drug, to facilitating proof-of-
principle and determining doses for subsequent trials, to determining drug efficacy, and, 
finally, to contributing to corporate decision making, such as whether to proceed with riskier 
and more expensive later-phase trials (Fig. 5). Fleisher et al [9] reviewed progress in 
developing neuroimaging biomarkers, either alone or in conjunction with CSF biomarkers, 
for subject selection, and in developing biomarkers functioning at later stages in disease, 
such as MRI measures of brain atrophy or changes in cerebral glucose metabolism detected 
by FDG-PET as outcome measures. This review also highlighted the need for biomarkers in 
drug development and discussed the use of imaging biomarkers in replacing cognitive end 
points in clinical trials.
Both common sense and regulatory policies of the Food and Drug Administration (FDA) 
and regulators in other countries require that treatment trials need to demonstrate a 
significant effect on cognition and function. Although effects on biomarkers would provide 
additional evidence of treatment effect and evidence of disease modification, there are no 
validated surrogates for AD trials, and such surrogates will take many years to develop. 
Different biomarkers are likely to be effective over different phases of the disease [11,41]. 
To be used as surrogates for clinical measures, biomarkers would need to be validated as 
reflecting clinical and/or pathological disease processes with a high degree of specificity and 
sensitivity. To qualify for validation as an outcome measure, the biomarker must be shown to 
predict clinical outcome over several trials and several classes of relevant agents by 
following subjects through disease progression and even possibly to autopsy [3,9,37]. This 
validation process is likely to be aided by the contribution of ADNI to standardizing 
procedures, particularly for imaging techniques, to reduce measurement errors in clinical 
trials [42]. A review by Petersen and Jack [11] discussed neuroimaging and chemical 
biomarkers, either alone or in combination, for the prediction of the development of 
dementia in MCI patients. These authors provided an excellent and succinct summary of the 
issues facing clinical trials for AD-modifying drugs and the role of both U.S. and worldwide 
ADNI in developing biomarkers to facilitate these trials.
A detailed discussion of the position of the FDA on biomarker validation is given by Carrillo 
et al [31], and it is likely that the process will require a wider population of well-
characterized subjects than is available through ADNI. To this end, and for the further study 
of therapeutic interventions for AD, Petersen [40] proposed the establishment of a national 
registry of aging. In their editorial in the Journal of the American Medical Association, 
Petersen and Trojanowski [39] introduced a paper that reports on the evaluation of CSF 
biomarkers in a large multicenter study. Placing this in the context of other work in the same 
area, and in research undertaken as part of ADNI, they concluded that as biomarkers become 
more sophisticated, they will play even greater roles in AD clinical trials, and may one day 
be of use in clinical practice in a diagnostic capacity. Hill [41] concluded in his perspective 
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on neuroimaging and its role in assessing safety and efficacy of disease-modifying therapies 
for AD: “…there is now sufficient experience of imaging for Alzheimer’s disease in both 
natural history and therapeutic trials for a clear recipe for success to be emerging.” Weiner 
[43] concluded that the use of biomarkers to select cognitively normal subjects who have 
AD-like pathology and as validated outcome measures in clinical trials “is the path to the 
prevention of AD.”
ADNI has proven to be a rich data set for industry-sponsored research, including an 
assessment of disease progression in the AD population [44]. Results from ADNI data have 
been combined with additional placebo data from clinical trials conducted in AD and are 
publicly available on the Coalition Against Major Diseases (CAMD) Web site for additional 
data mining [227]. Modeling efforts have highlighted the importance of age, baseline 
cognitive status, and APOE status on disease progression rates; a model is currently under 
qualification review through newly developed European Medicines Agency (EMA) and FDA 
qualification procedures. These types of models will inform clinical trial design and 
streamline analysis for drug studies conducted in mild-to-moderate AD.
ADNI has also enabled clinical studies in predementia, and many have been posted to 
www.clinicaltrials.gov, highlighting the use of CSF and amyloid PET biomarkers in 
cognitively impaired subjects to enrich for predementia clinical trials. Application to 
registration-level, phase III studies remains a challenge, as the biomarkers in ADNI have not 
yet been qualified for use or received regulatory approval. To address some of the remaining 
challenges, precompetitive and industry-sponsored initiatives were recently conducted to 
qualify CSFAβ-42 and t-tau as biomarkers for enrichment in predementia study with the 
EMA, and a positive qualification opinion was posted on the EMA site for these particular 
biomarkers. Additional efforts are ongoing with the FDA. For the most part, industry has 
been using the biomarkers as enrichment tools in predementia and mild-to-moderate AD 
studies, and as secondary or exploratory efficacy measures to assess impact of exploratory 
drugs on biomarker measures of disease progression.
In 2012–2013, ADNI has continued to provide an ever richer data set and important venue 
for precompetitive public-private interaction around biomarkers and clinical trial 
methodologies for AD, greatly facilitating the application of biomarkers and new methods in 
clinical trials. CSF and hippocampal volume biomarkers remain the focus of ongoing 
qualification efforts with the FDA. Amyloid biomarkers are actively used for subject 
selection in clinical trials of candidate therapeutics.
Amyloid biomarker substudies in the recent solanezumab and bapineuzumab phase III 
programs revealed that even in AD dementia populations, more than 20% of enrolled mild 
and moderate AD subjects were amyloid negative by CSF Aβ or amyloid PET. Subsequent 
trials of antiamyloid therapeutic candidates are requiring amyloid biomarkers at screening 
and amyloid positivity as an inclusion criterion. Longitudinal measures of amyloid are also 
being increasingly used later in the drug development process to assess potential disease-
modifying effects.
Weiner et al. Page 14













Hippocampal volume, as measured from structural MRI scans, decreases rapidly in the MCI 
phase preceding transition to AD and is strongly associated with imminent clinical decline. 
While not pathologically specific, screening for reduced baseline hippocampal volume 
selects a more homogeneous population of rapidly declining subjects, decreasing variability 
in longitudinal clinical outcome measures. Hippocampal volume was also recently qualified 
by the EMA for enrichment of amnestic MCI clinical trial populations, based in part on de 
novo analyses of ADNI data and coordinated in a precompetitive fashion by CAMD [357].
The widespread application of biomarkers in large, global trials owes much to the methods 
and data generated by ADNI.
3. Methods papers
A considerable proportion of papers published as a result of ADNI concerns the 
development and testing of methods for use in ADNI, in the cohorts of other studies, or in 
clinical trials. These run the gamut from papers examining the best way to reduce 
differences between scanners in multicenter studies to those describing a new way to 
discriminate between AD, MCI, and control subjects, to methods for enriching clinical trials 
to reduce required sample sizes and therefore the associated cost, to new methods for 
examining genotype–phenotype relationships in neuroimaging GWAS. This section presents 
an overview of these papers.
3.1. Standardization of ADNI procedures
3.1.1. Magnetic resonance imaging
3.1.1.1. Assessment of scanner reliability: A key feature of assessing the reliability of 
scanner hardware over longitudinal scans is the use of a high-resolution geometric 
“phantom” that can detect linear and nonlinear spatial distortion, signal-to-noise ratio, and 
image contrast, allowing these artifactual problems to be identified and subsequently 
eliminated. Although these are commonly used for periodic adjustments to quality control, 
they are scanned after every patient in the ADNI MRI protocol. Gunter et al [45] estimated 
that these artifactual problems would contribute to >25% imprecision in the metric used, and 
found that phantom analysis helped correct scanner scaling errors and/or miscalibration, 
thereby increasing the potential statistical power of structural MRI for measuring rates of 
change in brain structure in clinical trials of AD-modifying agents. The utility of a scanner 
phantom was once again underscored by Kruggel et al [46], who examined the influence of 
scanner hardware and imaging protocol on the variability of morphometric measures 
longitudinally and also across scanners in the absence of a phantom in a large data set from 
the ADNI cohort. Using different acquisition conditions on the same subject, the variance in 
volumetric measures was up to 10 times higher than under the sample acquisition conditions, 
which were found to be sufficient to track changes. Their results suggested that the use of a 
phantom could reduce between-scanner imaging artifacts in longitudinal studies. Accurate 
ventricular segmentation also has an important role in estimating disease progression. Khan 
et al. [358] described the construction and testing of a physical brain ventricle phantom 
constructed to accurately simulate brain tissue T1 relaxation times. The phantom proved 
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suitable for the validation of ventricular segmentation algorithms as it was life size, easy to 
fabricate, inexpensive, and accurately mimicked brain tissue.
Kruggel et al [46] also investigated the effect of scanner strength and the type of coil used on 
image quality and found that a 3.0-T array coil system was optimal in terms of image quality 
and contrast between white matter (WM) and gray matter (GM). Ho et al [47] similarly 
tested the ability of 3.0-Tand 1.5-T scanners to track longitudinal atrophy in AD and MCI 
patients using tensor-based morphometry (TBM). They saw no significant difference on the 
ability of either scanner type to detect neurodegenerative changes over a year, and found that 
TBM used at both field strengths gave excellent power to detect temporal lobe atrophy 
longitudinally. Marchewka et al [359] used voxel-based morphometry (VBM) with 
diffeomorphic registration to examine the effect of the different magnetic field strengths on 
the estimation of AD-related atrophy. They found slight grey matter volume differences 
related to field strength in the cerebellum, precentral cortex, and thalamus. The authors 
concluded that diffeomorphic registration was most accurate when scans were pooled across 
the study to create a common anatomic template regardless of scanner type or disease status.
While the scanning of a geometric phantom helps eliminate artifacts introduced by the 
machine, Mortamet et al [48] described an automated method for accounting for patient 
artifacts that can affect image quality, such as edge, flow, and aliasing artifacts. They 
developed two quality indices and tested their ability to differentiate between high- and low-
quality scans, as assigned by an expert reader at the ADNI MRI center. Both indices 
accurately predicted the “gold standard” quality ratings (sensitivity and specificity >85%), 
and the authors proposed that this method could be integrated into a real-time or online MRI 
scanning protocol to eliminate the need to rescan at a later date due to a poor-quality scan, in 
keeping with the goal of placing as minimal burden on the patient as possible. Clarkson et al 
[49] examined within-scanner geometric scaling drift over serial MRI scans, as assessed by 
geometric phantoms, and developed a nine degrees-of-freedom registration algorithm to 
correct these scaling errors in longitudinal brain scans of patients. They found that the nine 
degrees-of-freedom registration was comparable with geometric phantom correction, 
allowing atrophy to be measured accurately, and the authors suggest that this registration-
based scaling correction was the preferred method to correct for linear changes in gradient 
scaling over time on a given scanner. This in turn could obviate the need for scanning a 
phantom with every patient. Bauer et al [50] assessed the utility of collecting whole brain 
quantitative T2 MRI from multiple scanners using fast spin echo (FSE)/dual spin echo 
sequences, which have been shown to be useful in the early detection of AD pathology in 
MCI patients. Although FSE–T2 relaxation properties were related to the global dementia 
status, the authors concluded that the utility of the method was affected by the variability 
between scanners. Several papers were aimed at reducing between-scanner effects, including 
those by Gunter et al [45] and Clarkson et al [49]. Leung et al [51] presented a method 
aimed at overcoming variability in serial MRI scans for the detection of longitudinal atrophy 
by modifying the boundary shift integral (BSI) method of image analysis. Two 
improvements to the BSI method were made: (1) tissue-specific normalization was 
introduced to improve consistency over time, and (2) automated selection of BSI parameters 
was based on image-specific brain boundary contrast. The modified method, termed KN-
BSI, had enhanced robustness and reproducibility and resulted in a reduction in the 
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estimated sample sizes, required to see a 25% reduction in atrophy in clinical trials of AD-
modifying drugs, from 120 to 81 AD patients (80% power, 5% significance).
3.1.1.2. Development of protocols: Jack et al [52] described the development of 
standardized MRI procedures for use in the multiple ADNI centers, a process guided by the 
principle of maximizing the scientific benefit of a scan while minimizing the burden on the 
patient. Using technology widely available in 2004 to 2005, and limiting scanner platforms 
to three vendors, they succeeded in developing a protocol that could be run in <30 minutes 
and that included the use of a phantom scan to monitor scanner performance over time and 
across different centers, back-to-back T1-weighted magnetization-prepared rapid gradient 
echo scans to capture structural information while minimizing the need to rescan patients 
due to technical difficulties, and T2-weighted dual-contrast FSE sequences for the detection 
of pathologies. Postacquisition corrections were instituted to remove certain image artifacts. 
Serial MRI scans, such as those used in ADNI, often suffer from problems associated with 
the uniformity of signal intensity that introduce artifacts into the results. Boyes et al [53] 
tested the ability of nonparametric nonuniform intensity normalization (N3) to eliminate 
these artifacts on higher-field 3-T scanners, which had a newer generation of receiver coils, 
in serial 2-week scans of healthy elderly control subjects. They found that the robustness and 
reliability of the N3 correction were highly dependent on the selection of the correct mask to 
identify the region of the scan over which the N3 worked, and on the smoothing parameter 
used for head scans at different pulse sequences. Leow et al [54] also used serial scans, 2 
weeks apart, of healthy elderly control subjects to investigate the stability of different pulse 
sequences. They used TBM to generate maps of computed changes that could be statistically 
analyzed and to give information on MRI reliability, reproducibility, and variability. This 
optimization of pulse sequences contributed to the design of the ADNI MRI protocol, and 
authors concluded that TBM is a useful tool for the study of longitudinal changes in brain 
structure.
Vuong et al. [360] compared the accuracy or T1- versus T2-weighed MRI sequences in 
determining intracranial volume and found that the T2-based measurement improved the 
strength of associations between cognitive function and brain volume in MCI and AD 
patients compared with T1-weighted sequences in the standard ADNI protocol.
Although many methods have focused on the development of automated hippocampal 
segmentation, manual hippocampal segmentation remains the gold standard. Boccardi et al. 
[361] determined the most reliable orientation for manual segmentation to be anterior-
posterior permissive and defined four segmentation units able to account for inter-protocol 
differences (the minimum hippocampus, the alveolus/fimbria, the tail, and the subiculum). 
The results were presented to a Delphi panel to develop a harmonized manual hippocampal 
segmentation protocol. Nestor et al. [362] directly compared the performance of five 
hippocampal-labeling protocols for multiatlas-based segmentation selected by the 
Hippocampal Harmonization Initiative. Using ADNI-1 baseline and 24-month scans and a 
fully automated multiatlas segmentation technique, the Sunnybrook Hippocampal Volumetry 
(SBHV) tool, they found that protocols differed in voxel overlap accuracies between 
automatic and manual labels, the ability to distinguish between MCIc and MCInc patients, 
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and sample size estimates for clinical trials, suggesting that the choice of protocol for 
automatic multitemplate-based segmentation can influence segmentation accuracy.
3.1.1.3. Standardization of ADNI data sets: The lack of standardized ADNI data sets has 
hampered the direct comparison of results and the replication and evaluation of techniques 
published using ADNI data. The MRI core proposed offering a series of standardized data 
sets that include scans that have both passed quality control measures and have been 
performed on the same scanner to reduce interscanner variability. They proposed that 
deviation from the use of these prespecified data sets be reported in the published papers to 
facilitate comparison and replication of results. With the increasing role of multimodal 
studies, other ADNI cores are also working toward making available standardized data sets 
to achieve the same goals across the breadth of the initiative. Ongoing efforts by the ADNI 
Biomarker Core have also been directed toward the standardization of CSF biomarker assay 
methods to minimize the sources of analytical variability and to develop standard reference 
methods.
3.1.2. Aβ- and FDG-PET—Variability across scanners is also a major factor in ADNI 
PET studies, which are spread over 50 different centers and involve 15 different scanner/
software combinations. Joshi et al [55] tackled the problem of reducing between-scanner 
variability in PET images that has been observed despite the use of standardized protocols. 
Major sources of between-scanner variability are high-frequency differences, mostly related 
to image resolution, and low-frequency differences, mostly related to image uniformity and 
also to corrections for scatter and attenuation. Joshi et al [55] scanned a Hoffmann phantom 
at each participating center, and by comparing the scans to the Hoffman “gold standard” 
digital phantom, they developed corrections for both types of variability, which were tested 
on scans from the ADNI cohort. They found that the high-frequency correction, by 
smoothing all images to a common resolution, reduced interscanner variability by 20% to 
50%, but that the low-frequency correction was ineffective, perhaps due to differences in 
geometry between the Hoffman phantom and the human brain. Jagust et al [34] reported the 
development of a standardized protocol for the acquisition of FDG-PET and 11C-PiB PET 
data that first granted approval to participating sites based on the results from a pair of 
phantom scans on the three-dimensional (3-D) Hoffman brain phantom using defined 
acquisition and reconstruction parameters. These were assessed for image resolution and 
uniformity using a quality control process that used the digital gold standard phantom for 
comparison. In this way, corrections were made for differences in PET images across sites. 
A stable reference region is also critical to detecting metabolic changes with optimum 
sensitivity across different sites and scanners. Rasmussen et al [363] used an approach based 
on differences in coefficients of variation of FDG ratios over time across selected anatomic 
regions. They found the superior portion of the cerebellum to be the optimum reference 
region because of its stability over time compared with AD patients.
Amyloid PET using the longer half-life ligand Florbetapir was introduced into ADNI-2. 
Landau et al [364] compared amyloid imaging results in 32 individuals from ADNI cohort 
with both Florbetapir and PiB scans acquired on a variety of scanner types and processed 
using a variety of methods. They found that the numeric scale of cortical retention ratios was 
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affected predominantly by the type of radioligand and the reference region used for 
scanning, but not by image preprocessing or analysis methods. By estimating a conversion 
factor in a study population scanned by both ligands, they were able to account for 
differences in scales and found that both ligands were in excellent agreement in the 
categorization of patients as amyloid positive or negative.
3.1.3. Biomarkers—The measurement of CSF concentrations of Aβ-42, t-tau, and p-tau is 
recognized to reflect early AD pathology. Within ADNI, levels of these analytes are 
measured by flow cytometry using monoclonal antibodies provided in the INNO-BIA Alz 
Bio3 immunoassay kit (Innogenetics, Ghent, Belgium) with xMAP technology (Luminex, 
Austin, TX) [56,57]. The Biomarker Core of ADNI has worked to make this a standardized 
procedure across multiple ADNI sites, and Shaw et al [56] presented an analysis of 
withinsite and intersite assay reliability across seven centers using aliquots of CSF from 
normal control subjects and AD patients. Five CSF pools were tested, each pool made up of 
either AD patients (n = 2) or controls (n = 3). Each center performed three analytical runs 
using separate fresh aliquots of each CSF sample and data were analyzed using mixed-
effects modeling to determine assay precision. The coefficient of variation was 5.3% for 
Aβ-42, 6.7% for t-tau, and 10.8% for p-tau within center, and 17.9% for Aβ-42, 13.1% for t-
tau, and 14.6% for p-tau between centers. The authors concluded that although they found 
good within-laboratory assay precision, the reason for the reduced inter-laboratory precision 
is not fully understood and may be caused by many sources of variability. As for any test 
method, strict attention to the laboratory standard operating procedures, inclusion of CSF 
quality control specimens in each analytical run, and following the manufacturer’s guidance 
for test performance are essential to assure best performance of this immunoassay test 
system [228].
The ADNI Biomarker Core has continued to focus on improving chemical biomarker assays. 
Korecka et al [365] compared the diagnostic utility of ultraperformance liquid 
chromatography–tandem mass spectroscopy (UPLC-MS-MS) with the AlzBio3 
immunoassay for quantifying Aβ42. They demonstrated that a surrogate matrix consisting of 
artificial CSF containing 4 mg/mL of bovine serum albumin provided linear and 
reproducible calibration comparable to human pooled CSF. Analyses of CSF Aβ42 showed 
that UPLC-MS-MS distinguished neuropathologically diagnosed AD subjects from healthy 
controls with diagnostic utility at least equivalent to AlzBio3 indicating that this technique 
provides selective, reproducible, and accurate results and should be considered as a 
candidate reference method.
Kang et al [366] reviewed the clinical performance and reliability of immunoassays used in 
clinical studies of CSF Aβ42, t-tau, and p-tau181 as biochemical markers of the presence of 
AD neuropathology. They found that measurements of these biomarkers using the most 
widely used immunoassay platforms reliably reflected the AD neuropathology in patients 
with MCI or even in presymptomatic patients. These CSF biomarker tests were therefore 
deemed useful for early diagnosis of AD, prediction of disease progression, and efficient 
design of drug intervention clinical trials.
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3.2. Methods for MRI image preparation and processing
A large portion of ADNI research relies on the extraction of information from MRI images; 
therefore, the development of automated methods to reliably and robustly process thousands 
of scans from multiple centers is vital to the project. Processing steps include whole brain 
extraction, image registration, intensity normalization, tissue classification (segmentation), 
cortical thickness estimation, and brain atrophy estimation [58].
3.2.1. Whole brain extraction—The separation of brain from nonbrain voxels in 
neuroimaging data, known as whole brain extraction or “skull-stripping,” is an important 
initial step in image analysis. Inaccuracies at this step can lead to the introduction of artifacts 
adversely affecting further analysis; therefore, a robust and accurate automated method for 
this step is highly desirable. To this end, Leung et al [58] compared the accuracy of a 
technique, multiatlas propagation and segmentation (MAPS), previously developed for 
hippocampal segmentation ([59]; see later section), with three other widely used automated 
brain extraction methods: brain extraction tool, hybrid watershed algorithm, and brain 
surface extractor. They found that compared with the semiautomated “gold standard” 
segmentation, MAPS was more accurate and reliable than the other methods and that its 
accuracy approached that of the gold standard, with a mean Jaccard index of 0.981 using 
1.5-T scans and 0.980 using 3-T scans of control, MCI, and AD subjects.
3.2.2. Automated registration and segmentation—As manual registration and 
segmentation of images into WM, GM, and CSF is time-consuming, rater-dependent, and 
infeasible for a large study because of its often prohibitive cost, a number of studies have 
focused on developing automated registration and segmentation methods.
3.2.2.1. Atlas-based registration: Wolz et al [60] offered a solution in which atlases are 
automatically propagated to a large population of subjects using a manifold learned from a 
coordinate embedding system that selects similar images and reduces the potentially large 
deformation between dissimilar images, thereby reducing registration errors. This learning 
embeddings for atlas propagation method resulted in a more accurate segmentation of the 
hippocampus compared with other multiatlas methods [60].
The use of more than one atlas on which to register brain images has been recognized as a 
powerful way to increase accuracy of the automatic segmentation of T1-weighted MRI 
images, as it addresses the problem of brain variability. The steps of the process have been 
described by Lotjonen et al [61] and are presented in Fig. 6. Initially, multiple atlases are 
nonrigidly registered to the patient image, after which majority voting is applied to produce 
class labels for all voxels. Then, postprocessing by a variety of algorithms takes into account 
intensity distributions of different structures.
The addition of atlases has been found to increase segmentation accuracy in a logarithmic 
manner, that is, rapidly at first, but eventually slowing toward a maximum. This increased 
accuracy must be balanced by the increased computation time required for each additional 
atlas [61]. Lotjonen et al [61] obtained the best segmentation accuracy with relatively few 
[8–15] atlases, and, additionally, found that postprocessing using either the graph cuts or 
expectation maximization algorithms contributed to an optimized multiatlas segmentation 
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method that balanced accuracy and computation times. They also found that the use of 
normalized intensity differences in the nonrigid registration step produced segmentation 
accuracy similar to that found using the more computationally intensive normalized mutual 
information method.
The selection of the atlases is a critical step. Heckeman et al [62] described the case in 
which the use of atlases based on the brains of young people resulted in occasional gross 
segmentation failures due to ventricular expansion in the older AD subjects. To overcome 
this problem, they modified a hierarchical registration approach by changing the first three 
levels to a tissue classification algorithm, instead of using native magnetic resonance (MR) 
intensity data. This multiatlas propagation with enhanced registration approach was found to 
create accurate atlas-based segmentations and was more robust in the presence of pathology 
than previous approaches. Li et al [229] presented another approach to account for 
ventricular expansion and other variations in tissue composition that occur in older subjects, 
such as WM hyper- and hypo- intensities, and changes in subcortical shape and cortical 
thickness. They employed a deformable registration algorithm that embeds 3D images in 
surfaces in a 4D Reimannian space to topological changes caused by false deformation. The 
method compared favorably with other registration methods employing diffeomorphic 
demons when tested on MR images with lesions from the ADNI data set.
Leung et al [58] generated multiple segmentations using nonlinear registration to best-
matched manually segmented library templates and combined them using a simultaneous 
truth and performance level estimation algorithm. MAPS was then used to measure volume 
change over 12 months by applying the BSI. The accuracy of MAPS was found to compare 
favorably to manual segmentation, with a mean difference between automated and manual 
volumes of approximately 1% and a Dice score of 0.89 compared with other methods 
developed by ADNI (0.86: Morra et al [63]; 0.85: Wolz et al [64]; and 0.89: Lotjonen et al 
[61]).
The efficacy of three established manifold learning techniques (Isomap, Laplacian 
Eigenmaps, and Locally Linear Embeddings [LLE]) for the selection of atlases for multiatlas 
automatic hippocampal segmentation was compared by Hoang Duc et al [367] using the 
ADNI data set. LLE was found to result in the most accurate segmentations with a mean 
Dice similarity index of 0.883 on unseen data.
In heterogeneous populations, improvements in registration and segmentation may be gained 
by selecting atlases based on clusters of homogeneous morphologic features. The data-
driven and unsupervised framework of Ribbens et al [368], termed SPARC, automatically 
identifies such subgroups that largely correspond to clinical status and constructs 
probabilistic atlases for each cluster to guide segmentation.
3.2.2.2. Other registration methods: In addition to registration of images to one or more 
atlases, segmentation of images may use image statistics to assign labels for each tissue or 
use geometric information such as deformable models or active contours [65]. A method that 
combines elements of these two approaches was described by Huang et al [65], who used an 
edge-based geodesic active contour. They found that this method segmented a range of 
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images more accurately and robustly than those using individual statistical or geometric 
features only.
Calvini et al [66] developed software for the automatic analysis of the hippocampus and 
surrounding medial temporal lobe (MTL) and the calculation of a novel statistical indicator, 
the Δ-box, computed on intensities of the automatically extracted regions Their method did 
not directly segment the hippocampus, relying instead on the use of the Δ-box to assess 
intensities after a manual extraction step. A refinement and generalization of this method 
that standardizes the intensity scale of MR images, automatically extracts hippocampal 
volume, and generates templates using a clusterization method was subsequently described 
by Cataldo et al [369]. The authors propose that this simple and easily reproducible method 
could be easily applied to other regions of the brain.
A computational processing application to measure subtle longitudinal changes using 
nonlinear registration to the baseline image was described by Holland and Dale [67]. This 
method, called quantitative anatomical regional change (QUARC), used nonrigid 12-
parameter affine registration, image smoothing minimization, normalization of local 
intensity nonuniformity, direct calculation of the displacement field of the region of interest 
(ROI) rather than the Jacobian field, and bias correction. When QUARC was compared with 
four other common registration methods used on ADNI data, it produced significantly larger 
Cohen d effect sizes in several ROIs than FreeSurfer v4.3 (Athinoula A. Martinos Center for 
Biomedical Imaging, Massachusetts General Hospital, Boston, MA; http://
surfer.nmr.mgh.harvard.edu/), voxel-based morphometry, and TBM, and a similar whole 
brain effect size to the standard KN-BSI method. Although, unlike the other methods, the 
signal-to-noise ratio of the raw images obtained using QUARC was enhanced by back-to-
back repeat scans, the authors concluded that QUARC is a powerful method for detecting 
longitudinal brain morphometric changes in levels varying from the whole brain to cortical 
areas to subcortical ROIs [230]. Lorenzi et al [370] described a novel nonlinear registration 
method, LCC (local correlation coefficient)–Demons, designed for both intersubject and 
intrasubject studies. Based on the log-Demons diffeomorphic registration algorithm, it 
retained the computational efficiency of the log-Demons algorithm while using stationary 
velocity fields to parameterize the transformation. The algorithm was flexible, robust, and 
efficient when tested on ADNI cross-sectional and longitudinal data.
Robitaille et al [371] presented an alternative approach to tissue-based standardization called 
STandardization of Intensities (STI), which uses a spatial intensity correspondence between 
an input image and a standard determined using joint intensity histograms. The method was 
tested on the ADNI data set and was found to be superior to histogram-matching techniques.
3.2.3. Automated temporal lobe and hippocampal segmentation
3.2.3.1. Temporal lobe and hippocampus: In AD, atrophy in MTL and, in particular, the 
hippocampus is associated with declining cognitive function. It is not surprising, then, that a 
substantial body of work has been published on the subject of analyzing structural MRI T1-
weighted measurements of this region. Chupin et al [68] developed a fully automated 
method for hippocampal segmentation based on probabilistic information derived from an 
atlas built from the manually segmented hippocampi of 16 young subjects and anatomical 
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information derived from stable anatomical patterns. Wolz et al [64] used a fully automated 
four-dimensional (4-D) graph-cut approach to hippocampal segmentation that segmented 
serial scans of the same patient. Power analysis of the method revealed that a clinical trial 
for an AD-modifying drug would require 67 AD or 206 MCI patients to detect a 25% 
change in volume loss (80% power and 5% significance). Morra et al [69] developed the 
auto context model (ACM), a fully automated method to segment the hippocampus, based 
on the machine learning approach, AdaBoost. After training the classifier on a training set, 
ACM was able to discriminate between AD, MCI, and control groups, suggesting that the 
automatic segmentation is sufficiently sensitive to detect changes in hippocampal volume 
over the course of disease progression. This method was compared with manual and other 
automated methods for hippocampal segmentation, and also with TBM, which was used to 
assess whole brain atrophy in an earlier paper by the same group [63]. These authors found 
that ACM compared well with hand-labeled segmentation and that the volume atrophy over 
clinical groups and correlation with clinical measures with ACM were comparable with that 
found with other automated methods and better than TBM, suggesting that the latter method 
may not be optimal for assessing hippocampal atrophy.
Lotjonen et al [231] developed an automatic hippocampal segmentation method using an 
intermediate template space between unseen data and atlas spaces to increase processing 
speed and partial volume modeling to increase classification accuracy. The authors reported 
that this method more than halved the processing time on a standard laptop computer and 
resulted in a Dice overlap compared to manual segmentation of 0.869, in the range of 
previously reported accuracies (0.85 [63] and 0.93 [59]), supporting the feasibility of the 
method for clinical use. Tong et al [372] combined an alternative strategy, Fixed 
Discriminative Dictionary and Learning for Segmentation (F-DDLS) with fast coding 
techniques, for image reconstruction and reported computation burden. When the method 
was tested on hippocampal segmentation using ADNI cohort data, a Dice overlap of 0.879 
was obtained. A similar Dice overlap (0.903) was obtained using a method, STEPS 
(Similarity and Truth Estimation for Propagation Segmentation), based on the STAPLE 
algorithm, which used a local ranking strategy to estimate the voxel-by-voxel classifier 
performance [373]. Using STEPS, statistically significant differences were found between 
subject groups in both baseline hippocampal volume and hippocampal atrophy rates.
Automated hippocampal segmentation may gain accuracy by considering not only volume 
but surface geometric variations. Shi et al [374] used a surface fluid registration method 
based on the use of holomorphic one-forms to compute a global conformal parameterization 
that can map a service to a rectangular plane, followed by multivariate TBM to compare in 
morphometry between study groups. The method successfully detected differences in 
hippocampal shape between APOE ε 4 allele carriers and noncarriers in both control and 
MCI groups.
Automatic image segmentation is prone to systematic errors, which are introduced when 
these mostly knowledge-based protocols mistranslate manual segmentation protocols into 
the automatic format. Wang et al [70] presented a wrapper algorithm that can be used in 
conjunction with automatic segmentation methods to correct such consistent bias. The 
algorithm uses machine learning methods to first learn the pattern of consistent segmentation 
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errors and then applies a bias correction to the mislabeled voxels detected in the initial step. 
When the algorithm was applied to four different segmentation methods, it decreased the 
number of mislabeled voxels by 14% (multiatlas hippocampal segmentation) to 72% 
(FreeSurfer hippocampal segmentation) and resulted in a higher Dice overlap than other 
hippocampal segmentation methods, including some of those by Leung et al, Chupin et al, 
and Morra et al, described in this review [59,68,69].
3.2.3.2. Cortical thickness segmentation and estimation: Cortical thickness, which is 
correlated with disease progression, offers an alternative approach to ROIs to assessing 
disease progression. Consequently, the development of automated methods to analyze this 
region is an important step in monitoring disease progression [232]. Cardoso et al [233] 
presented a new method of post-processing for accurate segmentation of cortical thickness 
that reduced bias towards anatomical priors, explicitly models partial volume effects and 
improved the modeling of sulci and gyri using a locally varying Markov Random Field 
model. When the algorithm was tested on ADNI data, the authors reported an improvement 
in accuracy over established methods.
With the progression from ADNI-1 to ADNI-GO to ADNI-2, analysis of longitudinal ROI 
data has become of increasing importance. Several papers have focused on the accurate 
comparison of time points using 4D segmentation to determine rates of atrophy. Wang et al 
[375] proposed a method for longitudinal cortical thickness estimation in which all scans at 
every time point are included in the segmentation process, cortical thickness is maintained 
within a reasonable range using a spatial cortical thickness constraint, and artificial 
variations between time points are suppressed by a temporal constraint. When the method 
was compared in the ADNI data set to FreeSurfer (4D segmentation that lacks the temporal 
constraint), it produced more consistent and smoother thickness measurements in a more 
computationally efficient manner. Another approach, also involving temporal constraint, was 
described by Li et al [376]. First, they used a deformable parametric surface method to 
reconstruct the cortical surfaces of a group-mean image of all longitudinal images. They 
then used their mean surfaces to simultaneously reconstruct all longitudinal cortical surfaces. 
The method was tested on the ADNI cohort and found to be sufficiently sensitive to detect 
subtle changes in cortical surfaces such as a thinning of 0.02 mm over 24 months in normal 
aging.
Specific regions of the cortex may be of particular interest to researchers. For example, the 
perirhinal cortex may play a critical role in memory and has been shown to accumulate 
neurofibrillary tangles very early in disease progression. Augustinack et al [377] used 
probabilistic mapping on ADNI images to predict allocation for the perirhinal cortex and 
confirmed this with histologic staining. Using this method, they confirmed the utility of 
cortical thickness in this region as a specific metric for disease progression.
Segmentation bias can also be introduced when one baseline image is used as a reference in 
the comparison of multi-time point longitudinal images to estimate brain atrophy from 
changes in cortical thickness. Leung et al [230] developed a method based on BSI that 
utilized affine registration, differential bias correction and symmetrical global registration 
for multiple time points through the concept of a geometric mean to overcome this 
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asymmetry. They found that this locally adaptive cortical segmentation algorithm (LoAD) 
consistently reduced bias and increased cortical thickness estimation accuracy compared to 
established methods when tested on the ADNI data set. Another challenge in cortical 
segmentation is filtering geometric topological outliers without causing unintended 
shrinkage to other parts of cortical surface. Shi et al [378] used a unified Reeb analysis that 
offered an integrated regularization of these outliers and also enhanced tissue classification 
at the subvoxel level. When tested on images from ADNI, the method was shown to be 
robust, accurate, and computationally efficient, requiring roughly a third of the computing 
time of FreeSurfer.
3.2.4. TBM and DBM—Bossa et al [72] used the method of TBM, which examines the 
deformation fields generated when an image is registered to a template. Previous work used 
large deformation algorithms for the nonrigid registration step, as they have the flexibility to 
characterize anatomical variability in cross-sectional studies. These algorithms are, however, 
computationally intensive, and the authors proposed a simplified version of the large 
deformation algorithms, stationary velocity field diffeomorphic registration. When the 
method was evaluated using ADNI subjects, it provided brain atrophy maps at high spatial 
resolution with lower computational requirements. Hua et al [73] examined two methods of 
image registration in TBM and found that the method in which each image is aligned to a 
single template was a more effective measure of brain deterioration. They also found TBM 
to be better suited to analyzing morphometric changes over larger areas, such as the entire 
temporal lobe, rather than specific ROIs, such as the hippocampus, and that atrophic changes 
detected by their method correlated well with clinical measures of brain deterioration (Mini-
Mental State Examination [MMSE] and clinical dementia rating [CDR] scores). The use of 
multi-template registration was investigated by Koikkalainen et al [234], who developed and 
compared the classification accuracy of four methods with a single template registration 
method. They found that all four multi-template methods improved classification accuracy 
and resulted in smaller sample size estimates.
Yushkevich et al [74] examined the use of DBM, a technique closely related to TBM in 
estimating longitudinal hippocampal atrophy in the ADNI cohort. They found that without a 
correction for asymmetry that arises during longitudinal image registration, substantial bias 
can result in the overestimation of the rate of change of hippocampal atrophy. Park and Seo 
[75] tackled the problem of accurate registration algorithms required in DBM to compute the 
displacement field. They proposed a method that uses multidimensional scaling to improve 
the robustness of the registration step, and found that this method improves the ability of 
DBM to detect shape differences between patients. The same group reported a further 
advance using a manifold learning method, ISOMAP, embedding that represents high-
dimensional imaging data in the low dimensional manner [379].
3.2.5. Quantification of brain morphometric changes—Several papers have focused 
on the development of methods for quantifying structural changes across the whole brain 
from structural MRI scans. Chen et al [76] developed a semiquantitative brain and lesion 
index based on T1- and T2-weighted imaging. They found that both the T1-based and T2-
based scores correlated with age and cognitive performance and differentiated between 
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control, MCI, and AD subjects. Acosta et al [77] presented a new accurate and 
computationally efficient voxel-based method for 3-D cortical measurement. The method, 
which uses an initial Lagrangian step to initialize boundaries using partial volume 
information and a subsequent Eulerian step to compute the final cortical thickness, offered 
higher statistical power to detect differences between clinical groups with a slight increase in 
computational time compared with methods using only the Eulerian step. The authors 
proposed that the increased accuracy and precision are attributable to the Lagrangian step, 
which effectively achieves subvoxel accuracy.
The reliability of two common algorithms, Siena and Siena X, used for measuring changes 
in whole brain volume cross-sectionally and longitudinally in MRI studies, was assessed by 
Cover et al [235] using ADNI data. They found that Siena was more reproducible than Siena 
X, that both algorithms gave estimates of atrophy rates in the ADNI cohort in line with 
atrophy rates reported in other cohorts, and that the distribution of atrophy in the ADNI 
cohort appeared to have a non-Gaussian distribution. The study demonstrated the utility of 
ADNI data as a benchmark for assessing the reliability of future algorithms for measuring 
brain atrophy.
3.2.6. Fractal analysis—A different approach for detecting atrophy in disease 
progression based on fractal analysis has been described by King et al [78]. Recognizing that 
the cerebral cortex has fractal properties, such as being statistically self-similar, this group 
investigated the effect of AD on gyrification using fractal analysis. They found that fractal 
analysis of cortical ribbons was able to discriminate between AD and control subjects in all 
of the seven regions tested, apart from the hippocampus, and suggested that this method may 
play a complementary role to ROI approaches, especially at earlier stages of disease 
progression. In a subsequent work, King et al [79] presented a new method for fractal 
dimension analysis of the cortical ribbon that also measured cortical thickness. When this 
method was compared with gray/white and pial surface cortical models, they found that it 
was the only measurement to have a significant correlation with cortical thickness and 
ADAS-cog scores, and that it best discriminated between control subjects and AD patients. 
The authors concluded that the fractal dimension of the cortical ribbon has strong potential 
as a quantitative marker of cerebral cortex atrophy in AD. Li et al [80] presented a method to 
reliably measure cortical thickness for longitudinal studies by incorporating 4-D information 
from successive scans directly into processing steps. In the absence of a gold standard 
against which to test their method, they used power analysis of the correlation between 
cortical thickness and the MMSE to show that this method improved longitudinal stability 
compared with 3-D methods that do not take the temporal factor into account.
3.2.7. Other MRI methods—Risser et al [81] presented a new method to compare imaged 
shapes, either longitudinally or against an atlas, on several different scales simultaneously, 
and to quantify the deformations on a single scale using large-scale deformation 
diffeomorphic mapping. When the method was applied to examine hippocampal atrophy in 
ADNI patients using baseline and 24-month scans, it was found to be able to extract 
information at the desired scale among all the scales.
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A modification of the voxel-based analysis and statistical parametric mapping method for 
the detailed spatial analysis of image data without a priori defined ROIs was proposed by 
Zhang and Davatzikos [82]. Their method, optimally discriminative voxel-based analysis, 
uses non-negative discriminative projection applied to the spatial neighborhood around each 
voxel to find the optimally discriminative direction between two groups, determines a 
statistic for each group, and obtains a statistical parametric map of group differences. 
Optimally discriminative voxel-based analysis was found to perform well compared with 
traditional statistical parametric mapping using an ADNI data set.
Beyond volumetric analysis of ROIs, recent research has focused on extracting more 
meaningful information from the shape of brain structures, but most studies have not 
considered the pose, or location and orientation, of the structure. Bossa et al [71] presented a 
method for the statistical analysis of the relative pose of subcortical nuclei. The framework 
of the analysis was a variety of approaches based on similarity transformations with 
Reimannian metrics. Significant group differences were found between control subjects, 
MCI patients who did or did not subsequently convert to AD (MCI-c and MCI-nc, 
respectively) and AD patients, and the authors suggested that the method may be particularly 
useful as an AD biomarker in conjunction with shape analysis, as both approaches leverage 
complementary information. Two new approaches for analyzing longitudinal MRI data sets 
were reported by Skup et al [380] and Bernal-Rusiel et al [381]. The multiscale adaptive 
generalized method of moments [380] tackles the problem of analysis of longitudinal MRI 
data sets that have multiple response images per subject. The spatiotemporal linear mixed-
effects modeling approach [381] uses the large number of spatial locations in a mass 
univariate setting and offers large gains in statistical power over other methods especially in 
a small sample setting.
3.3. Methods for AD classification from imaging data
The development of automatic methods for the accurate classification of patients into 
clinical groups from imaging data has been the aim of multiple ADNI studies. Many of these 
classification methods are based on support vector machines (SVMs), a set of algorithms 
that uses supervised learning of pattern recognition in a training set to build a classifier to 
predict the category to which a new example belongs. Some methods condense imaging data 
into one score that is reflective of brain abnormalities associated with AD to allow the direct 
comparison of patients, thereby facilitating their classification into patient group [83–85], 
whereas others examine which combination of imaging, CSF biomarkers, genetics, and other 
factors results in the most accurate classifiers [86,87], or formulate novel approaches for 
identifying AD-like patterns [87–90]. Other methods leverage the changes in spatial 
connectivity between different areas of the brain that most likely occur, as functional 
connectivity becomes affected during disease progression [65,83]. Finally, some methods 
[91,92] use an alternative approach to machine learning, a relevance vector machine (RVM), 
which, unlike the binary SVM, is a probabilistic machine learning algorithm. A brief 
description of these methods is given later in the text, and their results are presented and 
compared with existing methods of classification in section 5.4.1.
Weiner et al. Page 27













3.3.1. Magnetic resonance imaging—Fan et al [83] used an SVM to construct a 
classifier based on patterns of spatial distribution of brain tissue from T1-weighted MRI 
scans of control subjects and AD patients and applied this classifier to scans of MCI 
patients. The classifier, which acts as an indicator of how the structural profile of an 
individual fits that of AD or control subjects, also produced a structural phenotypic score 
(SPS) that allowed direct comparison of patients. This approach differs from ROI or voxel-
based analyses, as it examines spatial patterns of atrophy rather than individual brain 
regions, and is also able to examine functional connectivity. Shen et al [89] also developed a 
method that integrated feature selection into the learning process, but used sparse Bayesian 
learning methods instead of an SVM. They reported that their automatic relevance 
determination and predictive automatic relevance determination, in general, outperformed 
the SVM used for comparison and classified patients more accurately than the method of 
Hinrichs et al [88]. Stonnington et al [91] used regression analysis based on an RVM to 
analyze T1-weighted MRI data and predict clinical scores, whereas Franke et al [92] used an 
RVM combined with an automatic preprocessing step and dimension reduction using 
principal component analysis to estimate the age of healthy subjects from T1-weighted MRI 
data, and found the method to be reliable, efficient, and scanner independent. In contrast to 
the supervised SVMs used in the aforementioned studies, Filipovych and Davatzikos [93] 
used a semisupervised SVM to classify MCI-c and MCI-nc patients. In the supervised 
approach, there is an assumption that patterns in a heterogeneous construct like MCI are 
known, but in a semisupervised approach, only some of the data, in this instance, baseline 
MRIs from AD patients and control subjects, are labeled, whereas scans of MCI patients are 
left unlabeled. Using a leave-one-out approach, scans were then classified as having a degree 
of AD-like or normal-like anatomic features, as defined by Fan et al [83]. Likewise, Spulber 
et al [382] derived a severity index reflective of the degree of AD-like neurodegeneration 
based on a priori–defined MRI regions from baseline MRI scans of NC and AD patients. 
They then used an orthogonal projection to latent structure algorithm as an alternative to 
SVM for analyzing high-dimensional data.
A more data-driven approach for patient classification that circumvents the need for a priori 
defined ROIs by using an initial independent component analysis (ICA) step was proposed 
by Yang et al [94]. Their preliminary study combined the ICA step to extract defining 
neuroimaging features with a subsequent SVM for classification of scans into AD, MCI, and 
control subjects, and the resulting method was tested on two cohorts, including ADNI. 
Pelaez-Coca et al [95] compared ability of anatomical versus statistically defined ROIs to 
discriminate between control and AD subjects. Using a variety of classifiers, they sought to 
restrict the number of features using principal component analysis and found that a higher 
number of features did not necessarily correspond with higher classification accuracy. When 
generalizability of the algorithm was tested by analyzing classification performance of 20 
different experiments in which different subsets of the cohort were used as training and 
testing sets, they found that the resulting variability was larger than within the different 
classifiers used. Finally, they found that statistically defined ROIs representing voxels with 
the largest significance difference in a group comparison with an unbiased atlas (belonging 
to voxels in the hippocampi and amygdalae) resulted in better classification accuracy than 
anatomically predefined ROIs in the hippocampi, lateral ventricles, and amygdalae.
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Shen et al [236] described a method to leverage differences in hippocampal shape for the 
discrimination of AD from control patients. The approach selected a subset of landmarks by 
using shape descriptors from statistical shape models that were further selected by statistical 
means for direct involvement in AD-specific neurodegeneration. Selected landmarks, 
including the CA1 subfield and the subiculum, were then used in a principal component 
analysis with SVMs for classification and their targeted use resulted in an increase in the 
discriminatory power of statistical shape models.
An alternative to a priori defined ROIs in AD classification is the use of cortical thickness 
estimates. Pachauri et al [232] used a topology-based kernel construction algorithm to 
measure cortical thickness. They suggested that this automated method can leverage 
discriminative information found on cortical surfaces that can be included in multimodal or 
multi-variate models to boost the signal of interest. Cho et al [237] employed an incremental 
learning method that represented cortical thickness data using the manifold harmonic 
transform to overcome problems of noise sensitivity in vertex based methods and the lack of 
detailed spatial variation of cortical thickness of region-wise methods. They found that this 
method was more robust than traditional methods and resulted in high classification 
accuracy. Park et al [383] reduced the dimensionality of selected ROIs of cortical thickness 
and sulcal depth using principal component analysis and trained an SVM on a small sample 
of ADNI patients. A novel approach for leveraging more information from cortical thickness 
measures by taking into account the relationship between morphological features was 
proposed by Wee et al [384]. By constructing a similarity map of correlations between pairs 
of ROIs, they augmented classification accuracy over ROIs alone. Beyond cortical thickness, 
differences exist in cortical folding patterns between patient groups in ADNI. Cash et al 
[385] described an alternative method to the fractal analysis of King et al [78] that uses a 
gyrification index as a summary statistic representing the degree of cortical folding in 
addition to indices describing cortical curvature and shape.
Increasingly, the ability to discriminate between MCI patients who will either remain stable 
or convert to AD is paramount to the selection of clinical trial populations. To this end, 
Eskildsen et al [386] defined differential patterns of cortical thinning in MCI patients 
depending on their time to conversion. They identified disease stage–specific 
neurodegenerative changes: initial thinning in the parahippocampal gyrus followed by the 
hippocampus and then the amygdala and occipital areas closer to conversion. Selected 
regions were applied to a linear discriminant analysis classifier. They also tested the effects 
of “double dipping”—the practice of reusing the training set in the test set—and found this 
artificially inflated classification accuracy.
ADNI acquires MRI data across multiple centers and scanner types. Abdulkadir et al. [238] 
investigated the effects of hardware heterogeneity on the classification accuracy of fully 
automated machine learning methods using an SVM classifier. They found that the negative 
effects of differences in scanner strength (1.5 T versus 3.0 T) on accuracy were offset by the 
gain made from the larger data sets available from multiple sites. A maximum accuracy of 
87% in the classification of AD patients from controls was reported using data acquired with 
heterogeneous scanner settings.
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Selection of MR features representative of change to a more AD-like morphometry has 
allowed the development of models that predicts future clinical decline from MR data. 
Zhang et al [239] targeted the use of both baseline and longitudinal data in a method that 
uses a longitudinal feature selection approach developed from a sparse linear regression 
model of each time point and which finally extracts a set of most relevant features 
longitudinally for input into a multi-kernel SVM. They found that the addition of 
longitudinal data substantially increased prediction accuracy. Aksu et al[240] used an 
approach intermediate between supervised and unsupervised machine learning to construct 
an automatic prognosticator of MCI to AD conversion and to define a conversion point 
between the two disease states. When an MCI patient showed any region of the brain as 
being “AD-like,” they were classified as converters which resulted in a higher prognostic 
accuracy than a CDR-based method.
Disease classification using MRI is plagued by the curse of dimensionality in which the 
number of voxels for whole brain analysis is so large that a direct SVM approach becomes 
prohibitively computationally expensive and does not necessarily lead to the best 
classification as not all features are relevant to disease pathology. Feature selection is one 
approach frequently used to address this challenge. In 2012 and 2013, there was a trend to 
considering higher level imaging features such as relationships between ROIs rather than 
low-level features such as voxelwise GM. The method of Suk et al [387] used as a stacked 
autoencoder to incorporate latent high-level information residing in patterns between low-
level features in combination with the lower level features, themselves. Liu et al [388] 
likewise took into account structural variability in pathologic degeneration both at coarse 
and fine levels using a tree-based method of feature selection. Cuingnet et al [389] 
accounted for the structural and functional connectivity of imaging data in their alternative 
method that included a regularization step to add spatial and anatomical priors. Using ADNI 
imaging data, all methods increased classification accuracy over methods with low-level 
feature selection alone. Interestingly, when the effects of feature selection and sample size 
on classification accuracy were systematically examined, larger sample size was found to 
generally have a greater effect in classification accuracy than feature selection [390]. One 
exception to this was when ROIs were used as a feature selection; in this case, a large 
sample size was less advantageous.
Liu et al [391] presented a modification of the Lasso algorithm for dimensionality reduction 
in which hierarchical tree–guided regularization is added to identify relationships between 
the imaging voxels. Testing this tree-guided sparse coding method on ADNI data, they found 
that inclusion of this step was able to achieve better classification to L1-regularized Lasso 
alone using fewer features that were concentrated in areas known to be most relevant to AD 
such as the hippocampus, entorhinal cortex, parahippocampal gyrus, and amygdala. The use 
of Lasso regularization for dimensionality reduction in the multimodal setting has also been 
reported [392–394] and described in Section 3.3.4.
Most classification methods are based on SVM and kernel approaches which, in the process 
of dimension reduction, may discard useful information contained in the images. An 
alternative approach that operates directly in the voxel space was proposed by Casanova et al 
[241] who used penalized logistic regression and coordinate-wise descent optimization to 
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overcome these problems of large scale classification. A subsequent paper by the same 
group [395] examined classification methods from structural MRI from the perspective of 
linear ill-posed problems and in the absence of dimensionality reduction techniques. They 
found that logistic regression, linear regression, and SVM classifiers were robust to 
increased dimensionality. Conversely, Liu et al [396] found that LLE as a method of 
dimensionality reduction improved classification accuracy universally using regularized 
logistic regression, SVM, and linear discriminant analysis. Their algorithm had the 
additional advantage of selecting the most discriminatory MRI features using unsupervised 
learning.
3.3.2. [18F]-fluorodeoxyglucose-positron emission tomography—Haense et al 
[84] also used a discrimination procedure, developed by the European Network for 
Standardization of Dementia Diagnosis, which generates a measure reflective of scan 
abnormality from FDG-PET data. This measure, AD t-sum, is calculated from the sum of 
abnormal t-values in voxels known to be affected by AD, and was used for discrimination of 
clinical groups. A similar approach was used by Chen et al [85], who developed an 
automatically generated hypometabolic convergence index (HCI) reflective of the degree to 
which the patient’s pattern and magnitude of cerebral hypometabolism corresponded to that 
of probable AD patients. Arbizu et al [397] combined the HCI with age and gender in a 
multivariate model to produce an AD score in an automated analysis method. To reflect the 
developing idea of AD as a continuum of disease rather than a progression of discrete states, 
they categorized patients into sixtile groups that had a progressive monotonic increase in AD 
scores. They also developed a similar index, the AD-conv-score, generated from FDG-PET 
data from the posterior cingulate index in combination with MMSE score and APOE ε 4 
genotype, gender, and age.
Huang et al [65] identified changes in spatial connectivity patterns based on sparse inverse 
covariance estimation using FDG-PET data. Salas-Gonsalez et al [90] developed an 
automated procedure to classify AD patients from FDG-PET data using a t test to select 
voxels of interest and factor analysis to reduce feature dimension. The resulting factor 
loadings were tested on three different classifiers, two Gaussian mixture models with either 
linear or quadratic discriminant functions and an SVM. Lemoine et al [87] used a 
combination of feature selection and data fusion to construct SVMs from both FDG-PET 
and clinical data. To extract the most meaningful features from FDG-PET scans, they used 
an evolutionary algorithm in which each feature corresponded to one gene, the number of 
features was arbitrarily selected to be 30, and which was complete when an area under the 
curve (AUC) of 0.98 was achieved on the training data set. SVMs were also constructed for 
a range of clinical features, and the results of these and the FDG-PET classifiers were 
weighted and data finally fused to create a final classifier. Martinez-Murcia et al [398] 
selected maximally discriminative voxels using significance measures and ICA for 
dimensionality reduction and finally used an SVM or Bayesian classifier. The method was 
robust and accurate when applied to ADNI FDG-PET data. Toussaint et al [399] used a 
combination of univariate voxel-based analysis using two sample t tests and multivariate 
(ICA) techniques to discern patterns of glucose hypometabolism. These patterns in 
conjunction with a SVM were used to discriminate between patient groups. Derado et al 
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[400] used a Gaussian process based on Bayesian theory as an alternative to an SVM to 
construct a hierarchical framework that used spatial correlations in the data. The method 
predicted glucose uptake patterns at 6 months for good accuracy and compared favorably 
with other methodologies.
Inspiration for improving classification accuracy increasingly comes from fields outside of 
neuroimaging. An alternative method for scoring brain images based on the principles of 
information retrieval, a computer science technique often used in Internet search engines, 
was described by Clark et al [242]. In this method, PET scores were arranges in a vector 
space with one dimension per voxel and orthogonal vectors were subtracted to refine 
queries. Cosine similarity between vectors was used between residual vectors to score the 
PET scan relevance to a diagnostic query. The resulting cosine similarity scores were used to 
construct classifiers. Keator et al [401] applied a biophysically inspired hierarchical filtering 
model for image recognition developed in the computer vision community to ADNI FDG-
PET data. The hierarchical filtering pipeline determined which steps were most important 
for classification accuracy and thus produced outputs for training on neural networks or 
logistic regression classifiers. This method performed well compared with others (e.g., 
[402]) and outperformed a human rater in classification accuracy.
The large, heterogeneous ADNI data set proved an ideal testing ground for assessing the 
efficacy of a previously described classification method [243] which included principal 
component analysis and Fisher discriminant analysis. Markiewicz et al [244] successfully 
verified their multivariate approach and found that the highest accuracy for the whole sample 
verification was achieved using 4 principal components.
One of the issues with the use of FDG-PET data the selection of an appropriate reference 
region for either longitudinal or group comparison studies that measure changes in brain 
metabolism that can be leveraged for classification purposes. The method described by 
Rasmussen et al [245] sought to improve this critical step by the selection of candidate 
reference regions based on heat maps of coefficients of variation of FDG ratios over time. 
They found that intensity normalization systematically isolated the superior portion of the 
cerebellum as the test reference region for detecting rates of decline and baseline deficits in 
AD patients.
3.3.3. Cognitive methods—Llano et al [96] developed a cognitive test based on ADAS-
cog as an alternative to imaging or CSF biomarkers for use as an outcome measure or for 
subject enrichment in clinical trials. The ADAS.Tree composite was derived by weighting 
test components of ADAS-cog based on their ability to discriminate between control, MCI, 
and AD subjects of the ADNI cohort using a Random Forests tree-based algorithm. 
ADAS.Tree discriminated between patient groups as well as, or better than, the best imaging 
or CSF biomarkers or cognitive tests. Optimal sets of markers for the prediction of 12-month 
decline were then determined using machine learning algorithms, and performance of the 
derived cognitive marker was found to be comparable with, or better than, other individual 
or composite baseline CSF or neuroimaging biomarkers. The authors suggest that the 
ADAS.Tree might prove more widely applicable than expensive and/or invasive imaging or 
CSF biomarkers.
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Tractenberg et al [246] presented an alternative method for quantitating neuropsychological 
decline using inter-individual variability in cognitive testing. They found that this approach 
resulted in similar effect sizes to the total scores of MMSE and Clock Drawing test for 
discriminating between both controls and AD, and MCI and AD patients. The authors 
suggested that this may be a useful addition for measuring neuropsychological performance 
that is reflective of underlying neurobiology. Measuring cognitive decline in longitudinal 
studies often requires using different versions of the same test that are assumed to be 
equivalent. Gross et al [403] compared three equating methods—mean, linear, and 
equipercentile—for testing equivalence of alternative versions of the AVLT used in ADNI. 
They found that the equipercentile method performed best as it accommodated tests more 
difficult than the reference test at different percentiles of performance and adjusted for retest 
effects in models of within-person change.
3.3.4. Combined modalities—The new machine learning algorithm of Hinrichs et al 
[88], which uses data from both MR and FDG-PET images, integrates a spatial 
discrimination step to identify AD-related patterns in different brain regions, rather than 
assessing these relationships at the pre- or postprocessing steps.
The development of a panoply of multimodal classifiers that leverage information from 
imaging, biological and neuropsychological sources has been a major focus of ADNI papers 
published in 2011–2012. Likewise, the selection of features that are most ‘AD-like’ across 
multiple modalities is a critical step in constructing an accurate classifier and new 
approaches to this step have been reported in a number of papers. Hinrichs et al. [247] 
developed a method based on the Multi-Kernel Learning framework to produce a classifier 
that, in addition to classifying control and AD patients, also produced a Multi-Modality 
Disease Marker (MMDM) that could be used for the prediction of MCI to AD conversion. 
The method leveraged information from FDG-PET and MR scans and the authors reported 
that this method consistently outperformed a similarly trained SVM using the ADNI data 
set. An alternative method for AD classification that uses a non-negative matrix factorization 
for feature selection in combination with SVMs with bounds of confidence for classification 
was reported by Padilla et al[248]. The authors found that this method was an accurate tool 
for classifying AD patients from a combination of SPECT and PET data. Zhang et al [249] 
reported the first work to combine not only imaging but also biological data in the form of 
levels of CSF biomarkers into multi-modal classifier. They used a linear SVM with an 
intrinsic feature selection mechanism to rank top features of 93 ROIs (MR or FDG-PET) and 
CSF biomarkers were added directly as features. This method achieved high classification 
accuracy.
The next step in utilizing these classifiers is to determine their effectiveness in the prediction 
of future cognitive decline in addition to classification problems. Combining MR, FDG-PET 
and CSF data is again the focus of a later paper by Zhang et al[250] who presented a 
method, multi-modal multi-task (M3T), that uses this disparate data to estimate both 
continuous variables, such as scores on neuropsychological tests (MMSE, ADAS-cog), by 
regression and a categorical variable (classification class). M3T combines a multi-task 
feature selection with a multi-modal SVM that fuses selected features for regression and 
classification. They found that M3T was more effective than a concatenation method of 
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combining features in both classification and prediction of future clinical scores and 
comparable to other reported prediction methods such as that described by Misra et al [118]. 
To account for the fact that brain structures in imaging data are interconnected, Wang et al 
[251] proposed the Sparse Multi-task Regression and Feature Selection (SMART) method 
that jointly analyzed all imaging and clinical data using a single regression model with 
sparse multi-task learning, and found that this method was an improvement on multi-variate 
regression when used to predict decline in AVLT scores.
In 2012 and 2013, there has been substantial improvement in the accuracy and 
computational efficiency of methods that use multimodal data. A modification by Liu et al 
[404] of M3T learning [25] tried to preserve complementary information between modalities 
by introducing a new constraint after treating the selection of features from each modality as 
a task. A further paper by the same group [392] describes a novel multiple kernel learning 
framework that improves on by the method of Zhang et al using Fourier transform 
approaches to approximate Gaussian kernels and reduce learning complexity to a linear 
scale. They used group Lasso regularization to enforce sparsity in the different modalities. 
The tree-based random forests algorithm was used by Gray et al [405] to derive consistent 
pairwise similarity measures from multiple modalities. The resulting embedding 
simultaneously encoded information on all features for multimodal classification. To 
combine data from both high- and low-dimensional modalities, Singh et al [406] used a 
partial least squares approach to allow the weighted fusion of these data and then achieved 
optimum classification accuracy using a quadratic discriminant analysis.
The prediction of continuous variables such as clinical scores has also received additional 
attention. Cheng et al [407] used a semisupervised multimodal relevance vector regression to 
predict MMSE and ADAS-cog scores of MCI patients. In a similar manner, Zhou et al [407] 
attempted to predict the scores over 4 years from baseline MRI data. The prediction of each 
time point (6, 12, 18, 24 months) was considered as a separate task, and the authors used two 
novel Lasso-based multitask regression formulations and longitudinal stability selection to 
identify patterns of biomarker change through disease progression. A similar method, 
temporally constrained group Lasso (tgLasso) used longitudinal data to predict clinical 
scores [394]. TgLasso trains a linear regression model and uses group regularization to 
group together weights corresponding to the same brain regions at different time points. 
When the model was used to predict clinical scores from longitudinal ADNI data, it 
outperformed other Lasso-based methods.
A number of studies have focused on using multimodal data to predict MCI to AD 
conversion. Young et al [408] made this prediction using a Gaussian process classification 
that integrates multimodal data in a probabilistic manner and reported that their method 
integrated multimodal data more efficiently than SVMs. Cheng et al [409] leveraged 
imaging and biomarker data from patient groups to discriminate between MCI converters 
and nonconverters. Their method, domain transfer SVM classification, uses auxiliary 
domain data combined with a modified SVM to help infuse domain knowledge. Yu et al 
[410] used a Bayesian classifier to determine which combinations of structural MRI, FDG-
PET, and CSF biomarker measures, along with APOE genotype and cognitive scores, most 
accurately predicted progression from amnestic MCI to AD within 2 years. Overall, 
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structural MRI measures were found to be the most predictive (78% accuracy), and a 
combination of MRI, genotype, and cognitive scores was found to provide the best trade-off 
between trial cost and time, in the context of clinical trial enrichment.
A multimodal approach reported by Casanova et al [411] distills information from multiple 
indices into a single index representative of the degree of AD-like features, the AD Pattern 
and Similarity (AD-PS) score. This method differs from scores such as STAND and SPARE-
AD, which use an SVM, in that it uses logistic regression with sparsity regularization 
combined with feature selection and dimensionality reduction techniques. The probabilistic 
model creates a hypercube in which each dimension represents a range from normal to AD 
characteristics of a component such as GM, WM, CSF, and cognitive score. The AD-PS 
score of an individual is determined by their position in the hypercube (Fig. 32). The AD-PS 
score can then be analyzed directly using an index-based receiver operational characteristic 
(ROC). An alternative to this is described by Wu et al [412] who constructed a multivariate 
ROC that directly incorporated information from multiple indices.
With the development of multimodal classification and prediction, it has become 
increasingly recognized that the incompleteness of data can be problematic in these 
approaches. For example, in the ADNI data set, there are half as many controls as AD cases 
with proteomic measurements, but 40% more control cases than AD cases with MRI 
measurements [413]. An assumption of most longitudinal studies is that missing data is 
random. Lo et al [414] used univariate and multivariate approaches to examine associations 
between baseline demographic and clinical features and loss of data at follow-ups for CSF 
biomarkers and found that the missingness of data was nonrandom but tended to be 
blockwise and predictable. Yuan et al [415] described an incomplete Multi-Source Feature 
(iMSF) learning model, which initially partitioned patients into disjoint groups possessing 
the same data source combinations. They then applied independent feature learning for each 
group before combining results from all groups and found that this method was an 
improvement over other missing value estimation methods and over single modality 
classification alone. However, this model was not able to discern the most relevant data 
sources or provide a consistent prediction model for a specific data source across groups. 
Xiang et al [416] proposed a new bi-level multisource learning framework (incomplete 
source feature selection [iSFS]) that unifies feature- and source-level information and avoids 
the direct imputation of missing data, instead presenting efficient algorithms for calculating 
the missing data.
One impact of missing or imbalanced data on classification performance is that they achieve 
a much lower sensitivity and specificity. Dubey et al [413] examined this problem by testing 
a variety of sampling approaches, six feature reduction techniques, and two classifiers and 
by determining the optimum ensemble of these techniques for classification accuracy and 
balance of sensitivity and specificity. They demonstrated that the K-Medoid under sampling 
approach was superior to other data resampling techniques. In combination with sparse 
logistic regression with stability selection, it yielded competitive results with both an SVM 
classifier and a tree-based random forest algorithm using both MRI data and proteomic data 
separately. This comprehensive study outlines promising methodology to aid other 
researchers in improving classification performance using ADNI data.
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For methods based on combined modalities to ultimately be useful in a clinical setting, they 
must present patient data clearly to aid in the physician’s diagnosis and ideally help reduce 
diagnostic errors. Mattila et al [252] and Soininen [253] created a diagnostic decision 
support system by representing cognitive, imaging, biological and genetic data in a graphical 
form termed a Disease State Fingerprint (DSF), as well as statistically distilling a score, the 
Disease State Index (DSI), that reflects the likelihood of a patient having AD (Fig. 26). The 
DSI can be used for both diagnostic classification and prediction of future decline. The 
PredictAD tool developed by this group has been further evaluated. This software increased 
classification accuracy over clinicians provided with test results directly in paper form and 
improved inter-rater agreement and the rater’s confidence in their decision [417]. Liu et al 
[418] examined the efficacy of PredictAD software in predicting AD conversion within 3 
years in comparison with currently recommended criteria for prodromal AD: episodic 
memory impairment, visual assessment of medial temporal atrophy, and abnormal CSF 
biomarkers. They found that the software significantly outperformed these criteria and were 
equally effective with the aid of clinician. Both papers provide further support for the utility 
of software that can integrate heterogeneous data and provide objective, evidence-based 
information on the state of the patient that is not limited to binary classification. Escudero et 
al [419] created a similar metric to the Disease State Index using an unsupervised K-means 
machine learning technique. The bioprofile was characteristic of the disease and predictive 
of MCI to AD progression, whereas individual bioindices measured the closeness of an 
individual’s data pattern to the profile.
An overarching consideration in the clinical setting is cost as many of the current biomarker 
tests are expensive to perform. Today’s health care environment requires biomarker tests that 
are maximally informative but minimally expensive. Escudero et al [420] proposed an 
approach to minimize the number of biomarkers required for diagnosis. This personalized 
and iterative approach initially attempts to classify the patient by comparison of available 
variables with data from a pool of local diagnosed patients. If this classification is below a 
threshold value of confidence, the method then selects a biomarker test that either minimizes 
the number of biomarkers required or maximizes cost-effectiveness.
3.5.5. Blood-based biomarkers—The identification of a blood-based biomarker for AD 
has been the goal of researchers for many years [254] and AD-NI’s extensive collection of 
biological specimens provides an ideal testing ground for new methods developed to this end 
[255]. The improved precision performance of a robotized version of the multiplex xMAP 
INNO-BIA plasma Aβ immunoassay for measurement of Aβ1–40 and Aβ1–42 in a 
longitudinal study of ADNI study subjects was described by Figurski et al [256]. Using this 
method in a longitudinal study of complementary measures of Aβ pathology (PiB, CSF and 
plasma Aβ) and other biomarkers in the ADNI cohort, Toledo et al [257] correlated baseline 
Aβ1–40 and Aβ1–42 plasma measurements in 205 cognitively normal subjects (CN), 348 
patients with MCI and 162 with AD with PiB PET, MRI, and CSF tau and Aβ1–42 
measures. Plasma Aβ1–42 levels were mildly correlated with other biomarkers of Aβ 
pathology and were associated with infarctions in MRI. They were also related to baseline 
and longitudinal diagnoses in addition to a number of health conditions. Longitudinal 
measurement of Aβ1–40 and Aβ1–42 plasma levels showed modest value as a prognostic 
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factor for clinical progression, suggesting that plasma Aβ measurements have limited value 
for disease classification and prediction over the three year follow-up. However, with longer 
follow-up, within subject plasma Aβ measurements could be used as a simple and minimally 
invasive screen to identify those at increased risk for AD. This study and a recent review 
[258] emphasized the need for a better understanding of the biology and dynamics of plasma 
Aβ as well as for longer term studies to determine the clinical utility of measuring plasma 
Aβ. Finally, Soares et al [259] recently reported a study conducted in collaboration with 
Biomarkers Consortium Alzheimer’s Disease Plasma Proteomics Project that sought to 
develop a blood-based test as a screen for AD for early intervention. A multiplex 
immunoassay panel was used to identify plasma biomarkers of AD using ADNI plasma 
samples at baseline and at 1 year. These were analyzed from 396 (345 at 1 year) patients 
with MCI, 112 (97 at 1 year) patients with AD, and 58 (54 at 1 year) healthy control 
subjects. Multivariate and univariate statistical analyses across diagnostic groups and relative 
to the APOE genotype revealed increased levels of eotaxin 3, pancreatic polypeptide, and N-
terminal protein B-type brain natriuretic peptide in MCI and AD patients, paralleling 
changes reported in CSF samples. Increases in tenascin C levels and decreases in IgM and 
ApoE levels were also observed. All participants with APOE ε 3/ ε 4 or ε 4/ ε 4 alleles 
showed a distinct biochemical profile characterized by low C-reactive protein and ApoE 
levels and by high cortisol, interleukin 13, apolipoprotein B, and gamma interferon levels. 
The use of plasma biomarkers improved specificity in differentiating patients with AD from 
controls, supporting the potential usefulness of these analytes as a screening tool. These 
studies have been extended by comparing the ADNI dataset with similar data obtained from 
ADNI independent cohorts followed at the University of Pennsylvania and Washington 
University as described by Hu et al [260]. This study used the same targeted proteomic 
approach described above and measured levels of 190 plasma proteins and peptides in 600 
participants from two independent. 17 analytes were identified as being associated with the 
diagnosis of very mild dementia/MCI or AD. Four analytes (ApoE, B-type natriuretic 
peptide, C-reactive protein, pancreatic polypeptide) were also found to be altered in clinical 
MCI/AD in the ADNI cohort (n = 566). Regression analysis showed CSF Aβ42 levels and t-
tau/Aβ42 ratios to correlate with the number of APOE ε /4 alleles and plasma levels of B-
type natriuretic peptide and pancreatic polypeptide. Notably, 4 plasma analytes were 
consistently associated with the diagnosis of very mild dementia/MCI/AD in these 3 
independent clinical cohorts, but further studies are need to determine if these plasma 
biomarkers may predict underlying AD through their association with CSF AD biomarkers.
Most studies have examined either serum or plasma for potential biomarkers, but not both. 
O’Bryant et al [255] sought to identify blood-based markers that were highly correlated 
across both plasma and serum and to construct a classifier using them. They found 11 
suitable proteins, including C-reactive protein, factor VIII, fatty acid binding protein and 
adiponectin, and tested the classifier using ADNI biological samples.
In 2012 and 2013, the investigation of blood- and plasma-based biomarkers as a less invasive 
and therefore more clinically useful tool for AD diagnosis has continued to produce 
promising results. A blood-based panel of analytes identified from the AIBL study and 
validated in the ADNI cohort [421] identified biomarkers that overlapped biomarkers 
selected in studies by O’Bryant et al [255] and Soares et al [259]. Llano et al [422] used 
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multivariate analysis to identify from a panel of 146 plasma analytes four proteomic 
signatures able to discriminate between AD and control patients. Associations between a 
panel of plasma analytes and amyloid burden as assessed by PiB-PET were investigated by 
Kiddle et al [423] who found a set of 13 analytes that along with the covariates age, APOE 
status, gender and education accounted for more than 30% of amyloid burden. This was 
more than double that of covariates alone, suggesting that these analytes reflect amyloid 
burden. Similarly, Burnham et al [424] selected five analytes in addition to APOE status, 
age, and CDR-SB scores to construct a blood-based biomarker signature able to predict 
amyloid burden. The most frequently reported analytes from these studies that are associated 
with diagnostic status are pancreatic polypeptide, brain natriuretic peptide, C-reactive 
protein, vascular cell adhesion molecule-1, α2-microglobulin, tenascin-C, and lymphocyte 
secreted protein B, and those most commonly associated with increased amyloid load are 
cortisol and interleukin 15. Panels of these analytes have been shown to classify AD patients 
with similar accuracy to other more established methods (Section 4.5.5) and therefore have 
exciting clinical potential.
3.4. Other imaging methods
Rousseau [97] presented a method for generating a high-resolution image from a low-
resolution input, using jointly one low-resolution image and intermodality priors from 
another high-resolution image to create a super-resolution framework, for instance, a high-
resolution T1-weighted image and a low-resolution T2-weighted image from the same 
patient. The method, when tested on clinical images from ADNI data, automatically 
generated high-resolution images from low-resolution input, and the authors suggest that this 
method may permit the investigation of multimodal imaging at high resolution.
The problem of representing a high dimensionality of brain images amassed in common 
neuroimaging applications was tackled by Gerber et al [98], who proposed that these images 
can be approximated by a low-dimensional, nonlinear manifold representative of variability 
in brain anatomy. They constructed a generative manifold model through kernel regression 
and tested this using ADNI data, and their finding was that important clinical trends were 
captured by this manifold when learned manifold coordinates and clinical parameters were 
subjected to analysis by linear regression.
3.5. Statistical methods
Interpretation of imaging data is a key facet in the process of extracting meaningful 
information from these scans. As the volume of neuroimaging data generated by ADNI 
studies burgeons, there is an obvious need for more sophisticated analysis techniques. 
Habeck and Stern [99] reviewed advances in multivariate analysis techniques that are being 
developed to supersede the more commonly used univariate, voxel-by-voxel analysis of 
imaging data. By evaluating the correlation or covariance of activation across brain regions, 
these multivariate techniques produce results that can be interpreted as neural networks, 
thereby addressing brain functional connectivity. Habeck and Stern [99] directed this review 
specifically at neuroscientists to explain the “bewildering variety of (multivariate) 
approaches …presented…typically by people with mathematics backgrounds.” In an effort 
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to further spread the word to neuroscientists about this technique, a video article is also 
available [100].
Wu et al [101] presented a method to assess the reliability of hypometabolic voxels during 
the statistical inference stage of analysis. The aim of this method was to incorporate the 
differential involvement of each voxel into the multiple comparison correction, as opposed 
to current methods in which each location is treated equally. They used statistical parametric 
mapping and bootstrap resampling to create a bootstrap-based reliability index and 
compared this approach with the commonly used type I error approach, and found a strong, 
but nonlinear, association between the two methods. The authors suggest that this approach 
could have utility in both cross-sectional and longitudinal studies, in the early detection of 
AD, and in tracking disease progression in clinical trials.
A method to control for the effects of confounding variables was described by Dukart et al 
[261] and applied to the problem of controlling for the effects of age in group comparisons. 
Using a linear detrending model in terms of the general linear model, the method is able to 
control for the effects of age between groups of subjects. The application of this correction 
to either SVM classification or to the detection of disease-related GM using VBM in AD 
patients who differed in age from control subjects resulted in substantial gains in accuracy.
Singh et al [102] presented a new method to relate complex anatomical changes observed in 
AD patients with changes in cognition based on a statistical analysis of large deformation 
diffeomorphic metric mapping. In this method, the diffeomorphic transformations were 
analyzed using a multivariate and partial least squares approach without segmentation or the 
use of a priori defined ROIs. They found that this approach associated ventricular expansion, 
cortical thinning, and hippocampal atrophy with worsening scores on neuropsychological 
variables such as ADAS-cog, Rey Auditory Verbal Learning Test (AVLT), and clinical 
dementia rating-sum of boxes (CDR-SB), confirming that this data-driven approach was able 
to reach similar conclusions as other studies based on predefined ROIs [261,262].
The selection of MCI patients likely to progress for clinical trials is made more challenging 
by well-recognized heterogeneity of the MCI construct. Tatsuoka et al [425] proposed an 
alternative approach for analyzing the neuropsychiatric tests given to MCI patients based on 
the statistical method of partially ordered set (poset) models. Poset models in this instance 
allow direct links to be established between a specific cognitive function and the risk of 
conversion to AD. When poset models were applied to baseline data of ADNI MCI patients, 
specific cognitive domains were correlated with conversion within 2 years.
Ziegler et al [426] present an overview of current statistical approaches for modeling age-
related structural brain decline and interindividual variations within this process. All 
analytical approaches are applicable to voxel- and surface-based whole brain MRI and 
include both parametric and nonparametric models. The focus of the overview is on 
estimating age trajectories of structural change and accounting for both nonlinear trajectories 
and differences in rates of change in specific regions.
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Genetic contributions to AD are being revealed by GWAS that search for associations 
between QTs in the form of imaging or biomarker data and genetic loci. The standard 
approach (mass univariate linear modeling), which compares each phenotype–genetic loci 
pair individually and then ranks the association in terms of significance, is extremely 
computing-intensive and can miss information from areas surrounding a particular 
association. Methods that boost power to detect genetic associations and therefore reduce 
sample sizes are considered necessary for replicable genetics results. Vounou et al [103] 
proposed a new method, sparse reduced rank regression, which overcomes these problems 
by enforcing sparsity of regression. They found sparse reduced rank regression to be less 
computing-intensive and to have better power to detect deleterious genetic variants than 
mass univariate linear modeling. Kohannim et al [427] reported a similar approach that used 
Lasso regression for dimensionality reduction of a multivariate GWAS investigating gene 
effects on temporal lobe volume. This gene-centric approach jointly considers groups of 
genetic variants that are correlated through a sparsity-driven LI penalty and associates them 
jointly in partial F tests with the MRI-derived temporal lobe volume measure. It identified 
more genes and at higher significance than traditional univariate methods. An alternative 
approach to reducing computational requirements, while retaining a high degree of 
significance to AD, has been presented by Chen et al [104], who used each of 142 
preselected imaging ROIs as QTs in a GWAS. Heat maps and hierarchical mapping were 
then used to organize and visualize results and to select target SNPs, QTs, or associations for 
further analysis.
Meda et al [263] presented a method for multivariate analysis of GWAS data based on the 
premise that genetic determinants are not randomly distributed throughout the genome, but 
tend to cluster in specific biological processes related to AD. Their method used a parallel 
ICA and a hypothesis-free, data-driven statistical technique to simultaneously examine 
multiple modalities. They found that the parallel ICA was effective on the large sample, 
sizes in ADNI and that it identified clusters of SNPs potentially related in different 
metabolic pathways associated with AD. Similarly, to address the issue of underlying 
interactions between SNPs and QTs such as imaging data, Wang et al [264] developed a 
novel method, Group-Sparse Multi-task Regression and Feature selection (G-SMuRFS) that 
is built on multivariate regression analysis with a new form of regularization. Application of 
the method using the ADNI data-set demonstrated its ability to predict continuous responses 
of brain imaging measures and to select relevant SNPs in a more efficient manner than 
conventional multivariate linear regression. Univariate and multivariate genetic analysis 
techniques and sparse regression methods aimed at reducing the dimensionality of imaging 
and genomics domains are reviewed by Shen et al [428].
In addition to computational challenges, imaging genetics studies with multiple testing are 
also prone to false-positive results, and both familywise error and false discovery rate 
corrections are used to adjust significance thresholds across multiple voxels. Silver et al 
[105] measured false-positive rates using VBM to investigate the effect of 700 null SNPs on 
GM volume in the ADNI cohort. They found that although false-positive rates were 
generally found to be well controlled, under certain conditions, such as under low cluster-
Weiner et al. Page 40













forming thresholds, the false-positive rates were substantially elevated. Consequently, they 
proposed the use of parametric random field theory cluster size inference and alternative 
nonparametric methods under different circumstances.
3.7. Methods for Clinical Trials
ADNI data has recently been utilized to test methods for improving clinical trials of 
compounds with the potential to attenuate the progression of AD. These are commonly 
designed as long-term, randomized, placebo-controlled trials (RPCTs), which present the 
problem of whether the exposure of pre-symptomatic AD patients to placebos long term is 
ethical. Spiegel et al [265] proposed a method to overcome this ethical dilemma with a 
placebo group simulation approach (PGSA) which involved construction of univariate and 
multivariate models based on baseline data of MCI patients in ADNI. Gender, obesity, 
Functional Activities Questionnaire (FAQ), MMSE, ADAS-cog and Neuropsychological 
Battery scores were used to predict ADAS-cog scores after 24 months and models 
corresponded closely to real observed values (R2 = .63, residual S.D = 0.67). These results 
suggest that the PGSA approach has the potential to complement future RCPTs for AD 
drugs. Another issue with RCPTs is the selection of a primary end-point, which is often 
either time-to-event (for example, progression to dementia) or a continuous measure of 
disease severity such as ADAS-cog to assess the effect of the treatment. Donohue et al[266] 
compared the power to detect an effect of these two methods by using Cox proportional 
hazard models to estimate time-to endpoint, and linear mixed models to estimate continuous 
variables and found that linear models consistently demonstrated greater power than Cox 
proportional hazard models when tested on the ADNI data-set (Fig. 27). The authors 
concluded that linear models may be more robust and appropriate for the detection of MCI 
to AD progression in clinical trials of MCI patients.
3.8. Methods papers: Summary and conclusions
Papers focused on method development have been instrumental in facilitating ADNI 
research thus far and promise to deliver improvements in reliability, efficiency, and 
effectiveness in ADNI-GO and ADNI-2. The establishment of standardized protocols that 
account for problems of variability, both across the multicenter setting of ADNI and 
longitudinally, has been a primary accomplishment. Likewise, the development of methods 
for automatic tissue registration and segmentation that avoid the necessity of time-
consuming and costly manual segmentation is critical for the analysis of ADNI data. The 
majority of these approaches are atlas-based, although statistically based registration has 
also been proposed. Automatic segmentation of the hippocampus, a prominent AD 
biomarker, poses particular challenges because of its size and location, and several studies 
have made contributions to the analysis of its volume, shape, and pose. TBM and DBM 
methods and fractal approaches offer an alternative to volumetric ROI analysis. Methods to 
allow the classification of patients according to disease status have primarily been based on 
SVMs and the related RVMs, which are used to build classifiers that can include MRI, FDG-
PET, biomarker, APOE ε4, and cognitive data. Finally, statistical methods have been 
developed to deal with the complexities of the volume and diverse types of data generated by 
ADNI studies.
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In the 2011–2012 year, focus has shifted from the establishment of standardized protocols 
and methods for automatic segmentation and registration of the hippocampus to other areas 
including extracting information from cortical thickness data and developing increasingly 
sophisticated and powerful classification methods that select and combine AD-like features 
from multiple modalities. Methods to predict future clinical decline have appeared, 
sometimes in conjunction with classifiers – ‘multi-tasking’ is a recent area of interest in 
methods development. Another trend has been the use of the ADNI data set, either images or 
biological materials, as a test set for approaches beyond the bounds of the original ADNI 
objectives, such as the development of blood-based biomarkers for AD. The importance of 
GWAS studies in unraveling the genetic contribution to AD is reflected in the publication of 
methods that capitalize on the underlying interconnectedness of genes with quantitative 
traits. Finally, finding solutions to ethical problems associated with RCPTs and increasing 
clinical trial efficiency have been the focus of two reports.
In 2012–2013, significant methodological advances have been made in the areas of MRI 
segmentation and Florbetapir imaging, multimodal classification, blood-based biomarkers, 
and genetics. In imaging, major advances include methods that address the four-dimensional 
segmentation challenges of longitudinal MRI studies and that leverage information 
contained within relationships between regions and in shape, rather than simple volumetric 
changes, and studies describing the use of Florbetapir radiotracer introduced into ADNI for 
amyloid imaging. Multimodal classification has largely evolved beyond identifying optimal 
combinations of modalities to finding the best way to combine them using feature selection 
methods and by maintaining data dimensionality. This research has also shifted away from 
binary disease classification toward probabilistic approaches that view AD as a continuum of 
disease and the prediction of MCI to AD conversion. The problem of missingness of data in 
the ADNI data set and its effect on classification accuracies has also been recognized. Some 
ADNI sections have proposed standardized data sets to circumvent these challenges. Blood- 
and plasma-based biomarker development has continued at an increasing rate, and this 
approach shows promise as a less-invasive first-screen clinical option. Software to aid 
clinicians in diagnosis and to optimize cost-effective use of biomarkers in a clinical 
environment has been developed and tested. Finally, genetics methods have progressed 
toward gene-centric approaches to reduce dimensionality.
4. Studies of the ADNI cohort
4.1. Clinical characterization
Central to achieving the goals of ADNI was the recruitment of a study population that 
mirrors cohorts used in MCI and mild AD trials. Petersen et al [106] presented a baseline 
and 12-month longitudinal clinical characterization of the ADNI cohort, comprising 229 
normal control subjects, 398 subjects with MCI, and 192 subjects with mild AD, and 
provided clear support for the success of ADNI in this regard. The demographic 
characteristics of the participant groups, given in Table 3, indicate that the cohort was mostly 
white and well educated, and that there were a high proportion of APOE ε4 carriers, 
consistent with populations recruited for clinical trials. At baseline, each study group 
differed significantly in a range of cognitive measures, with the MCI group intermediate 
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between the control and AD groups in measures of memory impairment and in levels of CSF 
biomarkers (Table 4). In contrast to AD subjects who were impaired in virtually all cognitive 
measures, MCI subjects were only mildly impaired in nonmemory cognitive measures. After 
12 months, 16.5% of MCI subjects had converted to AD, and a greater increase in the 
ADAS-cog was seen in the AD group compared with the MCI group. Little change was 
observed in control subjects. The study also found that baseline Aβ-42 levels were predictive 
of the progression of clinical measures over 12 months.
4.2. Medication use
Medication use among the ADNI cohort was investigated by Epstein et al [107]. They found 
a high rate of polypharmacy, with 85% of participants taking more than four medications, 
the average being eight (SD = 4). Moreover, 22% of participants reported taking one or more 
Beers list medications deemed to be potentially dangerous in the elderly population. The 
most common medications for symptomatic treatment of AD or MCI were the 
cholinesterase inhibitor donepezil and the N-methyl-D-aspartate partial receptor agonist 
memantine, which were frequently taken as a combination therapy. Despite the lack of FDA 
approval for use of these drugs to treat MCI, donepezil, memantine, and other 
cholinesterases were commonly used by MCI patients. Women, less educated, and more 
elderly participants were less likely to receive treatment. Schneider et al [108] focused on 
the use of cholinesterase inhibitors and memantine in the ADNI cohort. They found that 
44% of MCI patients and 85% of mild AD patients were treated with cholinesterase 
inhibitors, and that 11% of MCI patients and 46% of mild AD patients were treated with 
memantine. In both patient groups, use of these medications was associated with increased 
cognitive impairment at baseline, a higher rate of clinical decline over 2 years, and a more 
rapid progression to dementia in MCI patients. Cholinesterase inhibitors and memantine 
appeared to be more frequently prescribed to patients diagnosed as having MCI due to AD, 
despite a lack of evidence from clinical trials and lack of FDA approval for this treatment. 
The authors suggested that use of these medications may affect the interpretation of clinical 
trial outcomes. Medication has been implicated in an increased risk of falls in the elderly. 
Epstein et al [429] investigated the association between medications in mild MCI 
(memantine and cholinesterase inhibitors) and falls in the ADNI cohort. They found that the 
use of these medications increased the hazard of fall by approximately 63%.
4.3. Baseline and longitudinal studies of biomarker changes during disease progression
ADNI has afforded a unique opportunity to examine biomarker changes that occur during 
disease progression in a large, well-defined cohort. Using MRI, CSF, 11C-PiB PET, and 
FDG-PET data, cross-sectional and longitudinal studies focused either on evaluating spatial 
pattern and regional rates of atrophy or on characterizing biomarkers for varying disease 
stages have together resulted in a more detailed and coherent picture of this complex 
process.
4.3.1. Magnetic resonance imaging—A cross-sectional study by Fennema-Notestine et 
al [109] examined the feasibility of high-throughput image analysis to detect subtle brain 
structural changes in the early stages of AD. They further divided the MCI group, based on 
neuropsychological performance, into single-domain and multidomain groups, which they 
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proposed represented earlier and later stages in disease progression, respectively. Using 
comparisons of cortical thickness, they found a pattern of progressive atrophy from normal 
control subjects to single-domain MCI subjects, to multidomain MCI subjects, and finally to 
subjects with AD (Fig. 7). When ROIs were examined, they found that the regions that 
differed between the control group and the single-domain MCI group included not only the 
hippocampus and entorhinal cortex, which had the largest effect sizes, but also other 
temporal regions, the temporal horn of the lateral ventricle, rostral posterior cingulate, and 
several parietal and frontal regions. Relative to control subjects, multidomain MCI patients 
had greater differences in the same regions as well as in the lateral inferior, middle, and 
superior temporal gyri and fusiform cortices. Additional atrophy was seen in AD patients 
relative to control subjects in the inferior parietal, banks of the superior temporal sulcus, 
retrosplenial, and some frontal regions. Similar results were reported in a cross-sectional 
study by Karow et al [110], who found a pattern of atrophy spreading from the mesial 
temporal lobe in MCI patients to widespread areas in AD patients patients and by Asku et al 
[240] who differentiated between MCI converters and non-converters and found the most 
active areas of degeneration in converters tended to lie in the parietal and temporal cortex, 
whereas those areas discriminating between AD and control patients included occipital and 
frontal regions.
An emerging view of disease progression is that spatial patterns of structural changes are 
coordinated with distributed cognitive networks. Carmichael et al [430] identified data-
driven groupings of cortical regions that exhibited highly correlated rates of atrophy in 
amnestic MCI patients over 2 years. Conversion to AD was associated with groupings that 
included sections of the default-mode network and the prefrontal and medial-temporal 
structures, suggesting that multiple coherent modes of longitudinal brain atrophy may act 
simultaneously in the early stages of the AD pathologic process, with each grouping 
corresponding to a distinct biological substrate.
Fennema-Notestine et al [109] also explored the trajectories of change of ROIs over the 
course of the disease and found that although some regions, such as mesial temporal regions, 
exhibited a linear rate of atrophy through both MCI stages to AD, other regions, such as the 
lateral temporal middle gyrus, retrosplenial cortex, inferior parietal cortex, and rostral 
middle frontal cortex, exhibited accelerated atrophy later in the disease.
The idea that rates of change of atrophy are not uniform but vary by disease stage is 
supported by several studies. When MCI groups were classified according to subsequent 
clinical outcome, Leung et al [59] found higher rates of hippocampal atrophy in MCI-c than 
MCI-nc patients. McDonald et al [111] examined regional rates of neocortical atrophy in the 
ADNI cohort, dividing MCI subjects into two groups by their CDR-SB scores. The less 
impaired MCI group had CDR-SB scores of between 0.5 and 1.0, whereas the more 
impaired group had CDR-SB scores of between 1.5 and 2.5 (AD subjects had CDR-SB 
scores of >2.5). They found that over the course of disease progression, atrophy changed 
from the medial and inferior lateral temporal, inferior parietal, and posterior cingulate 
cortices initially, to the superior parietal, prefrontal, and lateral occipital cortices, and finally 
to the anterior cingulate cortex (Fig. 8). Moreover, the rates of change differed among the 
three groups. The least impaired MCI patients showed the greatest rates of atrophy in the 
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medial temporal cortex, whereas later in disease progression, rates of atrophy were higher in 
the prefrontal, parietal, and anterior regions. Similar patterns were found by several other 
groups using a range of MRI methods. Hua et al [112] and Leow et al [113] both used TBM 
to create 3-D maps of structural changes over 12 months. Risacher et al [114,115] examined 
a variety of structural MRI markers for their sensitivity to longitudinal change and clinical 
status using multiple methods, including VBM and ROIs, whereas Schuff et al [116] focused 
on changes in hippocampal volume, and McEvoy et al [117] calculated an atrophy score 
based on ROIs most associated with AD atrophy. A more recent comprehensive analysis of 
longitudinal ADNI MRI data by Leung et al [431] focused on global cerebral atrophy, 
hippocampal atrophy, and ventricular expansion over 6-month intervals to 3 years. They 
found expected between-group differences in atrophy rates and an acceleration of rates of 
ventricular enlargement in both MCI and AD patients of 0.27 and 0.88 mL/y, respectively. 
An acceleration of hippocampal atrophy rates in MCI patients of 0.22% was also observed, 
which appeared to be primarily driven by MCI patients who later converted to AD. This rate 
of acceleration is small compared with the actual rate of atrophy in MCI patients (around 
3.5%), suggesting that the transition to pathologic losses observed in AD occurs slowly. 
Collectively, these studies showed atrophy spreading from the MTL to the parietal, occipital, 
and frontal lobes over the course of the disease, with MCI patients, in general, having a more 
anatomically restricted AD-like pattern of change. MCI subjects who converted to AD 
within the time frame of the study (MCI-c) had a more AD-like pattern of atrophy, and 
nonconverters (MCI-nc) had a pattern more intermediate between control and AD subjects 
(Fig. 9). Several studies [114,115,118,119] divided the MCI group into those patients who 
converted to AD within a year and those who remained stable. Each group had distinct 
profiles when assessed using a score derived from patterns of structural abnormality, the 
future converters having mostly positive scores that reflected a largely AD-like pattern of 
brain atrophy. Conversely, the distribution of abnormality scores in the MCI-nc group was 
bimodal, reflecting the heterogeneity of this group that appears to contain some members 
who, with abnormality scores close to those of AD patients, are likely to convert in the near 
future.
The highest rates of change occurred in AD subjects and MCI-c patients in measures of 
hippocampal volume and entorhinal cortex thickness [115,120]. Schuff et al [121] found that 
atrophy was detectable at 6 months and accelerated with time to 12 months in MCI and AD 
subjects, with the highest rates of atrophy seen in AD patients (Fig. 10). Hua et al [120] used 
TBM to examine the effects of age and sex on atrophic rates and found that the atrophic 
rates of women were 1% to 1.5% higher than for men. They also observed a 1% increase in 
atrophic rate and a 2% increase in ventricular expansion for every 10-year decrease in age, 
with correlations strongest in the temporal lobe.
A different data-driven approach to determining the time course of brain volume changes in 
healthy elderly, MCI, and AD subjects without using a priori models was taken by Schuff et 
al [116]. Using generalized additive models to analyze serial MRI scans over 30 months, 
they found that atrophy rates varied nonlinearly with age and cognitive status, most 
noticeably in temporal regions, and that atrophy tended to level off in control and MCI-nc 
subjects, but decline further in MCI-c and AD patients. The authors suggest that these 
differences are a reflection of the different processes involved in healthy versus disease-
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related neurodegeneration. The regions with the greatest effect sizes between young control 
and AD subjects were the entorhinal cortex, the hippocampus, and the lateral ventricles, 
suggesting that rates of change in these regions have potential as biomarkers for the early 
detection of AD.
Beyond simple volumetric analysis, one approach to analyzing brain morphometric changes 
in greater detail has been to assess changes in shape of ROIs. Qiu et al [122] used large 
deformation diffeomorphic metric mapping to reveal that the anterior of the hippocampus 
and the basolateral complex of the amygdala had the most surface inward deformation in 
MCI and AD patients, whereas the most surface outward deformation was found in the 
lateral ventricles (Fig. 11). These results are in agreement with the volumetric findings of 
Apostolova et al [123] and also with many findings documenting the enlargement of the 
lateral ventricles with disease progression. Greene et al [267] examined atrophy of sub-
regions of the hippocampus over time and found that the head appears to be initially affected 
followed by the body and tail of the structure. Cash et al [385] examined changes in cortical 
folding patterns throughout disease progression, using several metrics to represent the 
degree of cortical folding, curvature, and shape. Stable MCI, MCI-c, and AD patient groups 
had a progressively lower degree of cortical folding and a progressive reduction in the depth 
and area of sulcal folds, suggesting a widening and flattening of these areas due to 
neurodegeneration.
Disease progression appears to be influenced by other factors such as genotype, gender and 
age differences. The influence of the APOE ε 4 allele on GM loss in MCI patients was 
investigated by Spampinato et al [268] who found greater atrophy in a variety of regions 
including the hippocampus, temporal and parietal lobes and insulae in MCI converters who 
were carriers compared to non-converter carriers. GM loss was greatest in the first 12 
months, supporting the idea of non-linearity of atrophy throughout disease progression. 
Furthermore, they found no difference in cognitive decline between carriers and non-carriers 
of the APOE ε 4 allele, suggesting that accelerated hippocampal and neocortical atrophy did 
not completely account for the cognitive deterioration in this study. Skup et al [269] 
examined longitudinal atrophy in selected ROIs to look for sex-specific patterns of atrophy. 
They found that female MCI and AD patients differed from controls in right caudate nucleus 
atrophy, that between MCI and AD patients, there were female-specific differences in insula 
and amygdala atrophy and male specific differences in the atrophy of the left precuneus, and 
that sex differences tended to be bilateral in MCI patients and side-specific in those with 
AD. These results suggest that disease progression has gender differences that may be more 
widespread during the MCI stage. The question of whether disease progression is a set 
process over a range of ages was examined by Stricker et al [270] who compared changes in 
cognition and brain morphometry in the young old (ages 60–75) and the very old (ages > 80 
years) compared to age-matched controls. In the very old group, there was comparatively 
less atrophy in a number of regions and less impairment in a number of cognitive domains 
than in the young-old group, likely a reflection of normal age-related changes in the control 
group. Conversely, atrophy of the hippocampus and MTL substantially eclipsed these age-
related changes and remained salient markers of AD, regardless of age. Rates of clinical 
decline and brain atrophy decreased with age in controls, MCI patients, and AD patients but 
increased with age in the normal elderly [432]. Consequently, rates of change of many 
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measures converged at a point close to 85 years. Baseline clinical measures did not differ by 
age, implying that the association between neuropathologic markers and AD attenuates with 
age and that in the oldest old, AD can be difficult to distinguish from normal aging.
While aging is associated with cognitive decline, improvements in cognition are well 
documented in MCI and even mild-AD patients, suggesting that cognition in aging is a 
dynamic process. Song et al [433] studied changes in cognition (MMSE and ADAS-cog) 
and structural brain changes (brain and lesion index [BALI] and Medial Temporal Atrophy 
Score [MTAS]) over 2 years. Although cognition and brain structure declined overall, 
increases in both the BALI score and cognitive improvements were observed in some 
patients. Two-thirds of patients who showed structural improvement on BALI also showed 
cognitive improvement, and no MCI patient with structural improvement converted to AD. 
These results suggest that brain aging is a dynamic process in which improvements in both 
structural and cognitive aspects may be observed despite the fact that decline dominates 
overall.
4.3.2 CSF biomarkers—In the first longitudinal study of CSF biomarkers in ADNI 
cohort, Toledo et al [434] investigated biomarker dynamics and trajectories in controls, MCI 
patients, and AD patients for up to 4 years. The longitudinal stability of Aβ42, p-tau181, and 
t-tau varied in patients with normal baseline levels of biomarkers: one group had stable 
biomarker levels, whereas another had decreasing Aβ42 and increasing p-tau181 levels over 
time. When the stable population was excluded from analysis, the time taken to reach cut 
point levels of biomarkers was significantly shortened, with changes in p-tau181 occurring 
before changes in Aβ42. Furthermore, whereas low baseline Aβ42 predicted greater 
increases in p-tau181 levels, the converse was not true, implying that changes in Aβ42 levels 
precede those in p-tau181 levels (Fig. 33).
4.3.3. PET—Toussaint et al [399] identified hypometabolic patterns in the areas 
constituting the default mode network known to be involved in memory processing and 
found that these patterns evolve in a specific manner with disease progression. Leveraging 
newly differentiated EMCI and LMCI cohorts from ADNI-GO and ADNI-2, Wu et al [435] 
studied the dynamics of amyloid deposition and its relationship to glucose hypometabolism 
in MCI patients. AV45 retention increased from control to EMCI to LMCI groups in diffuse 
areas, but no further amyloid burden was detected in AD patients. In contrast, FDG-PET 
indicated that hypometabolism was essentially unchanged in EMCI patients compared with 
controls but then increased sequentially in LMCI and AD patients in a variety of regions. 
These observed dynamics are in accordance with the model by Jack et al [15].
4.3.4. Cognitive—Johnson et al [436] examined baseline and longitudinal change over 36 
months of five cognitive factors (memory, executive function/processing speed, language, 
attention, and visuospatial awareness) in control and MCI patients. In the cognitively normal 
elderly, memory was the sole measure observed to decline over the study period, whereas all 
measures declined in MCI patients. Interestingly, executive function declined more rapidly 
than memory in these patients suggesting that different patterns of cognitive change exist in 
MCI compared with normal cognition. Executive function may therefore play an important 
role in distinguishing MCI from cognitively normal patients.
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4.4. Associations between characteristics of the ADNI cohort
A major area of focus in research using ADNI data has been the elucidation, both at baseline 
and longitudinally, of associations between various imaging, CSF, genetic, and clinical 
correlates in different clinical groups to gain a better understanding of the interplay of 
biomarkers throughout disease progression.
4.4.1. Magnetic resonance imaging
4.4.1.1. Temporal lobe: Structures within the temporal lobe have long been associated with 
AD decline because of their critical role in the formation of long-term memory, one of the 
first functions to be affected in disease progression. Leow et al [113] found temporal lobe 
atrophy to be associated with increased cognitive impairment in MCI patients, as indicated 
by changes in CDR, MMSE scores, and the AVLT (Fig. 12). Among the structures of the 
temporal lobe, hippocampal atrophy is the best studied structural biomarker, as it is one of 
the earliest structures to degenerate in AD. In a small initial study, Morra et al [63] found 
that bilateral hippocampal atrophy at baseline was strongly correlated with both MMSE and 
CDR-SB (Table 5). A further larger study by the same group [124] examined rates of 
hippocampal atrophy over 12 months and found that these correlated with both baseline 
cognitive scores on MMSE and global and sum of boxes CDR and with longitudinal change 
in these measures (Table 5). Wolz et al [64] also revealed significant correlations between 
rates of hippocampal atrophy and both baseline MMSE and CDR, and changes in these 
measures over 12 months (Table 5). Additionally, a study by Schuff et al [121] found that 
rates of change of MMSE and ADAS-cog were associated with rates of hippocampal 
atrophy (Table 5). Using TBM, Hua et al [73] found that baseline temporal lobe atrophy was 
associated with both baseline and change in the CDR-SB in MCI and AD patients, but with 
change in the MMSE only in the AD group, providing further evidence for the acceleration 
of atrophic change with disease progression.
The relationships between hippocampal volume and memory retention were examined by 
Apostolova et al [123], who found that MCI patients had bilateral associations between 
hippocampal volume and radial distance and three tests of delayed recall (DR): ADAS-cog-
DR, AVLT-DR, and the Wechsler Logical Memory Test II-DR, whereas associations 
between these tests in AD patients were stronger in the left hippocampus both at baseline 
and at the 12-month follow-up (Table 5). In addition, they found highly significant regional 
associations for memory performance, especially in the CA-1 subregion and the subiculum 
on the anterior hippocampal surface. Greene et al [267] examined the relationship between 
subregions of the hippocampus and neuropsychological measures and atrophy in other 
regions. Most cognitive decline measures were correlated most strongly with the 
hippocampal head, a subregion that includes the histologically defined CA1 and CA3 
subfields (Table 5). With both cognitive and volumetric measures, the strength of association 
diminished from the head to the body to the tail of the hippocampus (Table 5). In cognitively 
normal participants, Carmichael et al [437] reported that localized atrophy in several 
hippocampal subregions, and not whole hippocampal atrophy, was significantly associated 
with CSF measures of Aβ and tau. In contrast, both total hippocampal volume and various 
subregional measures were significantly associated with a wide range of neurocognitive 
measures included in the ADNI neuropsychological battery. These results suggest that 
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amyloid and tau abnormalities may be associated with atrophy in specific regions of the 
hippocampus in asymptomatic patients, whereas changes in cognition occur later in disease 
and are related to overall volumetric changes in the hippocampus.
Associations between temporal lobe degeneration and memory performance (Wechsler 
Memory Scale-Revised—Logical Memory, immediate recall and DR) were also found by 
Hua et al [73].
Along with hippocampal atrophy, ventricular expansion is a hallmark of brain morphometric 
changes that occur during AD progression and has great potential as a structural biomarker, 
as the lateral ventricles are comparatively easy to measure, because of their high contrast 
under MRI, and are highly sensitive to disease progression. Evans et al [125] found that 
ventricular expansion differentiated between patient groups was associated with ADAS-cog 
scores in AD patients, and that MCI-c patients had higher rates of ventricular expansion than 
MCI-nc patients. Chou et al [126] automatically mapped ventricular geometry and examined 
correlations between surface morphology, clinical decline, and CSF biomarkers. They found 
that ventricular enlargement at baseline correlated with diagnostic group, depression 
severity, both baseline and rates of change of cognitive function (MMSE and CDR-SB), and 
lower CSF Aβ-42. In a subsequent study by the same group [127] using automated radial 
mapping to generate statistical maps, ventricular enlargement was found to correlate with a 
large number of measures of clinical decline as well as with lower levels of CSF Aβ-42 and 
the APOE ε4 allele (Fig. 13). Chou et al [126] also noted expansion of the posterior regions 
of the ventricles in MCI patients and in the frontal regions of the superior horns in AD 
patients compared with control subjects, suggesting a topographic sequence of 
morphometric change throughout disease progression.
The relationship between hippocampal atrophy and regional neocortical thinning was 
investigated by Desikan et al [163] who sought to determine whether disruptions to the 
medial temporal lobe and heteromodal association areas, shown to preferentially accumulate 
amyloid plaques and neurofibrillary tangles, contribute to a functional isolation of the 
hippocampus. In all patients, the strongest associations with hippocampal atrophy were with 
thinning of regions in the temporal lobe. However, additional associations were identified in 
control and MCI, but not AD patients within the occipital, frontal and parietal cortices.
The studies of Morra et al [124], Wolz et al [64], Hua et al [112], and Risacher et al [115] all 
found that carriers of the APOE ε4 allele had higher rates of hippocampal atrophy than 
noncarriers. In contrast, Schuff et al [121] found that increased rates of hippocampal atrophy 
were associated with APOE ε4 in the AD, but not MCI or control, group. Using Structural 
Abnormality Index (STAND) scores to reflect the overall level of AD-like anatomic features, 
Vemuri et al [128] also found that the APOE ε4 allele contributed to MRI atrophy. Hua et al 
[112] found that the APOE ε4 allele had a dose-dependent detrimental risk with greater 
atrophy in the hippocampus and temporal lobe in homozygotes than heterozygotes in MCI 
and AD groups (Fig. 13). Hostage et al [438] quantified the effect of the APOE ε 4 and 
APOE ε 2 alleles on hippocampal volume across the disease spectrum, reporting that the 
APOE ε 4 allele had a dose-dependent effect on MCI and AD patients equating to an 
approximate loss of 4% volume per allele below mean hippocampal volume. Cognitively 
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normal participants were unaffected and APOE ε 2 appeared to confer a modest protective 
effect.
The recently identified AD risk allele GRIN2b was associated with higher rates of temporal 
lobe atrophy in the pooled group, but more weakly than APOE ε4 [120]. Other thus far 
unidentified genetic risk factors likely contribute to AD, with epidemiological studies 
suggesting maternal history of the disease increases the risk of developing AD. Andrawis et 
al [129] examined the influence of maternal history of dementia on hippocampal atrophy 
and found smaller baseline and 12-month follow-up hippocampal volumes in MCI patients 
with maternal, but not paternal, history. APOE ε4-positive patients also had decreased 
hippocampal volumes, regardless of parental history. These results suggest the involvement 
of maternally inherited genetic material, encoded on either the X chromosome or 
mitochondrial genome. The latter may be more likely, given that decline in mitochondrial 
function has been found to lead to increased generation of reactive oxygen species, enhanced 
apoptosis, cell loss, and brain atrophy [129].
4.4.1.2. Other ROIs: Although the caudate has not been the subject of intensive AD 
research, it plays a crucial role in the formation of new associations required for the 
acquisition of explicit memories. Madsen et al [130] found that baseline caudate atrophy was 
associated with a number of clinical and biochemical measures, including, most strongly, 
body mass index (BMI), in the AD group alone and in the pooled sample, and CDR-SB and 
MMSE scores at baseline (Table 5). There appeared to be preferential right caudate atrophy 
in AD patients, and the authors proposed that caudate atrophy might function as a 
complementary biomarker to other structural measures. The inferior parietal lobe (IPL) is 
involved in sensory and motor association and possibly comprises part of the memory 
circuitry. Greene and Killiany [131] examined the associations between subregions of the 
IPL (gyrus, banks, and fundus) and cognitive measures in control, MCI, and AD subjects. 
They found that compared with control subjects, MCI patients differed only in the thickness 
of the banks of the left IPL, a change that correlated with decreased scores in the AVLT-DR, 
whereas AD patients had significant morphometric changes in all subregions of the right 
IPL. These results suggest a temporal sequence of changes during disease progression, with 
atrophy beginning in the left IPL and spreading to the right.
Like the IPL and caudate, the role of the amygdala in AD has received comparatively little 
attention despite postmortem evidence to suggest that atrophy is similar to that observed in 
the hippocampus. Poulin et al [271] found a similar degree of atrophy in both structures in 
patients with early AD. They also found that amydalal atrophy had a comparable association 
with decline in the MMSE but a weaker association with decline in the CDR-SB than 
hippocampal atrophy (Table 5), suggesting that cognitive changes in mild AD may be 
caused by atrophy of both these MTL structures.
4.4.1.3. Multiple ROIs and whole brain studies: Other MRI studies have used approaches 
based on the whole brain or multiple ROIs, rather than specific ROIs. Evans et al [125] 
examined brain atrophy rates using the brain BSI technique and found atrophy to be 
associated with MMSE and ADAS-cog scores in MCI and AD patients. Within the MCI 
group, they found greater rates of change, in a range similar to that observed in the AD 
Weiner et al. Page 50













group, in subjects who converted to AD within the time frame of the study. Stonnington et al 
[91] found that whole brain GM at baseline predicted baseline scores on the ADAS-cog and, 
MMSE, but not on the AVLT (Table 5). Similarly, Zhang et al [272] used the Brain and 
Lexion Index (BALI), a score summarizing brain structural changes in aging, to assess 
changes in cognition throughout disease progression and found that it correlated 
significantly with baseline MMSE (β = −0.310, P = .008) and 2 year follow-up MMSE (β = 
−0.725, P = .0010 and ADAS-cog scores at baseline (β = 0.612, P = .013) and at follow-up 
(β = 0.126, P = .003). The latter is a more specific test of memory, and the authors suggest 
that whole brain methods may be preferentially more highly sensitive to tests, unlike the 
AVLT, that involve diverse brain regions. Vemuri et al [132] used STAND scores as a 
measure of the degree of AD-like anatomic features to assess correlations between brain 
morphometric changes and cognitive scores, and found that STAND scores were highly 
correlated with CDR-SB and MMSE scores in individual groups and the pooled sample 
(Table 5). These studies lend support for atrophy of the whole brain or multiple ROIs as 
biomarkers, based on their ability to differentiate between patient groups and healthy control 
subjects, and to track disease progression and clinical decline.
In addition to memory loss, AD is commonly associated with other neuropsychiatric 
symptoms such as depression, apathy, agitation, and aggression. Trzepacz et al [439] 
reported that frontolimbic ROIs involved in the salience network were associated with 
greater severity of agitation and aggression in MCI and AD patients, suggesting that AD 
may disrupt behavioral control via modulation of this neural network. Zahodne et al [440] 
examined the associations between both apathy and depression and longitudinal regional 
cortical atrophy in MCI patients. Apathy was not predictive of longitudinal cortical atrophy, 
but depression was associated with both baseline entorhinal cortex thickness and increased 
longitudinal atrophy in the anterior cingulate cortex. These results are consistent with 
hypotheses regarding the relationship between depression and AD: either depression is 
indicative of increased neurodegeneration or depression lowers cognitive reserve, which in 
turn allows more rapid progression of AD neuropathology.
A measure derived from a multidimensional scaling method for quantifying shape 
differences using DBM [75] had a strong inverse correlation with the MMSE (r = −0.53), 
although the findings were limited by small sample size. Using the related method of TBM, 
Ho et al [133] created regional maps of changes in brain tissue and used the resulting 
Jacobian values to represent brain tissue excess or deficit relative to a template. They found 
that lower brain volume in the frontal, parietal, occipital, and temporal lobes was associated 
with higher BMI in MCI and AD patients, and that ventricular expansion correlated with 
higher BMI in AD, but not MCI, patients (Fig. 14). Every unit increase in BMI was 
associated with a 0.5% to 1.5% decrease in brain volume in patients of the ADNI cohort.
Elevated levels of homocysteine, a risk factor for AD, are associated with cortical and sub-
cortical atrophy and may promote the magnitude of atrophy in the brain. Rajagopalan et al 
[273] found that elevated homocysteine levels (> 14µM) was significantly associated with 
atrophy in frontal, parietal and occipital WM irrespective of disease status and in the MCI 
group alone, suggesting that Vitamin B supplements such as folate that reduce homocysteine 
concentrations may help prevent AD.
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4.4.1.4. White matter changes: In addition to the well-recognized Aβ plaque and tau fibril 
deposition considered to be emblematic of AD, there is increasing evidence that white 
matter abnormalities play a role in exacerbating cognitive problems. Although patients with 
high risk for cerebrovascular disease are excluded from study in ADNI, cardiovascular risk 
factors are consistently associated with cognitive decline and AD. Provenzano et al [441] 
found that higher white matter hyperintensity (WMH) volume, an indicator of 
cerebrovascular disease, was associated with AD diagnosis independent of amyloid 
deposition, providing support for the idea that white matter damage may provide a “second 
hit” required for clinical manifestation of AD symptoms. Guzman et al [442] reported that 
temporal lobe WMH volume was independently associated with entorhinal cortex volume to 
a greater extent than Aβ42 or p-tau181. Lo et al [443] also investigated whether the presence 
of WMHs was associated with established AD biomarkers. Baseline WMHs were not 
predictive of changes in CSF biomarkers, glucose metabolism, or hippocampal atrophy but 
were significantly associated with cognitive decline, particularly executive function. These 
results suggest that vascular disease may target different cognitive domains than AD-type 
pathology and thus may be an independent additive factor contributing to the disease. 
However diagnostic groups within ADNI share most vascular factors and rates of 
longitudinal cardiovascular events, suggesting that vascular factors may already have 
contributed to cognitive decline [444].
Changes in the white matter architecture have been modeled as structural brain networks, 
and changes in the functional connectivity over the course of the disease can be studied 
using diffusion tensor imaging (DTI) included in ADNI-2. A preliminary study found that 
network measures of baseline connectivity were predictive of future white matter changes 
[445], suggesting that less optimal baseline small-world architecture may be a useful 
biomarker in predicting WM changes in the prodromal phase of the disease. Widespread 
group differences between MCI and AD patients were also detected using DTI, with the 
greatest effect sizes in the left hippocampal cingulate and throughout the temporal lobe and 
posterior brain regions. White matter disruptions were associated with MMSE, ADAS-cog, 
and CDR-SB scores [446]. Rowley et al [447] measured both mean diffusivity and fractional 
anisotropy in patients with amnestic MCI, nonamnestic MCI, and AD. No difference in 
either measure was detected between nonamnestic MCI patients and cognitively normal 
controls. However, patients classified as amnestic MCI had around 28% white matter 
abnormality compared with the control group, and AD patients had reduced structural 
connectivity between the hippocampus and the temporal, inferior parietal, posterior 
cingulate, and frontal regions suggesting that white matter abnormalities in the advanced 
patients have a significant influence on connectivity.
4.4.2. Glucose metabolism
4.4.2.1. [18F]-fluorodeoxyglucose-positron emission tomography: FDG-PET has been 
used by several groups to investigate relationships between cerebral glucose 
hypometabolism and other factors, including cognitive measures and CSF biomarkers. 
Several papers confirmed that there is a characteristic regional pattern of hypometabolism in 
MCI and AD patients. Wu et al [101] found that hypometabolic voxels were associated with 
the posterior cingulate/precuneus and parietotemporal regions. Lower bilateral cerebral 
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metabolic rate for glucose (CMRgl) at baseline in these regions and in the frontal cortex was 
associated with higher CDR-SB and lower MMSE scores in MCI and AD groups [134] 
(Table 5). Although the pattern of hypometabolism was similar in the two groups, the 
magnitude and spatial extent were greater with increasing disease severity. In the AD group 
alone, however, lower MMSE correlated with lower left frontal and temporal CMRgl, 
suggesting that the characteristic pattern of baseline reductions in glucose metabolism shifts 
to the frontal cortex after the onset of dementia. Chen et al [104] investigated declines in 
CMRgl in statistically predefined ROIs associated with AD over 12 months in the ADNI 
cohort and found significant changes in MCI and AD groups compared with control subjects 
bilaterally in the posterior cingulate, medial and lateral parietal, medial and lateral temporal, 
frontal, and occipital cortices. These changes correlated with CDR-SB, but not ADAS-cog, 
scores in both groups, and with MMSE scores in the MCI group (Table 5). Habeck et al 
[448] used the recently developed psychometric composite score of ADNI-mem [449] to 
represent memory. Impaired memory in MCI patients was associated with reduced 
metabolism in regions of the parietal and temporal lobes, whereas memory deficits in AD 
patients were associated with hypometabolism in the frontal and orbitofrontal regions. The 
differential location of hypometabolism in relation to memory in MCI and AD groups 
suggests that frontal regions may play a role in compensating for memory as the disease 
progresses. Landau et al [135] found a greater decline in CMRgl in all a priori defined ROIs 
in AD patients and in a composite score of ROIs in MCI patients compared with control 
subjects. Longitudinal glucose decline was associated with concurrent ADAS-cog scores and 
decline on the Functional Activities Questionnaire (FAQ), validating the relevance of 
longitudinal measures of glucose metabolism to both cognitive and functional decline. The 
annual decline in the ADAS-cog and FAQ was greatest in AD patients, followed by the MCI 
and control groups, in accordance with an acceleration of the disease process over time 
(Table 5). FDG-PET and hippocampal volume, but not whole brain volume, were 
independently related to ADAS-cog as a measure of disease progression [450]. The 
independence of glucose metabolism from other biomarkers in its relationship with cognitive 
decline suggests that cognitive decline in MCI patients with reduced hippocampal volume 
but higher glucose metabolism may be delayed or reduced. The hypometabolism index 
reported by Chen et al [85] correlated with cognitive measures of disease severity, 
hippocampal volume, and CSF biomarkers (Table 5). These papers support the use of 
glucose metabolism as a sensitive measure of cognition in AD.
4.4.2.2. Arterial spin labeling: Arterial spin labeled (ASL) MRI is an imaging technique 
that reveals alterations in cerebral blood flow (CBF) and that has been shown to overlap with 
FDG-PET measures of hypometabolism. ASL can be performed at the same time as 
structural MRI, obviating the need for a separate FDG-PET scan with its attendant costs and 
exposure to radioactive tracer. ADNI-2 has added an ASL protocol to a portion of the cohort, 
presenting an opportunity to assess the utility of this method as a biomarker in a multicenter 
study. Wang et al [451] examined associations between ASL measures in ROIs previously 
determined to be most emblematic of AD in FDG-PET studies and hippocampal volume 
with disease severity as measured by CDR-SB. They found that mean meta-ROI CBF was 
associated with group status in a manner comparable to hippocampal volume. However, 
whereas hippocampal volume differences only reached significance between control and AD 
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groups, differences in CBF reached significance between control and LMCI groups. 
Regression analysis indicated that CBF and hippocampal volume provide complementary 
information regarding disease severity. The results suggest that CBF may be an effective 
biomarker for an equivalent point in disease progression to FDG-PET.
4.4.3. Cognitive
4.4.3.1. Association with imaging or CSF biomarkers: A number of studies have focused 
on the relationship between cognitive function and imaging or CSF biomarkers. Atrophic 
changes in the episodic memory network (Fig. 15), which is composed of MTL structures, 
medial and lateral parietal cortical areas, and prefrontal cortical areas and is involved in the 
formation of new episodic memories, are presumed to underlie ongoing memory loss in AD. 
Walhovd et al [136] studied how baseline brain morphometry and metabolism within the 
episodic memory network and APOE genotype predicted memory, as assessed by the AVLT. 
They found that in the total sample of the ADNI cohort, hippocampal volume and 
metabolism, parahippocampal thickness, and APOE genotype predicted recognition, 
whereas hippocampal volume and metabolism, cortical thickness of the precuneus, and 
inferior parietal metabolism predicted learning, suggesting that MTL structures are related to 
learning, recall, and recognition, whereas parietal structures are involved solely in learning 
(Table 5). The authors concluded that MRI and FDG-PET imaging have differential 
sensitivity to memory in AD and thus provide complementary information. Episodic 
memory likely involves a number of different cognitive processes, such as initial encoding, 
learning on repeated exposure, and DR, which may be subserved by disparate components 
of the episodic memory network. Wolk and Dickerson [137] investigated whether verbal 
episodic memory could be fractionated into dissociable anatomic regions in mild AD 
patients, using cortical thickness of predefined “AD signature” ROIs and hippocampal 
volume as structural measures and different stages of the AVLT as a verbal memory 
measure. They found that initial immediate recall trials were most significantly associated 
with the temporal pole region, but that regions in the MTL became more significantly 
associated in later trials. In tests of DR, only the hippocampus correlated with performance, 
whereas the perirhinal/entorhinal cortex was most strongly associated with delayed 
recognition discrimination. The authors concluded that their results lend support to models 
hypothesizing that dissociable brain regions are involved in differential episodic memory 
processes. Associations between memory learning and brain morphometry in the MTL were 
found in a study by Chang et al [138]. MCI patients were differentiated into learning-deficit 
and retention-deficit subgroups using the AVLT. Low memory retention was associated with 
changes in the medial temporal regions, particularly the hippocampus and entorhinal cortex, 
whereas low memory learning correlated with a more widespread pattern of morphometric 
changes beyond the temporal lobe, including areas of the frontal and parietal lobes (Table 5). 
While memory loss is a hallmark of AD, a subset of MCI patients is impaired primarily in 
their executive function. Dickerson and Wolk [139] identified dysexecutive and amnestic 
phenotypes in patients with MCI or very mild AD based on performance on the Trail 
Making Test and ADAS-cog subscale: Word recognition. They found that the memory-
impaired group had a more frequent occurrence of the APOE ε4 allele status than the 
dysexecutive group, and that patients with low executive function had thinner frontoparietal 
cortical regions and were more impaired in daily life than those with predominantly memory 
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impairment. A further study by Chang et al [140] found that MCI patients with high 
executive function performed better on tests of verbal memory than those with low executive 
function, and that morphometric measures of the two groups differed primarily in the 
dorsolateral prefrontal and posterior cingulate cortices, where more thinning was evident in 
low executive function patients (Table 5). Results from both studies suggest that the 
dysexecutive phenotype may reflect differences in underlying pathology in brain regions 
beyond the MTL.
4.4.3.2. Neuroanatomic regions and cognition: The ideas that different brains regions 
subserve different cognitive functions and that MCI is a heterogeneous construct led Wolk et 
al [141] to examine the influence of APOE genotype on memory and executive function in 
AD. When cortical thickness in predefined ROIs was examined in carriers and noncarriers of 
the APOE ε4 allele who had a CSF biomarker profile consistent with AD, carriers were 
more impaired in measures of memory retention and had greater atrophy in medial temporal 
regions, whereas noncarriers were more impaired in tests of executive function, working 
memory, and lexical access and had greater frontoparietal atrophy. The finding that 
neuroanatomic regions thought to subserve different cognitive processes are differentially 
affected by APOE ε4 allele status supports the hypothesis that this allele exerts its effect on 
AD by influencing different large-scale brain networks.
The question of whether domain-specific cognitive deficits in MCI are caused by global 
atrophy or progressive atrophy within specific regions was studied by McDonald et al [142], 
who examined 2-year regional atrophy rates in MCI patients. Stepwise regression models 
revealed that left entorhinal atrophy, left lateral lobe thinning, left temporal lobe atrophy, left 
frontal lobe atrophy rate, and the right MTL atrophy rate were associated with memory 
decline (Logical Memory II), naming decline (Boston Naming Test), semantic fluency 
decline (Category Fluency Test), executive function (Trail Making Test B; TMT-B), and 
clinical decline (CDR-SB), respectively (Table 5). Semantic memory impairment (Boston 
Naming Test) in mild AD cases was associated with anterior temporal lobe atrophy, with the 
strongest correlation being with the dorsal temporal pole [452]. These studies afford a 
glimpse into the specific structure– function relationships that occur early in disease 
progression and enhance our understanding of the neural basis of cognitive impairments.
An alternative method to individual cognitive tests and ROI approaches for studying brain 
structure-cognition relationships was reported by Nho et al [453]. They used recently 
reported psychometric composite scores of memory (ADNI-Mem [449]) and executive 
function (ADNI-Exec [454]) in concert with voxelwise and cortical thickness whole brain 
measures of brain atrophy. Across the ADNI cohort, they found strong positive associations 
between memory and temporal lobe atrophy, particularly hippocampal atrophy in the MCI 
and AD groups. Executive function was strongly associated with cortical thickness and GM 
density across large areas of the brain, particularly bilateral parietal and temporal lobes. 
After adjusting for memory and GM density/cortical thickness in the pooled sample, 
executive function was additionally related to frontal lobe GM density and cortical 
thickness. This study provides insight into brain changes associated with different cognitive 
processes involved.
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4.4.3.3. Functional decline: Although studies, such as those described previously, have 
focused on the relationship between brain atrophy, APOE ε4 status, and cognitive decline, 
relatively little is known about the biomarkers of functional decline, a hallmark of AD. 
Impairment of instrumental activities of daily living (IADL) such as driving, handling 
finances or preparing meals, leads to a greater burden on care-givers and institutionalization 
as the patient loses independence. A number of papers have focused on the prevalence of 
functional impairment, its rate of decline and its association with cerebral atrophy, other 
cognitive measures and biological biomarkers. Brown et al [274] examined IADL in MCI 
and AD patients and found that, despite a definition that does not include substantial 
impairment of daily function, MCI was associated with a high prevalence of IADLs; nearly 
three-quarters of MCI patients reported deficits in some items of the FAQ, a measure of the 
ability of patients to maintain daily function, compared to 97.4% of patients with AD and 
7.9% of cognitively normal controls. Functional impairment was also associated with 
deficits in memory, processing speed and atrophy of the hippocampus and entorhinal cortex. 
The rate of decline in the FAQ, a measure of the ability of patients to maintain daily 
function, and how it is affected by cerebral atrophy and APOE ε4 allele status, was studied 
by Okonkwo et al [143]. They found that AD patients had a higher rate of functional decline 
than control subjects, with the rate of MCI patients intermediate between the two. Moreover, 
MCI patients who subsequently progressed to dementia had higher rates of decline on the 
FAQ than stable MCI patients. Increasing ventricle-to-brain ratio, the measure of 
neurodegeneration chosen for the study, correlated with increased functional impairment in 
MCI patients. Those patients who were both APOE ε4-positive and had elevated ventricle-
to-brain ratio were the most functionally impaired. These results have shown 
neurodegeneration and APOE ε4 status to be associated with cognitive decline. Whereas the 
APOE ε 4 allele is detrimental to disease progression, the APOE ε 4 allele may have a 
protective effect. Bonner-Jackson et al [275] found that at 24 months, carriers of the APOE ε 
4 allele showed significantly less functional decline that non-carriers in the pooled ADNI 
cohort and that individual groups showed the same trend. This allele was also associated 
with better scores in composite measures of memory and executive function in the pooled 
sample, suggesting that the APOE ε 4 allele may slow the rate of functional decline as well 
as positively influence neurocognition.
Okonkwo et al [144] investigated the relationships between CSF biomarkers and everyday 
function, as assessed by the FAQ. They found that biomarkers were more sensitive to 
functional decline in control subjects and MCI patients than in AD patients, and that in the 
latter group, scores on the ADAS-cog were more highly correlated with functional activity. 
Combinations of tau and Aβ-42 abnormalities had the steepest rates of functional decline 
across clinical groups. The authors suggested that the effect of CSF abnormalities on 
functional decline is partially mediated by their effect on cognitive status. The relationship 
between functional impairment and amyloid burden as assessed by 11C-PiB PET imaging 
was subsequently investigated by Marshall et al [276] in control and MCI patients of the 
ADNI cohort. They found that increased cortical PiB retention was associated with greater 
IADL impairment in the pooled sample (r2 = 0.40, P = .0002) and in the MCI group (r2 = 
0.28, P = .003) and that poorer performance on FAQ was also associated with poorer 
performance in the AVLT and MMSE in all subjects. A companion paper by the same group 
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[277] examined the relationship between functional impairment and executive function in a 
longitudinal study of the ADNI cohort. Executive dysfunction was strongly correlated with 
IADL impairment across all subjects (r2 = 0.60, P < .0001). MCI patients with impaired 
executive function also had greater impairment of IADL than patients with no executive 
dysfunction, possibly representing a portion of the heterogeneous MCI construct more likely 
to progress to AD.
Depression may also influence functional decline. A study of the effect of subsyndromal 
symptoms of depression (SSDs) on functional ability of MCI patients [455] reported that 
these symptoms, present in 77% of this group, increased the risk of having poorer FAQ 
scores by 1.77-fold. However, although SSDs were associated with higher disability at 
baseline, they were not associated with longitudinal decline in FAQ scores or faster 
conversion to AD. The authors posited that treatment of SSD may therefore reduce the 
burden of disability in MCI patients but is unlikely to slow AD progression.
4.4.3.4. Other neuropsychiatric symptoms: A number of neuropsychiatric symptoms and 
apathy, anxiety, hallucinations, depression, and psychosis are associated with AD and are 
highly prevalent in the MCI population. Despite this, their association with functional 
impairment has not been fully evaluated. Wadsworth et al [456] found that baseline apathy, 
anxiety, and hallucinations were all significantly associated with functional impairment, as 
measured by CDR-SB scores. Hallucinations and apathy at baseline were also associated 
with functional impairment over time and increased the risk of MCI to AD conversion, 
suggesting that these symptoms may be predictive of current and future disease progression. 
Similarly, Ramakers et al [457] reported that anxiety, but not depression or apathy, was 
associated with abnormal levels of Aβ42, t-tau, and t-tau/Aβ42, supporting the idea that 
anxiety may be a result of underlying disease pathology in these MCI patients. Richard et al 
[458] focused on the association between apathy and disease progression, finding that 
symptoms of apathy alone, but not symptoms of depression alone or symptoms of apathy 
and depression together, increased the risk of conversion to AD within the study period. 
Therefore, apathy and depression may differ in their effects on cognitive decline. One 
distinct variant of AD is AD with psychosis, which is associated with more rapid functional 
decline related to frontal lobe impairments. Koppel et al [459] investigated associations 
between psychosis and glucose metabolism and found both a decline in orbitofrontal brain 
metabolism and an accelerated functional decline in patients with active psychosis.
4.4.3.5. Association of cognition with body mass index: In elderly populations, in addition 
to brain atrophy or genetic studies, BMI has been associated with cognitive decline. Cronk et 
al [145] examined the relationship between BMI and cognition in MCI patients and found 
that lower BMI at baseline was associated with a decline in the MMSE, ADAS-cog, and a 
global composite of the ADNI neuropsychological battery, but not with CDR-SB scores or 
conversion to AD. The causal relationships between BMI and cognitive decline in MCI 
remain to be elucidated, but the authors suggest either that low BMI is a result of factors 
associated with MCI or that MCI patients with low BMI are predisposed to more rapid 
disease progression.
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4.4.3.6. Cognitive reserve: The concept of the cognitive reserve describes the mind’s 
resilience to neuropathological changes in the brain and may account for the observed 
dissociation between AD pathology and cognition. Vemuri et al [278] investigated whether a 
measure of cognitive reserve, the American National Adult Reading Test (AMNART) 
modified the relationship between biomarkers of pathology and cognition in AD. In 
cognitively normal patients, they observed that the AMNART, but not CSF biomarkers or 
STAND scores correlated with cognitive measures (MMSE, ADAS-cog, AVLT-memory, 
Trails B and Boston Naming tests) whereas in MCI patients, all three were associated with 
cognitive performance in an additive manner. The authors propose a model (Fig. 28) in 
which cognitive reserve acts to shift curves of cognitive decline relative to biomarker 
trajectories over time; high cognitive reserve delays cognitive decline whereas low cognitive 
reserve results in an earlier cognitive decline. This evidence is consistent with the early 
increase in Aβ levels and subsequent later increase in cerebral atrophy in the disease 
progression model of Jack et al [14]. Further evidence that cognitive reserve buffers the 
effects of the disease comes from studies by Ewers et al [460] and Pillai et al [461]. In 
cognitively normal patients identified as having preclinical AD by the abnormal levels of 
Aβ42, higher education was associated with lower glucose metabolism in the posterior 
cingulate and angular gyrus [460]. Thus, education appeared to buffer cognitive function in 
the presence of AD pathology that impairs glucose metabolism. This supports the idea that 
cognitive reserve has a compensatory function that acts to preserve a clinical state despite 
more advanced pathology. Higher education was associated with lower, not higher, cortical 
thickness in selected areas [461]. In addition, Guo et al [462] reported that larger initial brain 
volumes, as measured by intracranial volume (ICV), were associated with reduced clinical 
deterioration in amnestic MCI patients and also with a lesser impact of APOE status. ICV 
did not impact the effect of APOE on atrophy progression or the rate of atrophy itself. These 
studies support the idea that the nature of this compensatory function is an improvement in 
connectivity rather than a passive reserve of increased neural substrate. Guo et al [462] 
proposed that the brain reserve confers protective effects earlier in the disease, but beyond a 
certain threshold of neurodegenerative burden, it is no longer advantageous.
4.4.3.7. The ADNI special issue of Brain Imaging and Behavior, 2012: A special issue of 
Brain Imaging and Behavior was published in 2012 focusing on cognition research within 
ADNI. Mungas et al [463] introduced papers that had been presented at the Advanced 
Psychometric Methods in Cognitive Aging Conference, in June 2011 at Friday Harbor, WA. 
These papers will be discussed individually in this review and fall into four primary groups. 
The first set of articles focused on the measurement of cognition and on improving 
reliability, sensitivity, and validity of measurements of different cognitive domains [449, 
454, 464, 465]. A second set examined neuroimaging-cognition relationships [448, 453, 
466], and a third set examined sequencing of biomarker and cognitive changes in relation to 
the model by Jack et al [14, 467, 468]. A final area examined genetic contributions to 
cognition using high-dimensional genetic data [469–471].
4.4.3.8. Psychometric analysis of cognitive tests: As cognitive testing plays such a critical 
role in ADNI, confidence that the tests used accurately reflect subject cognition is 
paramount. To this end, psychometric analysis has been applied to a number of cognitive 
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tests to assess the validity of test components and their combined performance. The ADAS-
cog plays a critical role in detecting clinical change in ADNI. However, as the test was 
originally developed for AD, its sensitivity to cognitive decline at the increasingly targeted 
earlier stages of the disease has not been fully explored. Posner et al [472] reviewed two 
critical papers by Hobart et al that use different analytical approaches to evaluate the 
performance of ADAS-cog in ADNI data. Using traditional psychometric methods, Hobart 
et al [473] found that 8 of 11 components of the ADAS-cog had a limited response 
distribution that may underestimate performance differences and therefore limit the 
usefulness of this test in detecting clinical change in mild MCI populations. Other 
weaknesses of the test were identified using Rasch measurement theory methods [474]: the 
range of cognitive performance in every cohort was not well matched to the range of scale 
(Fig. 34), and 6 of 11 components of scale were bunched instead of evenly spread out across 
the continuum. In addition, the validity of the way in which the 11 components were 
combined to create a simple variable was questioned given that the scale was not constructed 
on a specific definition of cognition. These analyses may provide a starting point for specific 
improvements to make the ADAS-cog better suited to its role in the upcoming early 
intervention clinical trials.
Crane et al [449] derived a single composite memory score from elements of the RAVLT, 
MMSE, and Logical Memory, and ADAS-cog tests firstly to address questions of equality of 
different versions of word lists in ADAS-cog and RAVLT administered in ADNI study, and 
secondly to facilitate a statistically more simple analysis of relationships between memory 
and other factors such as imaging data, biomarkers, and clinical diagnoses. The memory 
composite score, ADNI-Mem, performed comparably to other memory measures in the 
prediction of clinical change over time and was able to differentiate changes over time in 
participants with or without the AD CSF biomarker signature. It was strongly associated 
with neuroimaging parameters previously associated with memory performance, suggesting 
this improvement could simplify ADNI protocol by allowing a single test for memory to be 
administered.
Trzepacz et al [475] developed three subscales of the Neuropsychiatric Inventory 
Questionnaire (NPI-Q) to measure agitation/aggression, mood, and frontal syndromes. They 
used principal component analysis to determine how the subscales relate to each other and 
evaluated them in two cohorts including ADNI. They concluded that the subscales were 
valid based on the similarity of results across the two cohorts.
4.4.4. CSF biomarkers
4.4.4.1. β-amyloid and tau: The relationship between CSF biomarkers and neuronal 
degeneration has been investigated by a number of groups within and outside ADNI 
following the seminal publication by Shaw et al [57], which defined cut points for CSF tau 
and Aβ-42 based on an ADNI-independent cohort of autopsy-confirmed AD patients as well 
as normal control subjects and then applied these cut points successfully to the ADNI 
cohort. Follow-up studies went on to test the hypothesis that changes in levels of biomarkers 
occur early in disease and thus are likely predictive of future brain atrophy, if not directly 
associated with all parts of the degenerative process. For example, Tosun et al [146] 
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examined how rates of regional brain trophy were related to levels of CSF biomarkers in 
MCI patients and healthy elderly control subjects. They found that lower CSF Aβ-42 levels 
and higher tau levels were associated with increased atrophy in numerous brain regions, 
beginning primarily in the temporal and parietal cortices in MCI patients and extending to 
regions not normally associated with amyloid pathology, such as the caudate and accumbens 
areas, in AD patients. Schuff et al [121] also found that increased rates of hippocampal 
atrophy were associated with lower levels of Aβ-42 in the MCI, but not AD or control, 
group. Leow et al [113] used TBM to examine rates of atrophy and found that lower CSF 
Aβ-42 levels, higher tau levels, and a higher p-tau/Aβ-42 ratio were significantly associated 
with temporal lobe atrophy in the pooled group, and, additionally, that within the AD group, 
levels of CSF p-tau and the p-tau/Aβ-42 ratio were also significantly associated. Fjell et al 
[147] investigated whether baseline levels of CSF biomarkers were associated with baseline 
brain morphometric differences between control, MCI, and AD subjects, as measured by 
cortical thickness in a number of ROIs. They found that although CSF biomarkers levels 
could not account for baseline differences, they were moderately associated with 
longitudinal change in multiple areas, including medial temporal regions and beyond. 
Stricker et al [467] examined associations between baseline levels of Aβ-42 and p-tau and 
rates of atrophy of the precuneus, the first area to be affected by amyloid deposition, and 
hippocampus, the first area to be affected by neurofibrillary tangles. Neither of the baseline 
CSF measures was associated with the thinning of the precuneus, but both were associated 
with the rate of hippocampal atrophy. Furthermore, lower baseline Aβ-42 levels in 
cognitively normal controls and higher baseline p-tau in the MCI and AD groups were 
associated with increased rates of hippocampal atrophy, suggesting that Aβ-42 exerts its 
effect earlier and that tau exerts its effect later in disease progression.
A second focus of research into CSF biomarkers has been how they are modulated by APOE 
genotype and their association with cognitive measures. Shaw et al [57] reported that Aβ-42 
concentrations were dose dependent on the number of APOE ε4 alleles, with the highest 
concentrations found in homozygotes. Vemuri et al [128] found that Aβ-42 is more closely 
associated with APOE genotype than cognitive function (MMSE, CDR-SB), but that APOE 
genotype had no significant effect on levels of t-tau (Fig. 16). An earlier study by the same 
group [132] investigated the relationship between CSF biomarkers and cognitive function 
(MMSE and CDR-SB), and found that the CSF biomarkers Aβ-42, t-tau, and p-tau181p were 
only significantly correlated with cognitive function in the pooled sample (Table 5). Ott et al 
[148] studied the relationship between CSF biomarkers and ventricular expansion with the 
hypothesis that ventricular dilation may reflect faulty CSF clearance mechanisms resulting 
in reduced levels of Aβ. They found that ventricular expansion was associated with reduced 
CSF Aβ levels in normal elderly carriers of APOE ε4, but that in APOE ε4-positive AD 
patients, ventricular expansion was associated with increased levels of tau and not Aβ. The 
authors suggested that the APOE ε4 allele may exert its effect through modulation of CSF–
blood–brain barrier function.
Toledo et al [476] examined the relationship between CSF and plasma apoE protein levels 
and APOE genotype with cognition and AD biomarker changes. At baseline, higher CSF 
apoE levels were associated with higher total and phosphorylated CSF tau levels. CSF apoE 
levels were also associated with longitudinal cognitive decline, MCI to AD conversion, and 
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GM atrophy rate but not changes in CSF Aβ or tau levels. Plasma apoE levels showed a mild 
correlation with CSF apoE levels but were not associated with longitudinal cognitive and 
MRI changes. The authors proposed that increased CSF apoE2 or apoE3 levels might 
represent a protective response to injury in AD and may have neuroprotective effects by 
decreasing neuronal damage independent of tau and amyloid deposition in addition to their 
effects on amyloid clearance.
The results from these studies support a model in which changes in the levels of CSF 
biomarkers are an early step in the course of the disease that reflects the degree of AD 
pathology, and in which Aβ-42 is modulated by the APOE ε4 allele, which functions in the 
early stages of pathology by reducing the efficiency of Aβ-42 clearance. As described in the 
Genetics section 5.3, Kim et al [149] performed a genomewide search for markers 
associated with CSF analyte levels in the ADNI cohort. Overall, CSF Aβ-42 and tau, in 
conjunction with imaging measures of atrophy, are promising biomarkers for early detection 
of AD.
Two recent studies by Ewers et al [279] and Vidoni et al [280] investigated the relationship 
between markers of early AD and BMI, which appears to have a paradoxical association 
with the disease; high BMI in mid-life increases the risk of the disease whereas it appears to 
be protective in later life [279, 280]. Vidoni et al found that the association between amyloid 
burden (measured by both CSF Aβ levels and global PiB uptake) and low BMI was 
strongest in MCI patients and cognitively normal controls (Table 6). Ewers et al found that 
BMI was significantly lower in patents with levels of CSF Aβ and t-tau above a pre-defined 
cut-point (F = 27.7, df = 746, P < .001), regardless of diagnosis. These results provide 
further evidence that AD pathology is present before the disease becomes a clinically 
evident and suggest that low BMI may either be a systemic response due to the presence of 
this pathology, or constitute a trait that predisposes an individual to its development. If the 
latter scenario is correct, then therapies that address BMI issues are of interest in the 
treatment of AD. Rajagopalan et al [477] investigated associations between BMI, regional 
brain volumes, and leptin, a hormone produced by adipose tissue which regulates appetite 
and energy expenditure. Higher levels of leptin were associated with lower volumes of the 
frontal, parietal, temporal, and occipital lobes, and the brainstem and cerebellum, and these 
associations persisted after controlling for BMI. As leptin levels can be manipulated, it may 
represent a promising therapeutic target for the treatment of AD.
4.4.4.2. α-Synuclein and dementias with Lewy bodies: AD is frequently comorbid with 
Lewy body diseases such as Parkinson’s disease, with α-synuclein (α-syn)–positive Lewy 
bodies found in 40% to 50% of AD patients. Faster cognitive decline has been noted in these 
patients, and this neuronal damage may be accelerated by the α-syn–mediated aggregation 
of Aβ and tau in the ADNI cohort. Levels of α-syn and p-tau181 were strongly correlated in 
AD, MCI, and Parkinson’s disease patients [478]. There was an inverse correlation between 
levels of α-syn and p-tau181, suggesting that this inverse CSF signature indicates 
concomitant AD and Lewy body disease pathology [478]. Korff et al [479] reported that 
CSF α-syn differentiated between patient groups and that increased α-syn was associated 
with decreased MMSE scores but not with APOE status. Clearly, further investigation of α-
syn as a biomarker for AD is warranted.
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At autopsy, a high percentage of coincident pathologies are reported in demented patients. In 
a consecutive series of the first 22 ADNI autopsies, Toledo et al [480] found that only four 
patients had pure AD pathology. Coincident dementia with Lewy bodies (DLB), medial 
temporal lobe pathology (TDP-43 proteinopathy, argyrophilic grain disease, and 
hippocampal sclerosis), and vascular pathology occurred in 45.5%, 40.0%, and 22.7% of 
patients, respectively. DLB was predicted by hallucinations and a severe dysexecutive 
profile, and coincident DLB was classified by occipital FDG-PET hypometabolism. These 
results suggest that biomarkers can be used to independently predict coincident AD and 
DLB pathology.
4.4.5. Amyloid imaging—A complementary method for assessing amyloid deposition 
is 11C-PiB PET imaging. Jack et al [16] investigated the relationship between amyloid 
deposition and ventricular expansion in the ADNI cohort by examining serial 11C-PiB PET 
and MRI scans. They found no difference in the rate of global PiB retention between clinical 
groups, and changes in global PiB retention only weakly correlated with concurrent decline 
on MMSE and CDR-SB. In contrast, ventricular expansion increased from control subjects 
to MCI to AD groups and correlated strongly with concurrent cognitive decline (Table 5). 
The relationship between PET and CSF biomarkers and cognitive measures in the ADNI 
cohort at baseline was investigated by Jagust et al [150]. CSF Aβ-42 and 11C-PiB PET were 
found to be in substantial agreement as measures of amyloid deposition, and neither measure 
correlated with MMSE scores. In contrast, FDG-PET, as a measure of cerebral glucose 
metabolism, was strongly correlated with MMSE scores, but much less so with CSF 
biomarkers (Table 6). Apostolova et al [151] also examined associations between 
hippocampal atrophy, CSF biomarkers, and average cortical, precuneal, and parietal uptake 
of 11C-PiB. They found that although all CSF biomarkers were associated with hippocampal 
atrophy, the strongest correlations were with p-tau181p and the weakest with Aβ-42. 
Precuneal 11C-PiB uptake was most strongly associated with hippocampal atrophy. Jack et al 
[152] examined the relationship between log relative hazard of progressing from MCI to AD 
and both hippocampal atrophy and amyloid load, measured as a composite of 11C-PiB PET 
and CSF Aβ-42 data. They found that although the risk profile was linear throughout the 
range of hippocampal atrophy, amyloid load reached a ceiling at a certain concentration 
earlier in disease progression. These papers support a disease model in which initial amyloid 
deposition occurs in the early stages and does not correlate with cognitive decline, but 
stabilizes later in disease, and in which neurodegeneration accelerates with disease 
progression with concomitant cognitive decline. A protocol using the longer half-life 
Florbetapir amyloid ligand was added to ADNI-GO and ADNI-2. An initial study compared 
Florbetapir binding with FDG uptake as differential indicators of metabolism [481]. The 
percentage of patients classified as Florbetapir positive increased from 29% of cognitively 
normal controls to 43% of EMCI patients to 62% of LMCI patients to 77% of AD patients. 
Additionally, cognitive decline in cognitively normal patients was more closely linked to 
Florbetapir binding than to FDG abnormalities, but the reverse was found in MCI and AD 
patients. Murphy et al [482] investigated associations between amyloid deposition, age, 
clinical status, and APOE status and found that while age was not associated with 
Florbetapir signal, APOE status had a strong influence on the uptake of this radiotracer. In 
all patient categories, APOE ε 4 + patients had higher densities of amyloid plaques across 
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all cortical regions than patients lacking this risk allele. APOE ε 4 status had a far larger 
effect on Florbetapir uptake than clinical status (Fig. 35). These results suggest that APOE 
status is a better predictor of amyloid deposition than age or clinical status and that high 
amyloid deposition precedes the manifestation of clinical symptoms, whereas glucose 
hypometabolism occurs later in progression in accordance with the Jack model of disease 
progression [14]. A second study by Landau et al [483] found that Florbetapir binding and 
levels of CSF Aβ were inversely correlated in 86% of subjects both longitudinally and cross-
sectionally. The number of subjects who were discordant for these measurements dropped 
threefold when a 5% confidence interval was applied to the cutoff point.
4.4.6. Combined modalities—The dynamics of CSF, MRI, and FDG-PET biomarkers in 
the ADNI cohort were studied by Caroli and Frisoni [153] in an effort to understand how 
they change over the course of the disease. Each biomarker differed between clinical groups 
after post hoc analysis, and the authors found that these measures of disease progression fit 
better in sigmoidal, rather than linear, models, suggesting that individual biomarkers vary in 
their rate of change during disease progression. Aβ-42 imaging signals increased early in 
disease progression and then plateaued, whereas CSF Aβ-42 declined early and then 
plateaued, and hippocampal volume followed a similar trajectory, with volumes increasing 
later in disease progression. In contrast, FDG-PET measures of glucose metabolism and 
CSF tau began to increase early in disease progression and only stabilized at later stages of 
disease, suggesting that there is an ongoing reduction in glucose metabolism and tau-
mediated neurodegeneration throughout the early stages of AD (blue line in Figs. 2 and 17). 
Carriers of the APOE ε4 allele had earlier hippocampal atrophy. A similar study by Beckett 
et al [154] also found that measures associated with early disease, such as Aβ-42, had 
greater changes in MCI patients than in AD patients, and that those associated with later 
changes, such as those in FDG-PET ROIs, were more evident in AD patients (Table 7). The 
authors hypothesized that changes in biomarkers may not be linear and that for each 
biomarker, there may be steeper rates of change in some stages of disease progression than 
others. An extension of this study examined trajectories of CSF Aβ42, FDG uptake and 
hippocampal volume loss and the influence of the APOE ε 4 allele study up to 36 months 
from the original 12 months [281]. Aβ42 levels declined most rapidly in cognitively normal 
participants, glucose metabolism declined most rapidly in AD patients and hippocampal 
atrophy accelerated with disease progression. Presence of the APOE ε 4 allele acted 
primarily to accelerate hippocampal atrophy in MCI and AD patients. These results are in 
keeping with the model of Jack et al [14], which was subsequently empirically tested in a 
further paper by the same group [282]. Using cut-points demarcating normal from abnormal 
levels of CSF Aβ42 and t-tau, and of hippocampal volume, Jack et al examined the 
distribution of these biomarkers in control, MCI and AD patients at baseline and 12 months 
using ADNI cohort data. They found support for the model in that the percentage of 
abnormal biomarker findings increased with disease severity as assessed by clinical status 
and MMSE score, and in the temporal progression of the appearance of biomarker 
abnormalities: Aβ42 first followed by t-tau and lastly by hippocampal volume (Fig. 29). 
Biomarker dynamics continue to be the subject of intense interest. With substantial 
longitudinal data now available through ADNI, ADNIGO, and ADNI-2 and with the 
addition of an E-MCI cohort in ADNI-2, a convincing body of evidence has accumulated for 
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the temporal ordering of biomarkers and the shape of their trajectories. Jedynak et al [484] 
computed a disease progression score for each patient in the ADNI cohort and produced a 
data-driven plot of biomarker dynamics that was in substantial agreement with the model by 
Jack et al [14]. One exception was the AVLT-30 test added to ADNI-GO and ADNI-2 
protocols, which appeared to be the first biomarker to become abnormal (Fig. 36). The 
sequential nature of these models predicts that in order to affect cognition, Aβ must be 
dependent on tau and neuroimaging variables, whereas tau must only be dependent on 
neuroimaging variables. The longitudinal study of Han et al [468] largely supported the 
prediction with two notable exceptions: Aβ was found to have effect on brain structure and 
function independent of tau, and tau was found to have effect on baseline cognition 
independent of neuroimaging measures. All study variables had significant overlap between 
clinical groups, suggesting that these groups differ quantitatively but not qualitatively. 
Risacher et al [485] characterized cognition and biomarker levels in the EMCI cohort. The 
status was associated with impaired cognition, abnormally high levels of tau, and brain 
atrophy, but not with increased amyloid deposition. In contrast, APOE ε 4 status was 
significantly associated with increased amyloid deposition and abnormal levels of tau in not 
only EMCI patients but also the cognitively normal controls. These results suggest that 
amyloid deposition occurs at an extremely early stage of the disease and that this event is 
substantially modulated by the APOE ε 4 allele in agreement with the results obtained in the 
Florbetapir study of Murphy et al [482]. Mouiha et al [486] examined biomarker trajectories, 
predicted in the model by Jack et al [14] to be sigmoidal in shape. Fitting the data to one of 
six possible models, they reported that the FDG-PET trajectory appeared to be linear in 
contrast to all other biomarkers, which best fit either a quadratic model (Aβ42) or a 
penalized B-spline model (p-tau, t-tau, and hippocampal volume). Some facets of the Jack 
model [14] were not supported by a study by Yang et al [487] who found that t-tau, p-tau181, 
and Aβ42 discriminated between controls and both MCI and AD groups, but only Aβ42 
discriminated between MCI and AD groups, suggesting that Aβ levels may plateau after tau 
in the pathologic cascade.
In seeking an optimum combination of imaging and CSF biomarkers to predict normal 
control/AD classification, Walhovd et al [155] examined the relationships between the best 
predictive biomarkers and changes in cognitive scores in the MCI group. They found that 
changes in MMSE scores correlated with retrosplenial volume and metabolism as well as 
entorhinal volume, but that only hippocampal volume was associated with the Logical 
Memory II-DR, and only retrosplenial volume was associated with changes in CDR-SB. No 
CSF biomarkers were significantly associated with cognitive scores in this clinical group 
(Table 5). Once again, these results are consistent with the disease progression model in that 
earlier changes that are reflected in CSF biomarkers do not correlate with clinical measures, 
whereas changes in brain metabolism and morphometry occur at later stages of the disease 
and therefore correlate better with cognitive measures. Further support for this model comes 
from the study of the annual change in MRI and CSF biomarkers and how these are 
influenced by APOE genotype in control, MCI, and AD subjects [156]. Levels of neither 
Aβ-42 nor t-tau changed significantly over 12 months in any clinical group, but annual 
changes in ventricular volume increased with disease severity and were correlated with 
worsening cognitive and functional indices. APOE ε4 carriers had higher rates of change in 
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ventricular volume, but not in levels of CSF biomarkers, consistent with the model in which 
levels of Aβ and tau plateau as neurodegeneration becomes detectable by MR measures.
The question of whether structural or metabolic measures are the most sensitive biomarkers 
of changes associated with early stages of AD was investigated by Karow et al [110]. 
Directly comparing the ability of MR and FDG-PET measures in prespecified ROIs to detect 
such changes by quantifying and comparing their effect sizes (Cohen d), they found that 
largest morphometric effect size (hippocampal volume: 1.92) was significantly greater than 
the largest metabolic effect size (entorhinal metabolism: 1.43). Both measures were 
significantly associated with ADAS-cog and AVLT scores in AD patients, but in MCI 
patients, the relationship was only maintained with hippocampal volume (Table 5). The 
authors concluded that for the detection of early AD, MRI may be preferable to FDG-PET, 
as it is more sensitive, more widely available, less invasive, and less costly.
4.4.7. Genetic associations—Following the identification of novel AD genetic risk 
factors (Section 5), several studies have focused on associations between these risk variants 
and biomarkers such as amyloid burden and brain atrophy. Nondemented elderly carriers of 
the AD risk variant rS3818361 SNP in CR1 (A/A or A/G) had a lower brain amyloid burden 
relative to noncarriers [488]. In addition, noncarriers of the allele (G/G) had a greater 
variability of amyloid burden, which could be partially accounted for by APOE genotype as 
the APOE ε 4 allele was associated with higher amyloid burden in noncarriers. However, in 
carriers of the risk allele, there was no significant difference between the amyloid burden of 
carriers and noncarriers of APOE ε 4 allele. The finding that carriers of this risk allele have 
a reduced amyloid burden and that the presence of APOE does not influence this suggests 
that the CR1 × APOE interaction might modify early changes in AD pathogenesis, 
influencing brain amyloid levels in nondemented older individuals. Sabuncu et al [489] 
generated a polygenic score from the aggregate of many genetic markers for disease 
susceptibility and examined its associations with clinical status, cortical thickness in defined 
ROIs, and CSF biomarkers. Their polygenic score was significantly associated with clinical 
status and cortical thickness measurements at predefined ROIs in cognitively normal 
individuals. Aβ, but not tau, was also significantly associated with a polygenic score and 
remained associated in individuals with subthreshold levels of CSF Aβ42. These results 
suggest that AD susceptibility genes may modulate neurodegeneration even in individuals 
who are cognitively normal and lack amyloid burden.
Recently, maternal history of AD has been linked to risk of LOAD. Honea et al [490] 
reported a confirmatory study in a larger ADNI data set that examined relationships between 
family AD history and biomarkers of AD pathophysiology. Patients with maternal but not 
paternal family history of the disease had significantly higher global PiB uptake and greater 
PiB uptake in parietal cortex, precuneus, and sensimotor cortex than those with no family 
history group. In MCI patients, only a maternal family history was associated with 
significantly increased CSF Aβ42 and higher t-tau/Aβ42. Results are consistent with earlier 
findings that suggest that early changes in the disease process are associated with a 
maternally inherited genetic factor.
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4.4.8. Summary and conclusions of papers concerning associations of the 
ADNI cohort—ADNI has succeeded in recruiting a cohort of MCI and mild AD patients 
that mirrors populations used for clinical trials of AD therapies. A number of cross-sectional 
and longitudinal studies have lent support to a model of disease progression in which the 
earliest indications of neurodegeneration occur within the MTL, particularly the 
hippocampus, and atrophy becomes more widespread in later stages, ultimately 
encompassing areas of the parietal, occipital, and frontal lobes. Rates of atrophy are initially 
fastest in the temporal lobe, but accelerate in other regions as the disease progresses. 
Cortical atrophy and that of specific regions identified in the model of disease progression as 
well as ventricular enlargement have been correlated with measures of clinical severity. 
Structure–function relationships within the brain are being elucidated with findings that 
atrophy in dissociable anatomic regions, especially within the episodic memory network, is 
associated with different cognitive functions. Patterns of glucose hypometabolism associated 
with AD have been identified, with the precuneus and posterior cingulate typically 
displaying the most reduced CMRgl and with reduced metabolism in these key areas being 
associated with lower scores on cognitive tests. The differential effects of an SNP in brain-
derived neurotrophic factor suggest that genetics may modulate glucose metabolism. Levels 
of CSF biomarkers, particularly Aβ and tau, have been associated with earlier stages of 
neurodegeneration. 11C-PiB PET Aβ imaging has largely confirmed that decreased levels of 
CSF Aβ and increasing 11C-PiB PET represent an early event in disease progression, and 
neither amyloid imaging nor studies of CSF biomarkers have found that levels of these 
biochemicals are strongly associated with cognitive decline. Levels of CSF biomarkers have 
been found to be abnormal (i.e., decreased CSF Aβ and increased CSF tau) early in disease 
and then plateau with little detectable change, whereas glucose metabolism remains 
relatively stable until the latest stages of disease progression. Presence of the APOE ε4 
allele has been shown to enhance neurodegeneration and to modulate levels of CSF 
biomarkers, but the exact mechanism by which it exerts its effect remains unclear. Likewise, 
the role of BMI has been the subject of contradictory reports, and it is unknown whether 
changes in BMI influence disease development or occur as a result of the disease.
In 2011–2012, evidence accumulated supporting the disease model of Jack et al [14], and 
detailing how hippocampal atrophy is associated with neocortical atrophy or 
neuropsychological measurements. The relationship between amygdalal atrophy and 
cognitive decline revealed parallels with the hippocampal atrophy – cognitive decline 
relationship, suggesting that this structure warrants further investigation. There was further 
development of the use of summary scores based on MRI data reflecting the degree of AD-
like neuroanatomical changes as an indicator of disease status. The importance of functional 
decline, in addition to decline in the traditional cognitive domains was reflected in a group 
of studies highlighting the associations between difficulties in performing daily living 
activities and various biomarkers. The association of the cognitive reserve with cognition 
and biomarkers was reported and provided evidence for a model in which the degree of 
cognitive reserve affects curves of CSF biomarkers throughout disease progression. Finally, 
studies provided insight into possible mechanisms by which the known AD risk factors, 
BMI and high homocysteine levels may act by investigating their associations with AD 
biomarkers.
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The model by Jack et al [14] was again well supported in numerous studies published in 
2012 and 2013, including a data-driven observational study across all ADNI participants. 
Florbetapir binding was shown to correlate with clinical status and CSF Aβ levels and to be 
modulated by APOE ε 4 allele, indicating this radiotracer to be an accurate biomarker of 
amyloid deposition. The deleterious effects of the APOE ε 4 allele were documented in 
repeated works, and studies of genetic associations extended to include novel risk variants 
identified and confirmed in GWAS studies. Glucose hypometabolism in specific regions was 
associated with measures of cognitive decline. The newly introduced ASL modality revealed 
that the changes in CBF in regions identified by FDG-PET as typically hypometabolic in 
AD occur later in disease progression. This technique warrants further investigation as a 
potential biomarker. Increasing recognition that AD patients may also harbor white matter 
changes leads to the inclusion of DTI in the ADNI-2 protocol. WMHs detected by this 
method were correlated with clinical status and may significantly disrupt structural 
connectivity in later stages of the disease. The common comorbidity of AD with Lewy body 
dementias suggests that α-syn, which was associated with clinical groups, CSF biomarkers, 
and memory measures, may also have potential as a biomarker. Finally, studies have 
suggested that cognitive reserve is the result of improved functional connectivity and not 
increased neural substrate.
4.5. Diagnostic classification of study participants
The ability to accurately diagnose to which clinical group a subject belongs is a crucial one 
in the clinical trial design. To this end, some researchers have investigated the ability of 
individual MRI, FDG-PET, and CSF biomarkers to discriminate between ADNI AD 
participants and ADNI control subjects, and between MCI-c and MCI-nc subjects. Others 
have tried to determine the optimum combination of these biomarkers for ADNI participant 
classification, with many studies leveraging knowledge of associations between various 
structural and fluid biomarkers and the sequence of brain morphometric change over the 
course of disease to guide development of marker combinations. Discrimination between the 
clinically distinct ADNI participant groups offers an important first step in identifying 
biomarker diagnostic tools that can be validated in representative population-based studies 
before clinical use. More recently, a view has emerged of AD as a continuum of increasing 
pathology and clinical manifestation of symptoms. Accordingly, more studies have focused 
on predicting continuous variables instead of binary classification.
4.5.1. Magnetic resonance imaging
4.5.1.1. Temporal lobe structures: Atrophy of the hippocampus, the best studied structure 
affected by AD, has been used in patient classification by a number of groups. Chupin et al 
[68] correctly distinguished AD patients from control subjects 76% of the time, and MCI 
patients who would convert within 18 months from control subjects 71% of the time (Table 
8). Karow et al [110] found that hippocampal volume discriminated between control subjects 
and AD patients with an AUC of 0.90, and between control subjects and MCI patients with 
an AUC of 0.75 (Table 8). The discriminative ability of the rate of hippocampal atrophy was 
investigated by Wolz et al [64], who found that their method correctly classified 75% to 82% 
of AD patients and 70% of MCI patients who converted to AD over 12 months. Their 
method was also able to discriminate between MCI-c and MCI-nc patients at a rate of 64% 
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(Table 8). Lotjonen et al [231] compared Wolz’s method to their own automatic 
hippocampal extraction method using the same data and found that it resulted in 
significantly more accurate classification of both AD patients from controls and MCI 
converters from non-converters (Table 8). The division of the hippocampus into head, body 
and tail subregions extracted further information from this structure for use in diagnostic 
classification. Greene et al [267] found that the combined left and right hippocampal head 
produced the most accurate classifications of any hippocampal subregions, but that the best 
accuracy was attained by a combination of left hippocampal body, right hippocampal tail, 
AVLT and Digit Symbol which classified controls, MCI and AD patients with accuracies of 
95.5%, 82.4% and 78.9%, respectively. Calvini et al [66] derived a statistical indicator from 
the hippocampus and other MTL structures and were able to discriminate between AD and 
control groups, and between MCI and control groups, with AUCs of 0.863 and 0.746, 
respectively (Table 8). The classification index of Chincarini et al [283] used seven 
maximally discriminative small volumes in the medial temporal lobe to distinguish between 
AD and control groups, MCI and control groups and MCI converters from non-converters 
with AUCs of 0.97, 0.92 and 0.74, respectively (Table 8).
4.5.1.2. Multiple ROIs and whole brain: Other methods have focused on many ROIs 
across the brain, using the degree of association with AD to construct a score reflective of 
the anatomic profile of AD. These include temporal, cingulate, and orbitofrontal regions. 
The classifier developed by Fan et al [83] produced an SPS that allowed direct comparison 
of patients and was able to discriminate between AD and control subjects, between MCI and 
control subjects, and between AD and MCI subjects with AUCs of 0.965, 0.846, and 0.750, 
respectively (Table 8). Similarly, Misra et al [118] extracted an abnormality score that 
discriminated MCI-c patients from MCI-nc patients with a classification accuracy of 81.5 
and an AUC of 0.77 (Table 8). Using a semisupervised SVM, Filipovych and Davatzikos 
[93] discriminated between MCI-c and MCI-nc patients with an AUC of 0.69, comparing 
favorably with fully supervised SVM methods (Table 8). They also found that 79.4% of all 
converters were classified as AD-like (the remainder being classified as normal-like). In 
addition, 51.7% of nonconverters were classified as normal-like and the remainder as AD-
like, perhaps representing a proportion of MCI patients who would convert to AD further in 
the future. The authors also found that semisupervised SVM performed better than a fully 
supervised SVM in instances when there were a small number of labeled images. The 
classifier developed by Yang et al [94], which relied on image features defined by ICA, 
discriminated between control and AD subjects with an accuracy of 80.7%, a sensitivity of 
81.9%, and a specificity of 79.5%, and between control and MCI subjects with an accuracy 
of 71.1%, a sensitivity of 73.2%, and a specificity of 68.6%, based on GM images and a 
training set-to-test set ratio of 90%:10% (Table 8).
McEvoy et al [117] presented data from their fully cross-validated linear discriminant model 
compared with partially cross-validated models, and found that the fully cross-validated 
model discriminated between AD and control subjects with an accuracy of 89%, a sensitivity 
of 83%, a specificity of 93%, and an AUC of 0.915 (Table 8). They noted that these numbers 
were lower than those obtained using the partially cross-validated model, suggesting that 
numbers presented by other studies using partially cross-validated models may be artificially 
Weiner et al. Page 68













high. Hinrichs et al [88] used a classifier based on GM probability maps and found that it 
discriminated between AD and control subjects with a sensitivity of 85% and a specificity of 
80%. Park and Seo [75] tested their method of multidimensional scaling (MDS) of DBM 
and compared it with the ability of hippocampal volume to discriminate between AD and 
control subjects. They found that their MDS method outperformed hippocampal volume, 
yielding accuracies of 86.3% and 75.0%, respectively (Table 8). Further details of classifier 
construction using SVMs are given in the Methods section 3.3.
Longitudinal measurements of cortical thickness were the focus of a classifier constructed 
by Li et al [157]. They found that although the pattern of cortical thinning was similar in all 
patient groups, the rate of thinning and ratio of follow-up to baseline measures provided a 
better tool for distinguishing between MCI-c and MCI-nc patients. An additional 
complementary component in the form of a brain network feature computed from the 
correlations of cortical thickness changes with ROIs further improved classification 
accuracy. The final classifier, comprising static, dynamic, and network measures, 
discriminated between normal control subjects and AD patients with an accuracy of 96.1%, 
and between MCI-c and MCI-nc patients with an accuracy of 81.7% (Table 8). The classifier 
of Park et al [383] based on cortical shape and sulcal depths discriminated between control 
and MCI patients with an accuracy of 73%, a sensitivity of 73%, and a specificity of 73%. 
Noise sensitivity and spatial variation problems of other cortical thickness estimation 
methods were overcome by more robust method of Cho et al [237] which discriminated 
successfully between control and AD patients or MCI converters, or between MCI 
converters and non-converters (Table 8). An automated method developed by Pachauri et al 
[232] to leverage information found in cortical surface topology boosted the classification 
accuracy of hippocampal volume in discriminating between AD and control patients by 4% 
and of other ROIs by around 3%.
The penalized logistic regression approach of Casanova et al [241] to the high dimensional 
classification of patients from MRI data discriminated between AD patients and controls 
with accuracies, specificities and sensitivities of 85.7%, 90% and 82.9%, respectively, using 
GM and 81.1%, 82.5% and 80.6%, respectively, using WM. The effect of registration to 
multiple templates on classification accuracy of TBM was investigated by Koikkalainen et al 
[234] who found that all 4 multi-template methods investigated resulted in better 
discrimination of both AD from controls patients and MCI converters from non-converters 
(Table 8).
Applying a correction to account for age-related atrophy in controls was shown by Franke et 
al [92] to increase the accuracy of classification of AD patients from controls from 83% to 
85%, indicating that controlling for the effects of such confounding variables as age is 
critical to achieving clinically useful classification accuracies with MR data.
Leveraging information contained within structural and functional connectivities in imaging 
data has increasingly been a focus for improving classification. Cuingnet et al [389] included 
a regularization step to take these relationships into account and found that the addition of 
the step to an SVM increased classification accuracy over an SVM alone. Using cortical 
thickness measures, AD patients were discriminated from normal controls with an accuracy 
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of 87%, a sensitivity of 83%, and a specificity of 90% compared with the SVM alone, which 
achieved an accuracy of 83%, a sensitivity of 74%, and a specificity of 90% in the same 
classification challenge. Likewise, a method [384] that takes into account the relationships 
between morphologic features of ROIs augmented classification accuracy over ROIs alone, 
and an approach that integrated the correlative data via multikernel SVMs further improved 
classification accuracy. The integrated approach discriminated between AD and controls 
with an accuracy of 92.4% and between MCIc and MCInc patients with an accuracy of 75%. 
The OLPS score of Spulber et al [382], reflective of the degree of AD-like 
neurodegeneration, achieved a sensitivity of 86.1%, a specificity of 90.4%, an accuracy of 
88.4%, and an AUC of 0.948 for the same classification challenge. An improvement to the 
feature selection step proposed by Liu et al [388], which takes into account pathologic 
degeneration, achieved classification accuracies of 90.2%, 87.2%, and 70.7% for the 
classification of AD patients versus controls, MCIc versus controls, and MCIc versus MCInc 
patients, respectively.
Combining automatically estimated features from different structural MRI analysis 
techniques augmented classification accuracy in a study by Wolz et al [284]. When TBM, 
hippocampal volume, cortical thickness and a manifold-based learning framework were 
combined, they improved classification accuracy over single features using both a SVM and 
linear discriminant analysis (Table 8). A novel dimensionality reduction approach [379] 
improved classification accuracies over a DBM–based technique and discriminated between 
AD and control patients and between MCI and control patients with accuracies of 84% and 
76%, respectively. Likewise, the tree-guided sparse coding method of Liu et al [391] was 
able to achieve better classification to L1-regularized Lasso alone using fewer features that 
were concentrated in areas known to be most representative of AD such as the hippocampus, 
entorhinal cortex, parahippocampal gyrus, and amygdala. The addition of LLE as a method 
of dimensionality reduction improved the efficacy of three different classifiers [396]. For 
example, MRI features alone using a SVM discriminated between control and AD patients 
with an accuracy of 50%, a sensitivity of 48%, and a specificity of 51%. The results 
improved to an accuracy of 90%, a sensitivity of 87%, and a specificity of 92% with the 
addition of LLE.
Normalization approaches in automated structural MRI processing pipelines can affect 
classification accuracy. Using non-normalized cortical thickness measures and volumetric 
measures normalized to intracranial volume, Westman et al [491] achieved a classification 
accuracy of 91.5% between control and AD patients and of 75.9% between MCI converters 
and nonconverters.
4.5.1.3. White matter hyperintensities: Provenzano et al [441] used the level of WMHs in 
patients who were PiB positive for diagnostic classification. At a cutoff of 1.25 cm3 for 
“high” WMH, they were able to discriminate between AD and control patients with a 
sensitivity of 83% and a specificity of 64%.
4.5.1.4. Comparison of MRI methods: Cuingnet et al [158] directly compared 10 methods 
for the automatic classification of AD patients from anatomical MR data using the ADNI 
database. Five voxel-based approaches, three cortical approaches, and two methods based on 
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hippocampal shape and volume were tested for their ability to discriminate between control, 
MCI-c, MCI-nc, and AD subjects. They found that voxel- or cortical thickness-based whole 
brain methods yielded highest sensitivities for AD versus control subjects (maximum of 
81%), but that sensitivities were substantially lower for discriminating between MCI-c and 
MCI-nc subjects (maximum of 70%). Casanova et al [411] compared classification data 
from a number of studies and illustrated the difficulty in directly comparing studies that 
differ in many aspects beyond simple methodology. Eskildsen et al [386] directly tested the 
effects of “double dipping” (the practice of reusing the training set as the test set) by using a 
dependent test set. They found that the practice artificially inflated classification accuracies, 
in one case to 87.4% from 74.6%. Young et al [408] noted the difficulty in comparing 
studies of the prediction of conversion because of differences in the length of time to 
conversion or because of the use of longitudinal data versus baseline data. These studies 
again emphasize the difficulty in comparing the results from different studies using different 
methodologies. For this reason, the 2012–2013 update has not included additional 
classification data in Table 8. As ADNI progresses, it is increasingly clear that standardized 
systematic studies of the cohort such as those reported by Cuingnet et al [158] are required 
to make sound conclusions regarding the efficacy of each technique.
Combining automatically estimated features from different structural MRI analysis 
techniques augmented classification accuracy in a study by Wolz et al [284]. When TBM, 
hippocampal volume, cortical thickness and a manifold-based learning framework were 
combined, they improved classification accuracy over single features using both a SVM and 
linear discriminant analysis (Table 8).
4.5.2. [18F]-fluorodeoxyglucose-positron emission tomography—As AD affects 
not only morphology but also metabolism in the brain, Haense et al [84] used the AD t-sum 
measure of scan abnormality from FDG-PET data to discriminate between AD and control 
subjects with a sensitivity of 83% and a specificity of 78% (Table 8). The HCI of Chen et al 
[85], which also capitalized on hypometabolism data across the entire brain, was 
significantly different in control, MCI-nc, MCI-c, and AD subject groups. The method of 
Hinrichs et al [88], described in the MRI section, was also used with FDG-PET data and was 
able to discriminate between AD and control subjects with a sensitivity of 78% and a 
specificity of 78% (Table 8). Huang et al [65] used FDG-PET data to examine functional 
connectivity between brain regions and then leveraged the patterns they found to be typical 
of AD for classification purposes. They found that compared with control subjects, AD 
patients had decreased temporal lobe inter-regional connectivity, especially in the 
hippocampus, and weaker between-lobe and between-hemisphere connectivity. In contrast, 
MCI patients had increased connectivity between occipital and frontal lobes compared with 
control subjects, illustrating the uniqueness of this condition. This method discriminated 
between AD and control subjects with a specificity of 88% and a sensitivity of 88% (Table 
8). Using their method based on feature selection using factor analysis and an SVM, Salas-
Gonzalez et al [90] discriminated between AD and control subjects with sensitivity, 
specificity, and accuracy of 98.1%, 92.5%, and 95.2%, respectively, and between MCI and 
control subjects with sensitivity, specificity, and accuracy of 92.1%, 80.8%, and 88.0%, 
respectively (Table 8). The classifier constructed by Clark et al [242] based on information 
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retrieval techniques was able to discriminate between control and AD patients with a 
sensitivity, specificity and accuracy of 94.4%, 92.5% and 93.6%, respectively and between 
MCI converters and non-converters with a sensitivity, specificity and accuracy of 89.7%, 
62.9% and 76.5%, respectively when the model include FAQ scores (Table 8). An alternative 
approach using non-negative matrix factorization was described by Padilla et al [248] and 
achieved an accuracy of 86.6%, a sensitivity of 87.5% and a specificity of 85.4% in the 
classification of AD patients from controls (Table 8). Having identified entorhinal 
metabolism as the FDG-PET measure with the largest effect size for the detection of early 
AD, Karow et al [110] found that this measure discriminated between control and AD 
subjects with an AUC of 0.71, and between control and MCI subjects with an AUC of 0.63 
(Table 8). Mormino et al used 11C-PiB PET imaging to deduce a cutoff point to optimally 
separate PiB-positive from PiB-negative MCI patients, and found that PiB-positive MCI 
patients had lower hippocampal volumes and greater episodic memory loss compared with 
MCI patients with 11C-PiB levels below the cutoff point of 1.465. The selection of 
maximally discriminative voxels using significance measures was used in a classifier 
described by Martinez-Murcia [398] and applied to ADNI FDG-PET data. It discriminated 
between AD and control patients with an accuracy of 91%, a sensitivity of 92%, and a 
specificity of 89%. The addition of longitudinal data to baseline data to improve 
classification accuracy from anatomically selected features of FDG-PET scans was the 
approach taken by Gray et al [285]. Across all categories, improved classification accuracies 
were reported, ranging from 65% in the MCI converter versus non-converter classification to 
88% in discriminating between control and AD patients (Table 8).
Arbizu et al [397] used their AD-conv score, based primarily on hypometabolism in the 
posterior cingulate area in addition to clinical and cognitive variables to divide MCI patients 
into groups with different probabilities of progressing to AD. These ranged from 8% in the 
first sixtile to 38% in the fourth sixtile to 100% in the top sixtile. This approach differs from 
conventional binary approaches to classification and emphasizes the concept of AD as a 
continuum of disease. The classification of MCIc versus MCInc patients by this method was 
improved significantly with the addition of clinical variables: the combined modalities 
reached an accuracy of 82%, a sensitivity of 85%, and a specificity of 80%.
A direct comparison of the diagnostic ability of three methods summarizing FDG PET data 
into a single score was made by Caroli et al [492] in three data sets including ADNI. In the 
ADNI cohort, the hyperbolic convergence index (HCI) [85] significantly outperformed the 
PMOD Alzheimer discrimination analysis tool [84] and a set of meta-analytically derived 
regions of interest (metROI) [135]. However, other methods were superior in other cohorts. 
Classification using all indices improved with increasing disease severity with AUCs 
ranging from 0.800 to 0.949 (PALZ), 0.774 to 0.967 (metaROI), and 0.801 to 0.983 (HCI), 
for the classification of MCIc and moderate AD compared with controls, respectively. The 
authors concluded that all three indices are differentially sensitive to disease severity and are 
therefore of utility in the detection of disease in both research and clinical settings.
4.5.3. CSF biomarkers—Shaw et al [57] examined CSF biomarkers in the ADNI cohort 
as well as in a cohort of non-ADNI autopsy-confirmed AD patients, with the goal of 
developing a “biomarker signature” best able to predict AD and to classify patients correctly. 
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Like many smaller studies, they found that t-tau and p-tau181p, as well as the t-tau/Aβ-42 
and p-tau181p/Aβ-42 ratios, all increased in MCI patients compared with control subjects, 
whereas CSF Aβ-42 decreased. The best single measure for discriminating between AD and 
control subjects was CSF Aβ-42, which had an AUC of 0.913, a sensitivity of 96.4%, a 
specificity of 76.0%, and an accuracy of 87% (Table 8). Linear regression analyses 
determined which variables, including APOE genotype, contributed most to the 
discrimination, and a final linear regression model, which included Aβ-42, APOE ε4 
carriers, and t-tau (LRTAA model), resulted in enhanced discrimination over individual 
factors (Table 8). De Meyer et al [159] used an unsupervised learning method that did not 
presuppose clinical diagnosis to identify biomarkers of AD. A mixture modeling approach 
derived a signature, consisting of both Aβ-42 and t-tau concentrations, which had a 
sensitivity of 94% in autopsy-confirmed AD patients from an independent cohort and was 
present in 90%, 72%, and 36% of patients with AD, MCI, and no cognitive impairment, 
respectively (Fig. 18). APOE ε4 carriers were over-represented in those patients with the 
AD biomarker signature by a factor of 6.88:1. Interestingly, when modeling single 
biomarkers, the cutoff concentration of Aβ-42 that optimally delineated AD patients from 
healthy elderly subjects was found to be 188 pg/mL, close to that found by Shaw et al [57] 
and Schott et al [160]. Moreover, the proportion of healthy elderly subjects with an 
identifying AD CSF biomarker signature was similar to that found by Schott et al [160], and 
likely reflects a proportion of cognitively normal elderly subjects who will progress to MCI 
and AD in the future. Further, De Meyer et al [159] examined another data set with MCI 
patients (n = 57) followed up for 5 years, and they showed that their model had a sensitivity 
of 100% in patients progressing to AD. The finding that AD pathology is detectable in 
significant numbers of healthy elderly control subjects has important implications for future 
clinical trials and suggests the possibility of presymptomatic treatment studies of potential 
AD-preventive compounds. Initial studies have reported that given the often shared 
pathology between AD and Lewy body dementias such as Parkinson’s disease, CSF levels of 
α-syn may have potential as a biomarker of AD. Korff et al [479] found that the marker 
alone offered only modest sensitivity (65%) and specificity (74%) and an AUC of 0.719 for 
the classification of AD from control patients. However, the addition of either α-syn levels 
alone or the ratio of α-syn to p-tau181 to established CSF biomarkers improved classification 
accuracy between both controls and AD patients and between MCI converters and 
nonconverters [478], suggesting that in combination of other markers, α-syn may represent a 
useful additional tool for AD diagnostics.
4.5.4. Clinical—Llano et al [96] compared the ADAS-cog and MMSE tests with a new 
form of ADAS-cog in which the subscores were given weights using a Random Forests tree 
algorithm, thereby resulting in a new metric, the composite ADAS.-Tree. Therefore, 
ADAS.Tree represents a multivariate model in which subscales have been weighted 
according to their importance in discriminating between AD and control subjects. When the 
ability of ADAS.Tree to classify control, MCI, and AD subjects was compared with that of 
ADAS-cog and MMSE, the composite model generated a numerically highest test statistic. 
The authors suggest that this derivative of an internationally recognized and easily 
administered test may offer a more widely useful and less expensive approach to other 
imaging and CSF biomarkers that can be invasive and/or expensive.
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Another cognitive test that may have utility in diagnosing MCI is the FAQ. Brown et al [274] 
identified two items of the FAQ, the ability to keep business papers organized and the ability 
to remember important dates and occasions, that effectively differentiated between control 
and MCI patients. Ito et al [493] proposed a bounded model which takes into consideration 
the nonnormal distribution of data at the boundaries of the FAQ scores. The censored 
approach greatly improved predictability of disease progression in FAQ scores over a 
standard approach.
4.5.5. Blood based biomarkers—A new direction of research in 2011–2012 has been 
the development of blood-based biomarkers for diagnostic classification as a potentially 
more clinically feasible alternative to more costly or invasive modalities as a first line 
screening method for the disease. O’Bryant et al [255] constructed a classifier from blood 
based markers that were highly correlated across both serum and plasma. These 11 proteins 
were comparable to CSF biomarkers in their ability to discriminate AD patients from 
cognitively normal controls, but the addition of demographic data (age, sex, education, 
APOE status) resulted in a model with similar classification accuracies to the best CSF-
based models (Table 8). A study of potential plasma based markers by Johnstone et al [286] 
identified 11 analytes that were maximally discriminative between controls and MCI 
converters. Once again, APOE status increased classification accuracy (Table 8). The 
refinement of the model by the addition of ‘metafeatures,’ able to identify and leverage 
information from potentially biologically linked features, further enhanced accuracy (Table 
8). A proteomic signature identified by Llano et al [422] from a bank of plasma analytes 
using a multivariate analysis contained 14 analytes and discriminated between control and 
AD patients with a sensitivity of 86.5%, a specificity of 84.2%, and an AUC of 85.3%. The 
blood-based panel of analytes developed by Doecke et al [421], which overlapped with 
biomarkers selected by both O’Bryant et al [494], was able to discriminate AD from control 
patients with an accuracy of 83% and an AUC of 85%. They found that the inclusion of 
APOE status, education, BMI, age, and sex also strengthened the model. Dubey et al [413] 
compared the diagnostic ability of proteomic versus MRI data and found that proteomic data 
were on a par with MRI data in discriminating between controls and AD patients and had 
increased accuracy, sensitivity, and specificity in diagnosing MCI patients.
4.5.6. Combined modalities
4.5.6.1. Early approaches: The approach of Kohannim et al [86] combined multiple factors, 
including MRI and FDG-PET measures, CSF biomarkers, APOE genotype, age, sex, and 
BMI, to enhance machine learning methods for AD diagnosis. They found that the optimum 
combination of factors to discriminate between AD and control subjects—hippocampal 
volume, ventricular expansion, APOE genotype, and age—yielded an AUC of 0.945 with an 
accuracy of 82%, whereas to detect MCI patients, the optimum combination of hippocampal 
volume, ventricular expansion, and age yielded an AUC of 0.860 and an accuracy of 71% 
(Table 8). Walhovd et al [155] likewise sought the optimum discriminatory combination of 
biomarkers. They found that the best MRI combination to discriminate between AD and 
control subjects consisted of hippocampal volume, entorhinal thickness, and retrosplenial 
thickness (85% accuracy); the best FDG-PET combination was entorhinal, retrosplenial, and 
orbitofrontal metabolism (82.5% accuracy); and the best CSF combination was t-tau/Aβ-42 
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(81.2% accuracy). Using stepwise linear regression, they developed a final model that 
included retrosplenial thickness and the t-tau/Aβ-42 ratio as predictors and which achieved 
88.8% accuracy in the classification of AD versus control subjects. For the discrimination of 
MCI from control subjects, the optimum combination of factors was found to be 
hippocampal volume and the t-tau/Aβ-42 ratio, with an accuracy of 79.1 % (Table 8). Ewers 
et al [161] tested a variety of cross-validated models of single or multiple predictors for their 
ability to discriminate between control and AD subjects. They found that the addition of 
neuropsychological tests, specifically the AVLT immediate free recall and DR and the TMT-
B, to models that included only CSF and/or genetic biomarkers and imaging measures 
resulted in increased overall classification accuracy. The best model, which included CSF t-
tau/Aβ-42, the number of APOE ε4 alleles (the previously described LRTAA model [57]), 
left entorhinal volume, and hippocampal volume, in addition to the aforementioned 
neuropsychological tests, resulted in an accuracy of 95.2%, a sensitivity of 92.2%, and a 
specificity of 97.5% (Table 8). Van Gils et al [162] also demonstrated that cognitive tests 
such as the CDR, MMSE, and the neuropsychological battery comprised the most important 
feature category of all classifiers designed to discriminate between different patient groups. 
The classifier constructed by Lemoine et al [87] from data fusion of both FDG-PET and 
clinical data discriminated between control and AD subjects with an AUC of 0.97, an 
improvement over the best single FDG-PET classifier (AUC = 0.94) or the best clinical 
classifier (derived from ADAS-cog data: AUC = 0.93) (Table 8). Vemuri et al [132] 
compared STAND score measures from MRI with CSF and concluded that CSF and MRI 
biomarkers independently contribute to intergroup diagnostic discrimination, and the 
combination of CSF and MRI provides better prediction than either source of data alone.
4.5.6.2. Multimodal classification: A significant technical advance in classification was the 
development of classifiers that combine information from multiple modalities. The multi-
kernel learning framework developed by Hinrichs et al [247] combined multiple modalities 
for classification of AD patients. They found that while the classifier based on all modalities 
performed best overall, cognitive scores alone separated AD patients from controls to almost 
the same level of accuracy (Table 8). Similarly, two studies by Zhang et al [249] focused on 
combining MR, FDG-PET and CSF biomarker data using different methods (multi-modal 
multi-task [250], and kernel combination [249]). They found that combination of different 
modalities outperformed single modalities in classification accuracy [250] (Table 8) and that 
the kernel combination method correctly identified 91.5% of MCI converters and 73.4% of 
MCI non-converters. Likewise, both Westman et al [495] and Yang et al [487] found that 
combinations of MRI measures representative of AD brain morphology changes and CSF 
biomarkers were most effective at discriminating MCI from control patients with accuracies 
of 77.6% and 72%, respectively. Yang et al [487] also reported improved classification 
accuracies using hippocampal and ventricular volumes rather than shapes.
With the optimum combination of modalities for classification largely established (usually a 
combination of MRI and CSF data, with APOE status, gender, and age), new methodologies 
have been developed that have realized further gains in accuracy by optimizing the ways in 
which features are selected and modalities combined. The multimodal classifier of Gray et al 
[405], based on the random forests algorithm, enhanced classification accuracy for AD 
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versus controls, and MCI versus controls over all single-modality classifications. However, it 
was no more accurate in discriminating between MCI converters and nonconverters than 
MRI data alone. The novel multiple kernel classifier of Liu et al [392] combined MRI and 
CSF data to improve on the classification accuracies attained by the SVM of Zhang et al 
[249]. The authors attributed this improvement to the use of group Lasso regularization to 
enforce sparsity in the different modalities. Instead of focusing on binary classification, the 
multimodal approach of Cheng et al [393] estimated clinical scores from MRI, FDG-PET, 
and CSF data using relevance vector regression. Their approach attained correlation 
coefficients of 0.80 and 0.78 for the estimation of MMSE and ADAS-cog scores, 
respectively. Not all multimodal approaches have proven optimal. Casanova et al [411], who 
condensed multimodal information to a single score, AD-PS, found that although this index 
improved MCIc versus MCInc classification accuracy beyond other summary indices such 
as STAND and SPARE-AD, it did not perform as well as individual structural or cognitive 
measures in other classification problems.
Can multimodal techniques improve diagnosis in the clinical setting? Simonsen et al [417] 
compared the accuracy of their PredictAD software with that of clinical raters asked to 
classify patients into a range of categories depending on their likelihood of developing the 
disease. The software increased classification accuracy over paper information alone from 
63.2% to 70% and additionally improved interrater agreement and increased the raters’ 
confidence in their decision. The PredictAD appears capable of beneficially combining data 
from different modalities and therefore may prove a useful adjunct for decision support in a 
clinical environment. The study of Escudero et al [420] addressed cost-effectiveness of 
biomarker-based diagnosis. They found that when the number of biomarkers was minimized, 
classification accuracies were comparable to methods that include all biomarkers. However, 
the selection of biomarkers solely to minimize costs lowered accuracies. This proof-of-
concept study supports the feasibility of a personalized clinical diagnostic aid for AD that 
can be optimized for cost and time efficiency.
4.5.6.3. Feature selection: Given the high dimensionality of imaging techniques, the 
selection of a minimum set of features that optimally preserve complementary information 
between modalities is a critical step. A number of feature selection techniques have been 
borrowed from computer graphics fields, and the incorporation of these into AD 
classification represents a significant advance. Using an automatic data-driven method for 
the selection of multi-modal features and SVM trained on AD and control patients, Cui et al 
[287] also found that combined optimal MR, CSF and neuropsychological features 
outperformed any single modality in the classification of MCI converters versus non-
converters. From baseline features, they predicted conversion of MCI to AD within 24 
months with an accuracy of 67.1%, a sensitivity of 96.4%, a specificity of 48.3% and an 
AUC of 0.796 (Table 8). Liu et al [404] reported an accuracy of 67.8%, a sensitivity of 
64.9%, and a specificity of 70% in the classification of MCIc versus MCInc groups. Dukart 
et al [496] used meta-analyses to combine MRI and FDG PET data for improved 
classification. The combination discriminated between control and AD patients with an 
accuracy of 85.7%, a sensitivity of 89.3%, and a specificity of 82.1%. Additionally, when 
ADNI data were used for training the SVM, classification in another cohort reached similar 
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accuracies, showing the applicability of ADNI data to the wider community. Suk et al [387] 
applied deep learning techniques developed for vision processing to neuroimaging to 
improve feature selection. The incorporation of high-level information such as relationships 
between features improved classification accuracy over the use of only low-level features, 
such as gray matter volumes.
4.5.6.4. The effect of age on classification: The possibility that different modalities may not 
be equally useful in classification of patients of different ages was explored by Schmand et 
al [288] who analyzed the efficacy of neuropyschological measures, CSF biomarkers and 
FDG-PET and MRI measures in classifying two age-stratified groups (younger and older 
than 75 years) within the ADNI cohort. They found that, regardless of age, 
neuropsychological and MRI measures resulted in the most accurate classification. 
Classifications based on CSF biomarkers were more accurate in those aged younger than 75 
but neither FDG-PET nor CSF data augmented accuracy in older individuals (Table 8). Once 
again, combined features resulted in the most accurate discrimination of the cognitively 
impaired (AD and MCI) from the cognitively normal.
4.5.6.5. Missing data: In any large study involving multiple tests, it is inevitable that some 
data will be missing from the overall data set. Two approaches for addressing the issue of 
missing data in multimodal classification represented by Yuan et al [415] and Xiang et al 
[416] who tested their methods (iMSF and iSFS, respectively) on the ADNI cohort and 
found both improved classification over other missing value estimation methods and over 
single-modality classification. A comparison of their results is presented in Fig. 37.
4.5.7. Diagnosis of MCI using National Institute on Aging-Alzheimer’s 
Association criteria—The NIA-AA criteria for MCI due to AD recently incorporated the 
use of biomarkers for both amyloid deposition (CSF Aβ42, 11C-PiB-PET) and neuronal 
injury (CSF tau, hippocampal and whole brain atrophy on MRI, FDG-PET) in addition to 
clinical information [497]. According to these criteria, MCI patients are classified into four 
categories: MCI high (a high likelihood of AD—both Aβ and neuronal biomarkers positive), 
MCI intermediate (an intermediate likelihood of AD—one or other of the biomarker types 
positive), MCI unlikely (unlikely to progress to AD—neither biomarker type positive), and 
MCI core (conflicting/missing biomarkers, no probability assigned). Petersen et al [353] 
compared these criteria in MCI patients in two cohorts including ADNI. Similar trends were 
observed in both cohorts regarding progression to AD, namely, a similar percentage of 
subjects progressed within 12 to 15 months, and of these, the highest proportion were 
positive for both neurodegeneration (MRI, FDG-PET) and amyloid (CSF Aβ42 and PiB-
PET) biomarkers. Progressors also included a smaller proportion of patients who tested 
positive for neurodegeneration biomarkers only, but none who were amyloid positive and 
neurodegeneration negative. The MCI group displayed expected heterogeneity: 55% had 
evidence for both neurodegeneration and amyloid deposition, 12% were amyloid positive 
but neurodegeneration negative, 17% were neurodegeneration positive but amyloid negative, 
and 16% were biomarker negative. This last group may include patients with cognitive 
impairment unrelated to AD. The results suggest that neurodegeneration is of primary 
importance in progression to AD and support the use of biomarkers as an adjunct to the 
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clinical diagnosis of AD. In the ADNI cohort alone, Guo et al [352] examined disease 
progression over 6 to 60 months in MCI patients classified by these criteria. The MCI-high 
subgroup was 2.3 times more likely to progress than MCI core (95% CI: 1.36–3.89, P = .
002), and no patients in MCI-low group progressed within the time frame. The authors 
concluded that the NIA-AA criteria are a useful set of diagnostic guidelines for stratification 
of MCI patients in terms of risk of progression to AD but that binary nature of biomarker 
cutoff points and also division of biomarkers into only two categories may miss opportunity 
for a more nuanced interpretation of the data. As only 48% of ADNI MCI patients were 
found to have consistent AD-like patterns across all biomarkers and could be classified as 
high probability for AD using the NIA-AA criteria, Lowe et al [354] proposed modifications 
to these guidelines (Fig. 38). Using these adjustments, when abnormal amyloid markers 
were prioritized over neuronal markers, only a positive amyloid biomarker and a single 
neuronal injury marker were required for diagnosis of an AD pattern. Eighty seven percent 
of subjects were then classified as having a high probability for AD, and 1% of subjects 
lacking abnormal amyloid and neuronal markers were categorized as having a “high 
probability of non-AD,” avoiding some of the NIA-AA categorizations of patients as 
“undefined” and “uninformative.” Clearly, operationalizing these criteria is a current priority 
to ensure the optimal stratification of patients across the AD spectrum.
4.5.8. Summary and conclusions of diagnostic classification papers—A variety 
of approaches have been used to diagnose MCI and AD, some based on single measures, 
others on composite scores of a single modality, and still others on a combination of factors 
from different modalities. It should be emphasized that ADNI was not designed as a 
diagnostic classification study; none of the imaging methods used in ADNI is as accurate as 
a clinical diagnosis, and the enrolled cohort represents typical cases rather than the types of 
difficult diagnostic problems that clinicians often confront. However, a number of 
conclusions can be drawn from the results of these studies. Single features, such as 
hippocampal volume, are not as accurate as multiple features, such as whole brain or cortical 
thickness measurements. The best classifiers combine optimum features from different 
modalities, including CSF biomarkers, MRI, FDG-PET, and cognitive measures, as well as 
factors such as age and APOE ε4 allele status. The most discriminative measures include 
hippocampal volume, entorhinal cortical thickness, entorhinal metabolism, the t-tau/Aβ-42 
ratio, and ADAS-cog scores. In some of these models, FDG-PET measures appear to lose 
significance to cognitive and MRI measures; however, glucose hypometabolism alone has 
been shown to have high classification accuracy. ADAS-cog scores, either used directly or in 
a model using weighted components, appear to be an excellent diagnostic tool, although the 
highest accuracies were found with the addition of MRI measures. Although most classifiers 
used baseline measurements, there is some evidence to suggest that longitudinal data may 
provide even more accurate diagnoses, but it remains to be seen whether this approach is 
more generally applicable to other modalities. Currently, the best classifiers are able to 
discriminate between control and AD subjects with accuracies in the mid-90% range, but 
have considerably lower accuracies when discriminating between control and MCI subjects 
or between MCI-nc and MCI-c subjects, although data for the latter diagnoses, arguably the 
more important distinction to make, are far less reported. It is as yet unknown whether the 
application of some of the promising classifiers to these problems will result in increased 
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diagnostic accuracy. Another key question is how methods that perform well in ADNI, with 
its sharply delineated diagnostic groups and exclusion of mixed dementias and borderline 
cases, will translate to the community or general clinic setting for wider diagnostic use. 
Validation studies in population-based samples will be required to address this issue.
Studies published in 2011–2012 continued to seek ways to improve classification accuracy 
within the ADNI cohort. Some works detailed approaches to leveraging more information 
from the hippocampus, from cortical thickness and topology and from maximally 
discriminative volumes by deriving statistical indicators. Others dealt with improving 
classification through methodological improvements such as registration to multiple 
templates and by accounting for age-related cognitive decline in control groups. While 
2011–2012 studies did not improve on the best classification accuracies of previous studies, 
they became consistently more accurate, and were able to discriminate between controls and 
MCI or AD patients with accuracies in the mid-90s and mid-80s, respectively. Classification 
of MCI converters and non-converters reached accuracies in the low 80s. The most accurate 
classification methods were generally longitudinal and combined multiple modalities and 
multiple features within each modality. The first reports of blood based biomarkers appeared 
and, despite being exploratory and preliminary, showed great promise for future clinical 
diagnosis. Classification methods developed in ADNI still remain to be validated in 
independent, population based cohorts. Burgeoning research in numerous fields led to many 
exciting developments in classification during 2012 and 2013. The widespread use of 
dimensionality reduction and feature selection techniques improved classifier performance 
over many SVMs. Shapes of subcortical structures and changes in structural and functional 
connectivities during disease progression were used to improve classification. New potential 
biomarkers such as WMHs and α-syn showed promise in distinguishing between patient 
groups, and the continued development of blood-based biomarkers led to their incorporation 
into classifiers for the first time. The nature of the classification problems targeted by 
research groups transitioned from primarily distinguishing AD patients from controls to the 
far more challenging problem of distinguishing MCI converters from nonconverters. 
However, there was increasing recognition of the difficulties in comparing results from 
studies using nonstandardized data sets and/or methodologies. Finally, introduction of new 
NIA-AA criteria for classifying MCI patients underscored the importance of assessing these 
criteria and operationalizing them for future ADNI studies.
4.6. Improvement of clinical trial efficiency
One of the primary goals of ADNI is to improve the efficiency of clinical trials of AD-
modifying treatments. Selection of the study population and development of more sensitive 
outcome measures are two approaches to increasing the power of clinical trials and therefore 
reducing the number of participants required, the length of time required before a disease-
modifying effect is observed, and therefore the overall cost. With the advent of early 
intervention trials, the prediction challenge has shifted toward detecting persons with normal 
cognition who are likely to progress to MCI or even AD within the time frame of the clinical 
trial. This involves the selection of a subset of those subjects who harbor AD pathology but 
to present no clinical manifestation of the disease. This section details the results of studies 
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examining the use of structural, fluid, and genetic biomarkers in the improvement of clinical 
trial efficiency.
4.6.1. Prediction of cognitive decline—Beyond the simple classification of clinical 
trial participants, an important strategy for increasing clinical trial efficiency is the 
enrichment of clinical trial populations, normally MCI patients, with participants who are 
likely to progress to AD within a short time frame. In particular, the early and reliable 
detection of MCI subjects who convert early to AD could support clinical decisions for or 
against therapy with disease-modifying drugs. Many studies have therefore focused on 
identifying baseline predictors of future decline, with “future decline” meaning both decline 
in clinical measures such as the MMSE, ADAS-cog, and CDR-SB, and conversion of MCI 
to AD status. However it is measured, it is desirable for appreciable decline to occur over a 
relatively short time frame, typically 12 months. Imaging measures, CSF biomarkers, and 
APOE ε4 allele status, in combination or alone, have been identified as baseline future 
predictors, and several studies have focused on determining the optimum combination of all 
modalities that results in the most power for clinical trials.
4.6.1.1. Magnetic resonance imaging
4.6.1.1.1. Temporal lobe: Hua et al [112] used TBM to create Jacobian maps of temporal 
lobe atrophy at baseline and examined the relationship between the maps and cognitive 
decline over the following year, as assessed by both the CDR-SB and the MMSE. They 
found that baseline temporal lobe atrophy predicted decline in the MMSE in AD patients 
and also predicted the conversion of MCI to AD over 12 months (Fig. 19; Table 9). Baseline 
atrophy of MTL structures was also found to best predict the progression of MCI patients to 
AD in a study by Desikan et al [163]. These measures, including the volumes of the 
hippocampus and amygdala and the thickness of the entorhinal cortex, temporal lobe, and 
parahippocampal gyrus, were found to be better predictors of clinical decline than levels of 
CSF Aβ-42 or FDG-PET ROIs. The combination of CSF biomarkers and FDG-PET ROIs 
predicted time to progression of MCI to AD with an AUC of 0.70, a sensitivity of 93%, and 
a specificity of 48% compared with MRI temporal lobe factors, which had an AUC of 0.83, 
a sensitivity of 87%, and a specificity of 66%. The addition of CSF or FDG-PET measures 
to the combined Cox proportional hazards model did not significantly increase prediction 
accuracy, with the combined model predicting conversion with an AUC of 0.83, a sensitivity 
of 90%, and a specificity of 69% (Table 9). Similar structures were found to predict future 
decline in cognitive status by Kovacevic et al [164], who used high-throughput volumetry to 
segment ROIs in control, MCI, and AD subjects. They found that after adjusting for age, 
education, and APOE genotype, smaller baseline volumes of the hippocampus and the 
amygdala and larger temporal horn volume predicted 6-month decline in both the MMSE (β 
[P] = 0.14 [.04], 0.18 [.004], and −0.2 [.003], respectively) and CDR-SB (β [P] = −0.19 [.
005], −0.12 [.06], and 0.2 [.005, respectively) in all groups (Table 9). Risacher et al [114] 
also found atrophy of structures within the MTL to be the best antecedent of imminent 
conversion of MCI to AD. The largest effect sizes were for hippocampal and amygdalar 
volume and cortical thickness of the entorhinal cortex and inferior, middle, and superior gyri 
(Fig. 20; Table 9).
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A major challenge for the selection of clinical trial populations is the heterogeneity of the 
amnestic MCI population as only 60% to 70% of these patients harbor AD pathology. 
Hippocampal volume has been shown to be effective in identifying subjects more likely to 
progress to dementia, but its use as a practical tool in subject selection has not been 
addressed. A systematic study by Yu et al [498] characterized hippocampal volume as an 
enrichment biomarker, investigating the selection of an appropriate cut point, the effect of 
outcome measures, and the performance of different hippocampal volume algorithms that 
generate different absolute hippocampal volumes. The study developed cut points based on 
percentiles of distribution of hippocampal volumes from a normal control cohort. At more 
stringent cut points of less than 25% of normal, effect sizes were maximized and sample 
sizes minimized, but trial costs were increased because of higher screen failure rates. 
Investigator costs were minimized with cut points in the range of 10% to 25% of normal, 
which corresponded to an approximate 30% to 40% saving. In general, the estimated trial 
time was unchanged. All four hippocampal volume algorithms tested had similar sample 
sizes, trial costs and trial duration, and effects of cut points on effect sizes. The authors 
hoped that the study would allow informed choice of hippocampal volume cut point, leading 
to the operationalization of hippocampal volume in clinical trials.
If hippocampal atrophy is predictive of future cognitive decline, what biomarkers are then 
predictive of hippocampal atrophy itself? Answering this question has clear implications for 
powering early intervention CTs for AD in which the ability to predict cognitive decline 
from an even earlier time point in the disease is crucial. Desikan et al [163] examined 
whether factors such as CSF biomarkers and measures of cortical thinning were able to 
predict hippocampal atrophy. They found that hippocampal atrophy was significantly 
predicted by decreased levels of Aβ and increased levels of tau in MCI and AD patients and 
by the baseline thickness of the entorhinal cortex and inferior temporal gyrus Aβ and tau 
positive individuals.
4.6.1.1.2. Ventricles: Baseline ventricular morphology has been shown to predict future 
clinical decline in studies of the ADNI cohort. Chou et al [126] found that this measure 
predicted decline in MMSE, global CDR, and CDR-SB over 12 months (Fig. 21; Table 9). 
These findings were confirmed in a subsequent larger study by the same group [127], and 
further extended by examining additional cognitive criteria. Only right ventricular baseline 
anatomy was correlated with future decline in DR memory scores, but there was no 
correlation between ventricular anatomy and changes in depression scores, despite a baseline 
association between these measures (Table 9). Yang et al [487] reported that hippocampal 
and ventricular shapes outperformed corresponding volumetric measures, predicting MCI 
conversion within 2 years with an accuracy of 66.7%, a sensitivity of 82%, and a specificity 
of 51.4%.
4.6.1.1.3. Other regions: Targeting the caudate, a region not traditionally associated with 
AD, Madsen et al [130] found that baseline atrophy in the right caudate predicted both the 
conversion of MCI patients to AD and cognitive decline of this group, as assessed by the 
MMSE (Fig. 22; Table 9). The predictive ability of atrophy in the posterior regions 
(posterior cingulate gyrus, precuneus, and parietal lobe) compared with MTL regions was 
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investigated by Lehman et al [499]. MTL atrophy was strongly associated with MCI to AD 
conversion and with decreased Aβ, whereas posterior atrophy was more weakly associated 
with conversion but more strongly associated with levels of tau. This differential association 
with biomarkers may be indicative of widespread neuronal loss in posterior regions at latter 
stages of disease. These results suggest that in late-onset MCI patients without MTL 
atrophy, posterior atrophy may predict conversion.
Querbes et al [165] created a normalized thickness index, which was derived from the 
cortical thicknesses of regions most likely to show atrophy in AD and to distinguish between 
MCI-c and MCI-nc patients, primarily the left lateral temporal, right medial temporal, and 
right posterior cingulate. They found that the normalized thickness index predicted 
conversion of MCI patients to AD with 76% accuracy compared with accuracies ranging 
from 63% to 72% by cognitive scores (Table 9). The additional dimension of time increased 
the ability of cortical thickness measurements to predict the conversion of MCI to AD in a 
study by Li et al [157]. By incorporating both static baseline and follow-up measures, 
dynamic measures of thinning speed, the ratio of follow-up to baseline thicknesses in ROIs, 
and a network feature that examined correlations between longitudinal thickness change in 
different ROIs, Li et al constructed a classifier that correctly identified 81.7% of MCI-c 
patients 6 months ahead of their conversion (Table 9).
White matter hyperintensities (WMH) may represent an accrual of nonspecific neuronal 
injury over a lifetime. Carmichael et al [166] investigated the relationship between WM 
disease and cognition over a year, and found that both baseline and longitudinal change in 
WMH were associated with worsening of ADAS-cog and MMSE scores over 12 months 
(Table 5), raising the possibility of the use of WMH as a biomarker and highlighting its 
ability to predict future clinical decline (Table 9). When the MCI group was divided 
according to the level of baseline WMH and amyloid burden (PiB uptake), Provenzano et al 
[441] found a monotonic increase in proportion of individuals converting to AD within the 
follow-up visit time frame from amyloid negative/low WMH to amyloid negative/high 
WMH to amyloid positive/low WMH to amyloid positive/high WMH (Fig. 39). The amyloid 
positive/high WMH group was strongly associated with future conversion to AD, providing 
further support for involvement of vascular factors in the pathogenesis of AD.
A number of studies have leveraged information on atrophy from multiple brain regions to 
distill a number or a score that is more predictive of future clinical decline than single 
regions alone. McEvoy et al [117] found that an atrophy score derived from mesial and 
lateral temporal, isthmus cingulate, and orbitofrontal areas was predictive of 1-year decline 
in MMSE scores and progression of MCI patients to AD. They found that the atrophy score 
was a better predictor than right or left hippocampal volume or the thickness of the left or 
right entorhinal cortex (Table 9). Similarly, a structural abnormality score extracted from 
baseline MRI data by Misra et al [118] was higher in MCI patients who converted to AD 
over the following year than stable MCI patients, and an SPS derived by Fan et al [83] from 
a complex pattern of spatial atrophy predicted decline in MMSE scores within a year from 
baseline (Table 9). Vemuri et al [167] found that STAND scores that reflected greater 
baseline atrophy in regions associated with AD predicted greater subsequent decline on the 
CDR-SB and also a shorter time to conversion for MCI patients than CSF analytes (Table 9). 
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Davatzikos et al [119] focused on structural changes occurring at the early stages of AD and 
derived SPARE-AD scores (Spatial Pattern of Abnormalities for Recognition of Early AD) 
largely from changes in the temporal regions, posterior cingulate cortex, precuneus, and 
orbitofrontal cortex. They found that higher SPARE-AD scores predicted conversion of MCI 
to AD (Table 9). In a follow-up study, Da et al [500] found that the inclusion of neither 
APOE status nor CSF biomarkers significantly improved the prediction, although ADAS-
cog was equally effective as SPARE-AD alone in predicting time to conversion. Intriguingly, 
when the MCI patients were stratified by amyloid status, SPARE-AD remained highly 
predictive in the amyloid negative group, contrary to the model of disease progression put 
forward by the amyloid hypothesis. Zhang et al [501] compared the ability of two further 
summary scores of medial temporal lobe and whole brain atrophy, Medial Temporal Lobe 
Atrophy Score (MTAS) and Brain and Lesion Index (BALI), to predict MCI to AD 
conversion over 2 years. MTAS was a stronger predictor than common changes in the aging 
brain represented by BALI. However, BALI scores increased prediction accuracy when 
combined with MTAS (Table 9), suggesting that structural brain changes outside and within 
the MTL have an additive effect. The OLPS score of Spulber et al [382] distinguished 
between MCIc and MCInc patients, with an accuracy of 67.6%, a sensitivity of 69.6%, a 
specificity of 66.8%, and an AUC of 0.675. Moreover, the distribution of scores in MCI 
patients who did not convert during the course of the 3-year study was broad, and higher 
scores were associated with greater age and a higher likelihood of an APOE ε 4 allele. These 
results support the idea of the MCI nonconverter group being highly heterogeneous and 
consisting of a subgroup displaying structural hallmarks of AD likely to progress in the near 
future.
Longitudinal data are increasingly being leveraged for the prediction of future decline. 
Macdonald et al [502] compared the ability of hippocampal and temporal horn baseline 
volumes and 12-month volumetric rates of change to predict conversion in MCI patients 
over the subsequent 12 months. All measures were predictive of future decline, but rates of 
volumetric change were better predictors than baseline volumetric measures. In addition, 
they found some evidence that temporal horn expansion is more predictive than hippocampal 
atrophy. The longitudinal stability selection technique of Zhou et al [407] revealed MRI 
regions predictive of decline in ADAS-cog and MMSE scores at different stages of disease 
progression. Strikingly different patterns were observed for ADAS-cog and MMSE. No 
regions were strongly predictive of MMSE scores for more than 2 years, whereas a number 
of medial temporal regions were predictive of ADAS-cog decline for as long as 3 years (Fig. 
40).
Similarly, disease state–specific neurodegenerative changes were found by Eskildsen et al 
[386], who divided the ADNI cohort into groups determined by their time to conversion: 6, 
12, 24, and 36 months. In each group, ROIs representing differential patterns of cortical 
thinning were identified. MTL regions predominated. Initially, the parahippocampal gyrus 
was selected in the 36-month group followed by the hippocampus in the 24-month group. 
The amygdala and occipital areas were selected in groups closer to conversion, implying a 
progression of the disease through these areas. Selected regions were applied to a linear 
discriminant analysis classifier, and the authors found that prediction of conversion 
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improved in groups closer to conversion, with an accuracy of 74.6% obtained in the 6-month 
group compared with 67.8% in the whole MCI cohort (Table 9).
Prediction of future cognitive decline in cognitively normal individuals has been an 
increasingly important focus in ADNI studies in 2011–2012. Dickerson et al [289] used a 
predefined cortical thickness measure as an MRI biomarker suggestive of early AD 
neurodegeneration to examine this group over 3 years. They found that cognitively normal 
individuals with the low cortical thickness signature were at increased risk of cognitive 
decline (CDR-SB, AVLT and TMT) and were more likely to have Aβ42 levels below the 
192 pg/ml cut-point designating AD-like higher risk (Fig. 30). Chiang et al [290] identified 8 
baseline MRI ROIs from predominantly the temporal lobe that predicted 12 month cognitive 
decline of greater than one standard deviation from the mean with an accuracy of 79% in 
cognitively normal individuals. These results suggest that these MRI biomarkers may have 
utility in identifying individuals harboring AD pathology with a greater likelihood of 
imminent cognitive decline emblematic of AD.
McEvoy et al [168] also investigated enrichment strategies for constraining recruitment into 
clinical trials by selecting MCI patients most likely to progress. Their first strategy, which 
selected MCI patients with an APOE ε4 allele, reduced sample sizes by an estimated 10% to 
40%, but this was discounted because of the possibility that restricting patient genotype may 
invalidate trial findings. Their second strategy, based on baseline MRI atrophy in regions 
previously shown to be predictive of disease progression, resulted in an estimated sample 
size reduction of 43% to 60% (Table 11).
4.6.1.2. [18F]-fluorodeoxyglucose-positron emission tomography: Chen et al [85] 
reported that their HCI outperformed other measures such as hippocampal volume, cognitive 
scores, APOE genotype, and CSF biomarkers in the prediction of conversion of MCI 
patients to AD. In a univariate model, patients with an HCI above a predefined cutoff had an 
average Cox proportional hazards ratio for the estimated risk of conversion to probable AD 
within 18 months of 7.38 compared with 6.34 for hippocampal volume, 4.94 for p-tau181p, 
and 3.91 for ADAS-cog, the most significant of the other measures tested. Moreover, 
patients with a combination of both high HCI score and hippocampal volume below a 
similarly defined threshold value had a Cox proportional hazards ratio of 36.72 (Table 9). 
This study suggests that data from FDG-PET analyses represent a powerful tool for the 
prediction of future decline in AD that is complementary to MRI data. Herholz et al [291] 
assessed the utility of an alternative composite score in predicting MCI to AD conversion 
within 24 months from baseline data and found that their PET score predicted disease 
progression with a sensitivity of 57%, a specificity of 67% and a AUC of 0.75, compared to 
AUCs of 0.68 and 0.66 for ADAS-cog and MMSE scores, respectively (Table 9). The PET 
score appeared to be reflective of AD pathology and highlighted the heterogeneous nature of 
both MCI and control groups, especially evident after 24 months (Fig. 31). When an 
alternative composite, the AD-conv score of Arbizu et al [397] was used to divide MCI 
patients into groups with different probabilities of converting to AD within 18 months, the 
overall AUC for conversion within this time frame was 0.804. While the overall conversion 
rate was 29.7% for the pooled group, it ranged from 75% in the high-probability group to 
7.5% in the very low probability group (Fig. 41). This approach differs from conventional 
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approaches that interpret a biomarker as being positive or negative by using the AD-conv 
score to render probabilities of conversion that may more accurately reflect the slow 
progressive nature of the disease.
The ability of FDG-PET and Florbetapir imaging to predict future cognitive decline and 
conversion from normal cognition to LMCI and from LMCI to AD was compared by 
Landau et al [481]. In normal subjects, Florbetapir status but not FDG uptake was associated 
with ADAS-cog change. However, LMCI patients who were positive for both FDG uptake 
and Florbetapir had greater change in ADAS-cog scores. FDG positive status was associated 
with an OR of 10.9 of conversion from LMCI to AD compared with an OR of 3.0 for 
Florbetapir positive status, underscoring the differential temporal involvement of amyloid 
deposition and glucose metabolism in disease progression.
4.6.1.3. CSF and blood biomarkers: Vemuri et al [167] examined the ability of CSF 
biomarkers to predict decline in CDR-SB and MMSE scores over 2 years and the time to 
conversion from MCI to AD. Although all CSF biomarkers were predictive of future decline, 
the best predictor was log (t-tau/Aβ-42), which was comparable with the MRI-derived 
STAND scores. In contrast, Aβ-42 alone was only weakly predictive of conversion to AD, 
reflecting its status as a marker of early AD pathology. Used in combination with STAND 
scores, only log (t-tau/Aβ-42) improved the predictive ability of the MRI measure (Table 9). 
Jack et al [152] compared the ability of amyloid load, measured either by levels of CSF 
Aβ-42 or by 11C-PiB PET imaging, and hippocampal volume to predict MCI to AD 
progression. Using a new method to pool CSF and 11C-PiB PET data [169] and to extract a 
score representative of Aβ load from the pooled information, they found that the group of 
MCI patients classified as being Aβ positive had higher frequencies of the APOE ε4 allele 
and smaller baseline hippocampal volumes and a threefold higher chance of progressing to 
AD within 3 years than the Aβ-negative group (Fig. 23; Table 9). Thus, both baseline 
hippocampal atrophy and Aβ load were significant predictors of future decline. Interestingly, 
when risk profiles were constructed from the log relative hazard of progressing and degree 
of hippocampal atrophy or Aβ load, the relationship was linear for hippocampal atrophy, but 
plateaued at higher Aβ loads, consistent with a model in which Aβ deposition is an early 
event in AD progression, whereas neurodegeneration, as evidenced by hippocampal atrophy, 
occurs later and is thus a better indicator of progression toward dementia.
Using the ADNI database, Schneider et al [170] empirically tested the recommendation that 
low Aβ-42 and a high t-tau/Aβ-42 ratio can help select those MCI patients most likely to 
progress to AD throughout the course of a clinical trial. After statistically simulating a 
number of different clinical trial scenarios with MCI patients with or without biomarker 
enrichment, they found that selection with either of the biomarker criteria resulted in only 
minor increases in power for the trial, and concluded that the use of these criteria would 
likely not result in more efficient clinical trials. In contrast, Beckett et al [154] calculated 
that restricting a trial population to MCI subjects with CSF Aβ-42 levels of <192 pg/mL 
would reduce the sample size required from 375 to 226 subjects per arm to detect a 25% 
change using ADAS-cog as an outcome measure, demonstrating a clear beneficial use of 
CSF biomarkers in clinical trial population selection (Table 10). Schott et al [160] tested the 
use of the same cutoff point of CSF Aβ-42 levels in cognitively normal elderly subjects as a 
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selection tool for presymptomatic treatment studies in AD. Those participants with CSF 
Aβ-42 levels of <192 pg/mL had higher levels of t-tau and p-tau and higher ratios of 
tau/CSF Aβ-42 and p-tau/CSF Aβ-42, were more likely to be carriers of the APOE ε4 allele, 
and had significantly higher whole brain atrophy, ventricular expansion, and hippocampal 
atrophy over 1 year than participants with higher CSF Aβ-42 levels. Of the six participants 
who later converted to MCI or AD, five had low or borderline baseline CSF Aβ-42 levels, 
suggesting that the roughly one-third of healthy elderly subjects with a CSF profile 
consistent with AD were at greater risk for development of the disease. When sample sizes 
for clinical trials were calculated for both CSF Aβ-42 levels and APOE ε4 genotype as 
selection criteria and using whole brain atrophy, ventricular expansion, or hippocampal 
atrophy as the outcome measure, the smallest size per arm [140] was calculated using 
selection by CSF Aβ-42 levels and whole brain atrophy as an outcome measure (Table 10). 
Samtani et al [503] studied the relationships between CSF biomarkers and disease 
progression measured by ADAS-cog scores in MCI patients. Baseline Aβ42, p-tau181, and 
ptau181/Aβ42, but not t-tau levels, had a bimodal distribution, supporting the idea of the 
state of prodromal disease being a heterogeneous population of those likely and unlikely to 
progress. Baseline levels of these biomarkers had good negative predictive value. Eighty-
four percent of subjects below the cutoff did not convert to AD within 3 years. In contrast, 
the positive predictive value of this measure was lower as only 67% of those above the cutoff 
converted within this time frame. The study suggests that in clinical trials, CSF biomarkers 
may play a more important role in the exclusion of MCI candidates unlikely to progress than 
in the selection of candidates likely to progress.
Llano et al [422] reported that they were unable to derive a proteomic signature derived from 
plasma analytes that was able to predict MCI to AD conversion over 12 to 24 months with 
an accuracy greater than 55% to 60%. However, more promising results were reported for 
the prediction of amyloid burden rather than disease progression. A panel of 13 plasma 
analytes developed by Kiddle et al [423] predicted PiB positivity with a sensitivity of 0.918 
and a specificity of 0.545. The combination of five analytes, APOE status, age, and CDR-SB 
scores predicted abnormal neocortical amyloid burden in all AD patients, 69% of MCI 
patients, and 34% of cognitively normal controls with a sensitivity of 79% and a specificity 
of 76%. These studies suggest that while blood-based biomarkers do not yet predict disease 
progression sufficiently accurately to be clinically relevant, they represent a promising 
approach that warrants further development.
4.6.1.4. Cognitive: Ito et al [171] evaluated disease progression in clinical studies and drug 
trials performed between 1990 and 2008 by using a model to assess the effect of 
cholinesterase inhibitors and placebos on longitudinal ADAS-cog scores in mild-to-
moderate AD patients. They found no significant differences in the rate of disease 
progression between patients taking the placebo versus patients receiving cholinesterase 
treatment. The only significant covariate in disease progression was baseline ADAS-cog 
score, suggesting that those patients with a higher (worse) ADAS-cog score at baseline had a 
significantly worse prognosis and higher rates of cognitive deterioration than those with 
lower (better) baseline scores (Table 9). In a further work by the same group [44], 
longitudinal ADAS-cog data from ADNI was used to construct a model that included 
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baseline severity, APOE status, age and gender identified as covariates to predict a 
curvilinear rate of disease progression. Samtani et al [262] also used longitudinal changes in 
ADAS-cog scores and developed a non-linear mixed effects model for disease progression in 
AD. They found that years since disease onset and hippocampal and ventricular volume 
were the primary covariates affecting baseline disease status, whereas age, total cholesterol, 
APOE status, and cognitive scores (TMT-B and ADAS-cog) most influenced the rate of 
disease progression in the model. The time of entry into the study may not be equivalent to 
disease onset time. Delor et al [504] developed a natural history population disease 
progression model based on CDR-SB scores that allows biomarker profiles to be 
synchronized at disease onset rather than at study entry. This approach virtually expanded 
the observation period of the population from 3 to 8 years (Fig. 42).
Llano et al [96] used a new Random Forests tree-based multivariate model of ADAS-cog in 
which the subscores had been weighted according to their contribution to patient 
discrimination. This model, ADAS. Tree, predicted conversion of MCI to AD more 
accurately than baseline MMSE or ADAS-cog and, in addition, was a better predictor of 
conversion than the best single imaging (left inferior temporal cortex), metabolism (left 
precuneus), or CSF (p-tau181p/Aβ-42) biomarkers. The significance of association varied by 
several orders of magnitude, with the ADAS. Tree four orders of magnitude higher than the 
next MRI marker, and FDG-PET and CSF biomarkers several orders of magnitude lower 
than the MRI marker. Moreover, the addition of these markers to the ADAS. Tree model did 
not result in substantial improvement, providing support for this modified form of ADAS-
cog as a useful and effective predictor of future decline (Table 9).
The analysis of neuropsychiatric tests using poset models by Tatsuoka et al [425] allowed 
correlations to be made between specific cognitive domains and MCI to AD conversion 
within 2 years. While the overall conversion rate for all MCI subjects was 37.7%, the rate 
for subjects with a high level of episodic memory impairment at baseline was 61.2%. Those 
subjects who additionally possessed an APOE ε 4 allele had a conversion rate of 84.2%. In 
contrast, subjects who were APOE ε 4 negative and whose episodic memory functioned 
relatively higher had less than a 10% chance of conversion in 2 years. Lower scores in 
cognitive flexibility and perceptual motor speed were also associated with greater rates of 
conversion. This preliminary study suggests that poset modeling may be an extremely useful 
tool in the selection of clinical trial populations.
As depression is a recognized risk factor for AD, there has been some interest in depression 
as a symptom of prodromal AD and therefore as a surrogate clinical marker. Mackin et al 
[292] investigated whether subsyndromal symptoms of depression (SSD), with a prevalence 
of up to 70% in MCI patients may be associated with conversion to AD and thus may predict 
future cognitive decline. They found that increased endorsement of only one symptom – 
memory problems – longitudinally, predicted MCI to AD conversion. Lee et al [293] used 
TBM to compare patterns of brain atrophy over 2 years in MCI patients with or without 
depressive symptoms. They detected greater frontal (P = .024), parietal (P = .030) and 
temporal (P = .038) WM atrophy, and larger cognitive deficits in a range of 
neuropsychological tests in subjects with depression and found that 62% of those with stable 
depressive symptoms converted to AD within the time of the study compared to 27% of 
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asymptomatic individuals. These studies suggest that depression and its related syndromes 
may have potential as clinical markers for the identification of patients likely to progress.
4.6.1.5. Combined modalities: As in diagnostic classification, combinations of different 
modalities are proving to be powerful tools in the prediction of future cognitive decline 
[239,247,251,252]. Lorenzi et al [172] tested two strategies for the enrichment of MCI 
patients in clinical trials using changes in brain structure or metabolism, or changes in CSF 
biomarkers well known to herald future disease progression. They used hippocampal 
atrophy (MRI); temporoparietal hypometabolism (FDG-PET); CSF Aβ-42, t-tau, and p-tau; 
and cortical amyloid deposition (11C-PiB PET) as biomarkers to either screen in MCI-c or 
screen out MCI-nc. Although both strategies substantially reduced the estimated sample 
sizes required, the authors found that there was a trade-off between the high proportion of 
converters screened out in the first strategy and the decreased power and increased estimated 
sample sizes using the second strategy (Table 10). Kohannim et al [86] investigated the 
utility of their machine learning classifier, based on MRI hippocampal and ventricular 
summaries, APOE genotype, and age as features, in subject stratification and found that it 
reduced the numbers of AD and MCI patients required to detect a 25% slowing of temporal 
lobe atrophy with 80% power to fewer than 40, a substantial reduction over other methods 
(Table 10). Walhovd et al [155] examined baseline MRI, FDG-PET, and CSF biomarker data 
to determine the optimum combination of these biomarkers for the prediction of decline over 
2 years. They found that in MCI patients, retrosplenial and cortical thickness predicted 
decline on the CDR-SB, retrosplenial and entorhinal metabolism predicted decline on the 
MMSE, and hippocampal volume predicted decline in delayed logical memory. The tau/
Aβ-42 ratio also predicted decline in the CDR-SB and MMSE, but less significantly than the 
MRI and FDG-PET measures (Table 9). Beckett et al [154] found that in MCI and AD 
patients, baseline glucose metabolism in a range of ROIs predicted cognitive decline, as 
measured by ADAS-cog in a multivariate model. In univariate models, hippocampal and 
ventricular volume, Aβ-42, and tau also predicted cognitive decline in MCI patients (Table 
9). Both papers support the idea that reduced metabolism and greater brain atrophy at 
baseline are associated with more rapid cognitive decline, and that CSF biomarkers are less 
useful indicators of future change. Shaffer et al [505] reported that while the addition of 
MRI or FDG PET ROIs, or CSF biomarkers to clinical covariates (age, APOE status, 
ADAS-cog, education) improved both prediction accuracy and reduced the percentage of 
misclassification, the effect of MRI and CSF biomarkers was minimal and FDG PET data 
added the greatest gains (Table 9). This may be due to a shared variance between the APOE 
ε 4 allele and Aβ and also between the APOE ε 4 allele and hippocampal volume; FDG-
PET is a modality that provides truly novel data that are not related to other covariates. A 
degree of agreement with these results was found by Landau et al [173], who studied a range 
of predictors of conversion to AD and cognitive decline, including FDG-PET measures, CSF 
biomarkers, APOE ε 4 status, and hippocampal atrophy, that were defined dichotomously 
according to their ability to separate AD and control subjects. Although all biomarkers were 
predictive of decline in univariate models, only reduced glucose metabolism and episodic 
memory (measured by the AVLT) predicted conversion to AD and, in contrast to the studies 
by Beckett et al [154] and Walhovd et al [155], only p-tau181p/Aβ-42 predicted decline in 
ADAS-cog scores in multivariate models (Table 9). Ewers et al [161] compared the 
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effectiveness of single variables and multiple variables in predicting the conversion of MCI 
to AD. They found that these best single predictors (right entorhinal cortex and the TMT-B) 
were comparable in accuracy with the best multiple predictor models, which included right 
hippocampal volume, CSF p-tau181p/Aβ-42, TMT-B, and age (Table 9). In ADNI and an 
additional cohort, Prestia et al [506] reported that the optimal combination of biomarkers for 
identifying prodromal AD was hippocampal volume and CSF Aβ. Examining MR, CSF, 
cognitive and demographic data, Gomar et al [294] found that their most predictive model 
included 2 measures of episodic memory (AVLT-delayed memory and Logical memory 
delayed total) and one MR measure (left middle temporal lobe thickness) (Table 9).
In 2011–2012, the emphasis of these studies has shifted toward using methods that 
automatically combine and leverage the most pertinent information from a range of 
modalities and away from the construction and comparison of individual linear regression 
models. The multi-modal multi-task learning method of Zhang et al [239] was able to 
combine most predictive features from MRI, FDG-PET and CSF data and predict 2 year 
changes in both MMSE (r = 0.511) and ADAS-cog (r = 0.511) scores in MCI patients (Table 
9). A subsequent paper by Zhang et al [239] used both baseline and longitudinal data to 
achieve even higher prediction accuracies. Their best predictions of 2 year changes in both 
MMSE (r = 0.786) and ADAS-cog (r = 0.777) scores used baseline, 6, 12 and 18 month 
data. The conversion to AD from MCI within the same time frame was predicted with 
accuracy of 78.4%, a sensitivity of 79%, a specificity of 78% and an AUC of 0.768 (Table 
9). Similarly, the Multi-Modality Disease marker developed by Hinrichs et al [118] used 
longitudinal data to predict conversion more accurately than baseline data alone and found 
that combined biological, imaging and neuropsychological data outperformed single 
modalities (Table 9). Another method recently developed by Wang et al [251], SMART, 
which takes into account the interconnectedness of brain structures and other measures, 
consistently resulted in better prediction of AVLT scores in control, MCI and AD patients. 
An approach using the weighted fusion of data from both high- and low-dimensional 
modalities [406] found that MCI to AD conversion was optimally predicted with an 
accuracy of 68% by a combination of FDG PET, MRI shape information (ventricular 
expansion and cortical thinning in specific regions), and CSF biomarkers, although CSF 
biomarkers added only minor improvement. Integration of multimodal data in a probabilistic 
manner using a Gaussian process classification approach [408] predicted conversion of MCI 
to AD over 3 years with an accuracy of 72.2% compared with 69.4% using the multimodal 
method of Zhang et al [249]. The disease state index of Mattila et al [252], which included 
demographic and genetic information as well as imaging data and cognitive scores, was able 
to predict the conversion of MCI to AD with an AUC of 0.752 (Table 9). Soininen et al [253] 
used the same tool and found that it could discriminate between MCI converters and stable 
MCI patients with an accuracy of 68.6%, but that when patients were assigned to categories 
of risk for AD based on threshold values, the prediction accuracy increased to 84.4% for 
those having strong evidence and to 93.7% for those with very strong evidence of AD 
pathology (Table 9). The Predict AD software developed by this group significantly 
outperformed currently recommended criteria for prodromal AD in predicting conversion 
within 3 years. Liu et al [418] found that, with the aid of a clinician, this tool had an 
accuracy of 72%, a sensitivity of 75%, and a specificity of 68%, supporting the utility of 
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software that can integrate heterogeneous data and provide objective and evidence-based 
information about the state of the patient that is not limited to yes/no answers and that places 
patients on a disease spectrum on the basis of this information.
While the above papers developed a range of automatic multi-modal methods of the 
prediction of disease progression, Heister et al [295] asked whether MCI to AD conversion 
can be predicted using clinically available biomarker systems (commercially available 
software for fully automated volumetric MRI and commercial CSF analysis). They stratified 
the MCI cohort by degree of MR atrophy, CSF biomarker levels or the degree of learning 
impairment on AVLT. Cox proportional hazard models were used to assess the contribution 
of each factor to MCI to AD conversion. They found that a single risk factor resulted in a 1.8 
to 4.1 fold risk of converting to AD within 3 years and that more than one risk factor was 
associated with a greater risk of conversion. Patients with both learning impairment and 
increased MR atrophy were at the highest risk with a HR of 29.0 for conversion. This study 
supports the use of commercially available CSF and MRI biomarkers in combination with 
neuropsychological tests in predicting the risk of MCI to AD conversion.
The degree to which prediction models developed in one cohort are generalizable to 
different settings was investigated by Devanand et al [296]. They developed a variety of 
models that included different combinations of imaging, cognitive and demographic data in 
the Questionable Dementia study and tested these in the ADNI cohort. Prediction accuracy 
of the MCI to AD conversion was consistently lower by a similar degree in the ADNI 
setting, suggesting that these models are portable and robust in clinical settings. Gross et al 
[466] combined cortical thickness and cognitive data to predict MCI to AD conversion. They 
used regression analysis to develop cortical signatures of cognition specific to memory, 
executive function, language, and visuospatial processing domains, empirically defined by 
their correlation with domain-specific cognitive factor scores derived from new ADNI 
neuropsychological battery scores [112]. The combination of the baseline thickness of these 
cortical signatures of cognition for memory and language and the corresponding 
neuropsychological factor scores predicted future clinical decline. One standard deviation 
decrease in the combined memory cortical signature and memory factor score corresponded 
to a 2.3-fold increase in hazard of conversion. Casanova et al [411] developed AD-PS scores 
that, when combined structural MRI and cognitive scores, were able to detect AD-like 
patterns of atrophy and cognitive decline across clinical groups and were strongly associated 
with MCI to AD conversion times.
What role does age play in the prediction of future decline in MCI patients? The logistic 
regression analyses conducted by Schmand et al [507] revealed that some biomarkers had 
differential predictive abilities depending on the age of the participants. Whereas MRI and 
neuropsychological tests were relatively stable predictors regardless of age, CSF biomarkers 
were only effective in patients younger than 75 years and FDG-PET did not significantly 
currently predict conversion at any age. None of the measures predicted MCI to AD 
conversion with an AUC of greater than 0.73 at any age, although combined markers had 
improved predictive abilities (AUCs of 0.79 and 0.74 in participants younger and older than 
75 years, respectively). The study supports the idea that age is an important characteristic of 
the observed heterogeneity in MCI patients.
Weiner et al. Page 90













Does the predictive ability of biomarkers change over different lengths of time? Dickerson et 
al [508] examined how a structural MRI measure of neurodegeneration, the AD signature, 
and hippocampal volume compared with a measure of amyloid deposition (CSF Aβ) in 
predicting conversion of MCI patients over both 1- and 3-year periods. The AD signature 
biomarker outperformed CSF Aβ at predicting dementia within 1 year, whereas both 
biomarkers had similar prognostic abilities over 3 years. In addition, 1-year conversion to 
AD in MCI subjects with normal CSF Aβ levels was best predicted by the AD signature 
biomarker, suggesting that evidence of neurodegeneration is prognostically useful in these 
individuals. These results are consistent with the model of development of AD 
pathophysiology by Jack et al [14] in that the deposition of Aβ is an earlier event and 
therefore should predict conversion over a longer period than the later-occurring 
neurodegeneration.
The need to select clinical trial participants who are cognitively normal but who are likely to 
progress to MCI or AD has driven research into predicting clinical progression in the elderly 
healthy subjects. Ewers et al [509] examined 54 healthy control subjects from ADNI and 
tested the ability of MRI regional GM volume, FDG-PET a priori–defined ROIs, and 
executive function measures to predict clinical change over 3 to 4 years. The combination of 
FDG-PET measures in the medial temporal and parietal regions combined with TMT-B 
scores proved to be the most accurate predictor of clinical progression with an accuracy of 
93.4%, a sensitivity of 82%, and a specificity of 93%. Of the 54 subjects, 11 converted to 
MCI or AD over the course of study.
4.6.1.6. Comparison of modalities: The trend toward a multimodal approach to prediction 
is fueled by studies reporting improved accuracy with the use of more than one modality. 
Most studies report that optimum combinations of modalities for prediction include MRI 
measures of the temporal lobe, hippocampus and entorhinal cortex, and another imaging 
modality, perhaps with the addition of CSF biomarkers, genetic, or clinical information. 
However, for the first time, the effectiveness of three different imaging modalities (MRI, 
PiB-PET, and FDG-PET) in the prediction of conversion of MCI patients to AD was directly 
compared by Trzepacz et al [510] in ADNI MCI patients who converted within 2 years. 
Eliminating genetic or clinical data from their models, they found that the best single 
predictors were MRI measures of temporal lobe, hippocampal and entorhinal cortex volume, 
along with amyloid deposition in the temporal cortex measured by PiB-PET. MRI was the 
single modality with the highest predictive accuracy (67%) followed by PiB-PET (66%) and 
FDG-PET (62%). In combination, MRI increased the accuracy and sensitivity, but not 
specificity of both PiB-PET and FDG-PET measures (Fig. 43). MRI in combination with 
PiB-PET increased accuracy to 76% with a sensitivity of 53% and a specificity of 90%. This 
systematic review confirms results from a variety of previous studies.
4.6.2. Adjustments for normal aging and baseline characteristics—McEvoy et al 
[168] also examined the effect of normal aging on the detection of longitudinal change and 
found that although this did not affect clinical outcome measures such as ADAS-cog and 
CDR-SB, neuroimaging outcome measures were far more sensitive to atrophy associated 
with normal aging. They suggested that larger sample sizes are required in clinical trials to 
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account for this effect, and that clinical trials run the risk of being severely underpowered if 
normal aging is not taken into account. Schott et al [174] proposed an alternative method for 
increasing the statistical power of clinical trials without resorting to subject selection 
procedures that can potentially limit the applicability of studies. They found that by 
statistically adjusting for a range of baseline characteristics that might account for 
interindividual differences, and also for normal aging, sample sizes were reduced by 15% to 
30% in AD subjects and by 10% to 30% in MCI subjects (Table 10). The importance of 
appropriate controls in AD disease-modifying clinical trials was studied by Holland et al 
[297] who estimated required sample sizes using either absolute change relative to baseline, 
change relative to controls or change relative to healthy controls who tested negative for Aβ. 
While their calculations suggested that larger sample sizes were required for measures 
relative to Aβ negative controls, the authors felt that this approach would most accurately 
reflect the actual effect of a drug on AD pathology. The study compared 5 publically 
available methododologies to measure structural changes in neuroanatomical subregions and 
smallest sample sizes were calculated using the QUARC approach to quantify the entorhinal 
cortex (Table 10).
4.6.3. Development of outcome measures—A number of studies have focused on 
determining the effectiveness of different biomarkers as outcomes in clinical trials by 
calculating sample size estimates for a hypothetical clinical trial, per arm at either 90% 
(N90) or 80% (N80) power to detect a 25% improvement in annual rate of decline. Schuff et 
al [121] used hippocampal volume loss over time, assessed by MRI, as an outcome measure 
and found that the greatest reductions in sample size were achieved when three serial scans 
(0, 6, and 12 months) were combined with APOE ε4 data using Markov chain analysis to 
exploit correlations between observations (Table 11). The inclusion of Aβ-42 level data did 
not further reduce sample size. All MRI hippocampal measures were substantially better 
than cognitive measures (ADAS-cog and MMSE) as outcome measures. Wolz et al [64] used 
a 4-D graph cut method to segment the hippocampus and subsequently calculated N80s in 
the same range as the best combinations of Schuff et al [121] (Table 11). Nestor et al [175] 
investigated the use of ventricular expansion as an outcome measure and found that 
ventricular expansion over 6 months was sufficiently sensitive to produce N80s for a 
hypothetical trial at least an order of magnitude lower than clinical scores (MMSE and 
ADAS-cog). Moreover, sample sizes were further reduced when the trial population of AD 
subjects was restricted to carriers of the APOE ε4 allele (Table 11). Holland et al [176] 
examined the utility of longitudinal volumetric change in a variety of ROIs as an outcome 
measure with which to measure putative disease-modifying medications for AD and MCI. 
ROIs, including temporal lobe structures and ventricles, and whole brain atrophy were 
compared with clinical measures in two separate models, one in which the putative drug was 
presumed to affect both disease and aging-related changes (model T for “total”), and one in 
which the drug putatively affected only disease-specific changes (model D for “disease-
specific”). They found that although imaging measures generally resulted in smaller sample 
sizes than cognitive measures in both models, model T was the more conservative model for 
cognitive measures, whereas model D was more conservative for imaging measures. The 
authors emphasized the importance of comparing both models when comparing across 
imaging and cognitive outcome measures (Table 11).
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Hua et al [177] compared a variety of nonlinear registration methods used in TBM with 
standard clinical outcome measures and found that a substantial reduction in sample size at 
80% power (N80s) was achieved over clinical measures using all TBM methods, with the 
best TBM measure presenting an eightfold improvement over the best clinical measure 
(CDR-SB) (Table 11). The same group [120] subsequently compared the use of TBM to 
measure GM of the entire brain and WM atrophy in the temporal lobe with 1-year changes 
in CSF biomarkers as outcome measures in a hypothetical clinical trial. The N80s for CSF 
biomarkers were much larger than those from neuroimaging measures, reflecting their 
poorer reproducibility, especially in later stages of the disease process (Table 11). Ho et al 
[47] compared 3.0-T and 1.5-T MRI for tracking disease progression using TBM and an 
alternative method for measuring the overall percentage brain volume change, Structural 
Image Evaluation, using Normalization, of Atrophy. The lowest calculated N80 resulted 
from using TBM on a 1.5-T MRI scanner to detect changes in brain atrophy as an outcome 
measure (Table 11). Leung et al [51] estimated N80s for both the classic brain BSI MRI 
technique and their improvement on this, the KN-BSI method, and found that the improved 
method resulted in lower N80s (Table 11). More recently, using a newly revised TBM 
method that enforces inverse consistency, Hua et al [178] reported that to demonstrate a 25% 
slowing of atrophic rates with 80% power, 62 AD and 129 MCI subjects would be required 
for a 2-year trial and 91 AD and 192 MCI subjects for a 1-year trial. A longitudinally 
unbiased method that uses machine learning techniques to maximize the ability to track 
three-dimensional change in lateral ventricles over time was described by Gutman et al 
[511]. Using linear discriminant analysis on the generated data, they estimated N80s over 1 
year to be 104 for MCI patients and 75 for AD patients, compared with estimates of 165 and 
94 for MCI and AD patients, respectively, using the statistical ROI method. Pardoe et al 
[512] derived a model using a genetic programming approach that takes into account study-
specific parameters such as the type I error rate, the level of smoothing applied, and the 
thickness difference to be detected in clinical trials measuring cortical thickness. Sample 
size estimates were heterogeneous over the cortical surface, with lobe-specific N80s for the 
detection of a 0.25-mm thickness change ranging from approximately 25 to 30 to 50 in the 
occipital lobe, frontal and parietal lobes, and the temporal lobe, respectively. Thus, 
accounting for cortical thickness spatial variability may be critical when designing clinical 
trials.
Beckett et al [154] compared a number of promising MRI and FDG-PET outcome measures. 
They calculated the sample size that would be required in a two-arm, 1-year clinical trial 
with 80% power to detect a 25% effect, and found that MRI measures of overall brain 
change, using either ROIs or BSI techniques, or hippocampal volume required fewest 
subjects. Brain metabolism measures were generally less effective, requiring substantially 
larger sample sizes, although the best FDG-PET measure, a data-driven functional ROI, was 
comparable with many of the MRI measures (Table 11). In contrast, Herholz et al [291] 
found their composite PET score, based on FDG-PET data, to be a better outcome measure 
than ADAS-cog scores due mostly to its higher test-retest reliability which resulted in 
smaller required sample sizes. Relative to a sample size of 100 required at 12 months with 
ADAS-cog as an outcome measure, the PET score outcome measure required a sample size 
of 28. At 6 and 24 months, the PET and ADAS-cog sample sizes were 120 and 397, and 13 
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and 35, respectively. The PET score was linearly associated with ADAS-cog scores, 
emphasizing its validity as a measure of cognitive impairment.
The accepted standard outcome measure in AD disease modifying clinical trials is the 
ADAS-cog. Schrag et al [298] empirically determined the minimum clinically relevant 
change in ADAS-cog and compared it to the current standard of expert consensus. Using 
MMSE, CDR and FAQ scores, they ascertained that a 3 point decline in ADAS-cog over 6 
months was clinically relevant, a point less than the consensus FDA recommendation, 
suggesting that the FDA standard may be too stringent and may consequently miss an 
important drug effect.
4.6.4. Genetic risk factors in subject selection—The addition of APOE status has 
consistently been shown to improve the accuracy of predictive models. Kohannim et al [513] 
examines the utility of the recently identified AD genetic risk alleles, CR1, CLU, and 
PICALM, in selecting cohorts for clinical trials. Control and MCI subjects from ADNI were 
ranked depending on the relative risk from these four genes, and N80s were obtained using 
an MRI-derived 2-year atrophy rate as an outcome measure. They found a statistically 
significant reduction in sample size of approximately 50% in the combined control and MCI 
group beyond the effect of the APOE ε 4 allele alone when these three risk alleles were 
included in the model. In a mixture of MCI and control APOE ε 4 carriers, the N80 was 
reduced from 94 to 69 using selection with these three genetic risk factors. The results 
suggest that genetic profiling with additional risk genes may be an effective strategy in 
reducing sample sizes in clinical trials of early intervention therapies.
4.6.5. Combining enrichment and stratification strategies—Increasing attention 
has been given to optimizing enrichment and stratification strategies to select the small 
cohorts of cognitively asymptomatic and MCI subjects required for viable clinical trials. 
Using the full standardized ADNI data set [514], Hua et al [515] calculated sample size 
estimates using temporal lobe atrophy measured by TBM as an outcome measure combined 
with stratification based on APOE ε 4 status. For a 2-year trial, N80s of 73 (95% CI: 57–94) 
and 122 (95% CI: 80–229) were estimated for MCI and cognitively normal patients, 
respectively. In MCI patients, Holland et al [516] found that stratification with p-tau181 
combined with the use of entorhinal cortex atrophy as an outcome measure produced the 
smallest estimated sample sizes. All MRI atrophy outcome measures outperformed the best 
clinical measure, CDR-SB (Fig. 44). However, as the FDA has not yet accepted biomarkers 
as outcome measures, Grill et al [517] tested combination of enrichment strategies and 
clinical outcome measures. In MCI subjects, the CDR-SB as an outcome measure 
consistently produced lowest sample sizes over virtually all enrichment strategies in 
agreement with Cedarbaum et al [518]. Estimates for N80s with this outcome measure 
ranged from 258 with enrichment using the t-tau/Aβ to 458 with no enrichment. In contrast, 
the lowest sample size in the cognitively normal group (499) was obtained using enrichment 
with APOE ε 4 status and AVLT-total as an outcome measure. The studies support the use of 
biomarker inclusion criteria for predementia and early dementia clinical trials and suggest 
that the CDR-SB may be a more sensitive clinical outcome measure of these trials. However, 
both studies using cognitive tests as outcome measures reported that in contrast to biomarker 
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outcome measures, sample size estimates for cognitively normal populations had 
prohibitively high upper bounds. This suggests that in order for clinical trials in 
presymptomatic cohorts to be feasible, a biomarker-based outcome measure should be 
considered.
4.6.6. Other improvements to clinical trials—Clinical trials for AD modifying 
treatments require special considerations due to the advanced age of the participants and 
their high rates of medical co-morbidities. Hendley et al [299] studied patients taking 
placebo in recent AD clinical trials and ADNI control participants to determine the rates of 
adverse events, serious adverse events, discontinuation from trials and frequencies of death. 
The authors hoped that the accumulated reference data would aid in the design of future long 
term AD studies. Thompson et al [300] reviewed methodologies for characterizing disease 
trajectories over a lifespan using ADNI as an illustration of a longitudinal unstructured 
multi-cohort study. They reported that, while this study design is superior to a cross-
sectional design in terms of eliminating a number of confounding factors, it is still 
susceptible to age cohort effects due to the randomness of participant ages (ranging from 55 
to 90). They suggest an improved structured longitudinal model in which age cohorts would 
be tiered but overlapping. As ADNI is a convenience sample and not population based, the 
ADNI cohort may select people more predisposed to cognitive decline. Therefore, sample 
sizes based on hippocampal atrophy may result in trials underpowered to detect treatment 
effects in the general population [519]. Hua et al [515] tested the effect of selective data 
exclusion, that is, the removal of apparent outliers, and found that this practice resulted in 
the underestimation of N80s and therefore constitutes a major source of bias in ADNI 
experiments. The use of the standardized ADNI data set [514] will hopefully circumvent this 
issue.
The clearance of Aβ by immunotherapy approaches under study in some clinical trials may 
increase the risk of microhemorrhage and siderosis. Kantarci et al [520] investigated the 
prevalence of these conditions in the ADNI cohort and their association with amyloid load. 
Focal hemosiderin deposits indicating microhemorrhages occurred in 25% of the cohort. 
Their prevalence increased with age and Aβ deposition, and the risk of subsequent 
microhemorrhage increased with increasing baseline occurrence. The study suggests that 
microhemorrhages are a common imaging finding that should be taken into consideration in 
the planning of clinical trials of amyloid-modifying agents for disease prevention and 
treatment.
4.6.7. Summary and conclusions of papers focused on the improvement of 
clinical trial efficiency—Strategies for the reduction of sample sizes in clinical trials by 
the selection of subjects with a significantly worse prognosis and through the use of more 
effective outcome measures have been developed over the course of ADNI. Studies have 
found that baseline MRI measures, particularly of hippocampal volume and of whole brain 
atrophy, outperform measures of glucose hypometabolism or CSF biomarkers in the 
prediction of future decline. In one instance, a score derived from AD-like patterns of 
hypometabolism outperformed other single MRI, cognitive, or CSF biomarker measures, but 
this too was enhanced by the addition of MRI measures. Of the CSF biomarkers, the t-tau/
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Aβ-42 ratio and the use of a cutoff value of approximately 192 pg/mL Aβ-42 have been 
shown to best predict future decline. In a manner similar to classification of AD subjects, the 
use of multiple modalities appears to enhance the prediction of future decline. Interestingly, 
a weighted version of the ADAS-cog [96] has been shown to outperform any single MRI 
measure tested as a predictor of future change and was not improved by the addition of any 
MRI measure tested. In contrast, MRI and FDG-PET, which have strikingly better signal-to-
noise ratios, clearly outperformed cognitive tests as outcome measures of rates of change. 
Calculated sample sizes for clinical trials required to see a 25% effect at 80% power were 
lowest for MRI measures of overall morphometric change or of hippocampal volume, 
followed by those for hypometabolism ROIs and cognitive scores. CSF biomarkers were the 
least effective outcome measures by several orders of magnitude. Finally, it also will be 
necessary to study the comparative effectiveness and cost-effectiveness of the AD 
biomarkers studied in ADNI to determine the optimal way to make use of these biomarkers 
in the diverse applications needed in AD research. For example, based on the recent studies 
of Wiegand et al [169], it is possible to impute Aβ measures determined by Aβ imaging 
using far less expensive measures of CSF Aβ-42 levels. Additional similar studies as well as 
others focused on the economics of the use of biomarkers in clinical trials and clinical 
practice are needed.
A major emphasis in papers published in 2011–2012 is the prediction of future decline at an 
even earlier stage, with some works focusing on identifying cognitively normal individuals 
at high risk of disease development. Both levels of CSF biomarkers and volumetric MRI 
were successfully used in this application, in agreement with the Jack model for disease 
progression [14]. As in classification, the prediction of MCI to AD conversion was most 
accurate when longitudinal data and/or combined modalities were used, and a number of 
papers focused on the use of automated methods to select the most pertinent information 
from multiple modalities. Depression was identified as a novel predictor. From a 
methodological standpoint, the use of an Aβ negative control group in clinical trials was 
recommended to reflect the largest drug effect, and the minimum significant change in 
ADAS-cog scores was calculated to be lower than the FDA-recommended change. Both 
methods reduced sample sizes.
Approaches for the prediction of future decline continued to be developed in 2012 and 2013. 
In particular, studies of longitudinal data found that the predictive ability of biomarkers is 
dynamic in relation to the time to conversion, with modalities reflecting amyloid deposition 
having a greater predictive ability at time points further from conversion and glucose 
metabolism being more predictive closer to conversion. The predictive ability of brain 
atrophy also progressed from temporal to frontal lobes with time to conversion. There was a 
focus on distilling a single composite score of brain atrophy to predict decline, as structural 
changes appeared more useful over a longer period of time, reflecting the ongoing nature of 
atrophy in disease progression. Blood-based biomarkers were not reported to be effective 
predictors, but their development is ongoing, and they do hold some promise as a cost-
effective alternative to imaging techniques. For the first time, the genetic risk alleles other 
than APOE ε 4 were shown to enhance prediction accuracy, and these may be a useful 
addition to the clinical trial subject selection process. Other studies suggested that 
hippocampal volume was an effective enrichment biomarker but that CSF biomarkers may 
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function better to exclude participants. Although MRI measures were shown to be superior 
as outcome measures, a lack of FDA approval turned the focus to evaluating and improving 
existing cognitive tests. CDR-SB was shown to outperform ADAS-cog in more than one 
study. Together, these studies suggest that sample sizes of MCI patients will soon be 
sufficiently small and have a high enough probability of progressing to make clinical trials 
of disease-preventing or altering therapies viable.
5. Identification of genetic risk factors for AD
The influence of genetics on the dynamic trajectory of brain development and aging is well 
established, if not well understood. Studies of twins have estimated the heritability of AD to 
be between approximately 60% and 80% [179], and until recently the only established 
genetic risk factor for AD was the APOE ε4 allele, which accounts for approximately 50% 
of AD heritability [180]. The question of accounting for the up to 30% of heritability 
remaining has only begun to be addressed, and although there have been a number of 
candidate genes proposed, the majority of them await independent confirmation. ADNI is in 
the unique position of providing a large cohort with genotype information in addition to 
imaging and biochemical data that can be leveraged as QTs in uncovering new genetic 
associations, and as such plays an increasingly important role in the discovery and 
confirmation of novel genetic risk alleles. As of the end of 2014, there were 2065 distinct 
APOE genotype data results available, and GWAS data were available for 1252 participants 
within ADNI.
Three main approaches have been taken to investigating the genetic basis of AD. Case–
control studies that search for loci with differential frequency between patient groups have 
identified a number of candidate genes. Typically, markers are used to tag susceptibility loci, 
usually in 10-kb to 20-kb regions in the genome, that are rarely found to be causal. Using 
this method, the association of APOE ε4 allele with AD has been confirmed, and three new 
risk loci, CLU, PICALM, and CR1, have been identified and confirmed [181–183]. Further 
studies have focused on examining relationships between SNPs in a limited number of genes 
of interest and quantifiable phenotypic characteristics or QTs, such as imaging data or levels 
of CSF biomarkers. GWAS evaluate a large and dense set of SNP markers distributed 
throughout the genome, providing an unbiased search for the discovery of new candidate 
genes. With more than 500,000 markers typically included in a GWAS, a stringent 
correction for multiple testing is required with typical thresholds of P < 10−8 used to reduce 
false detections. These stringent corrections also greatly reduce power and require extremely 
large sample sizes to achieve significance in case–control designs. However, the use of 
quantitative phenotypes such as cognitive, imaging, and fluid biomarker measures can 
greatly increase the power to detect associations. Where a binary case–control design might 
require many thousands of samples to detect a gene effect, samples on the scale of ADNI are 
sufficient for detecting associations with quantitative phenotypes [184]. Structural 
neuroimaging data have been most commonly used as a quantitative phenotype as the whole 
brain, brain circuits involving multiple regions of interest, or individual regions of interest 
[521]. The emerging field of imaging genetics, which uses imaging data as QTs in GWAS, 
promises the power to reveal patterns of genetic associations throughout the brain, but is 
hampered by the computational load required for such high-dimensional studies. Further 
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development of this field, including improvement of existing GWAS methods, is a major 
goal of the Genetics Core of ADNI [6].
The rich multimodal ADNI data set also offers the possibility of discovering novel 
susceptibility loci associated with risk for AD or for the disease itself [521]. By the end of 
2013, APOE and nine other risk genes had been identified and confirmed. However, together 
they account for only about 50% of the estimated 80% of AD heritability, indicating that 
other genes must be involved. The hunt for the missing heritability continues, even as newly 
discovered susceptibility loci are examined for their potential as targets for the development 
of disease-modifying agents.
5.1. Case–control studies
Jun et al [185] conducted a meta-analysis case–control study of AD patients and healthy 
elderly control subjects from 12 different studies, including ADNI, to examine the 
association of APOE ε4, CLU, PICALM, and CR1 with AD. They found that CLU, 
PICALM, and CR1 were significantly associated with AD only in Caucasian populations. In 
contrast, APOE ε4 was significantly associated with AD in all ethnic groups and with 
PICALM in white populations, suggesting that APOE ε4 and PICALM act synergistically 
and may participate in a common pathological pathway (Table 12). Two of the largest case–
control GWAS studies of AD were recently published as companion reports in Nature 
Genetics [186,187]. Both reports included the ADNI-1 data in their analyses (Table 12). 
These multistage meta-analytic reports included discovery and replication data sets and 
confirmed each other. These new results bring the total set of confirmed and replicated 
candidate genes to 10 (APOE/TOMM40, ABCA7, BIN1, CD2AP, CD33, CLU, CR1, 
EPHA1, MS4A4/MS4A6A, PICALM).
Mitochondrial genes are also of great interest in AD, and Lakatos et al [188] studied the 
incidence of AD in patients belonging to different subgroups (HV, JT, UK, and IWX) of 
mitochondrial haplogroup N in the ADNI cohort. They found that haplogroup UK had the 
strongest association with AD, and that this relationship remained significant after adjusting 
for APOE ε4 allele dose. Additionally, they identified five mitochondrial SNPs that were 
associated with increased risk of AD and suggested that, given the vital role of mitochondria 
in maintaining cellular energy balance, dysfunctional mitochondria may contribute to AD by 
causing neuronal oxidative damage. In another case–control design, Kauwe et al. [189] 
attempted to replicate a study that found that epistatic linkage between two SNPs in the 
transferrin and hemochromatosis genes was associated with AD risk, suggesting a role for 
iron in AD pathology. Using synergy factor analysis, they found significant association 
between bicarriers of the minor alleles of both SNPs and risk for AD in several U.S. and 
European study populations, including ADNI, providing support for the iron hypothesis 
(Table 12). Erten-Lyons et al [301] investigated the association between microencephaly 
genes, responsible for regulating brain growth in utero, and AD in two cohorts including 
ADNI, but were unable to detect any increase risk associated with common variants of these 
genes.
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5.2. Studies of limited loci using quantitative phenotypes
Several studies have used knowledge of the model for AD progression by testing the 
associations between genes potentially involved in AD pathology and CSF biomarkers. 
Cruchaga et al [190] examined associations between SNPs in 35 genes putatively involved in 
tau posttranslational modification and CSF levels of p-tau181p. They found that SNPs in the 
gene for protein phosphatase B were associated with higher levels of p-tau181p, and that an 
SNP in the regulatory subunit of protein phosphatase B was more highly expressed in AD 
patients compared with control subjects (Table 12). These results suggest that genetic 
variants that alter the activity of protein phosphatase B could contribute to AD pathology by 
affecting tau phosphorylation. A further study by the same group [191] found that the SNP 
in the regulatory subunit of protein phosphatase B was associated with the rate of disease 
progression, and not with the age of onset or risk of AD. In contrast, APOE ε4 was 
associated with lower levels of CSF Aβ-42, increased disease risk, and lower age of onset, 
providing support for a model in which amyloid deposition is an early event in disease 
progression and accumulation of hyperphosphorylated tau occurs at a later stage (Table 12). 
Kauwe et al [192] also used levels of CSF biomarkers as a QT to investigate the predicted 
biological effects of SNPs in three genes associated with AD. They found that a 
nonsynonymous coding substitution in the gene for calcium homeostasis modulator 1 
(CAHLM1), proposed to affect levels of Aβ by modulating intracellular calcium levels, was 
associated with increased CSF levels of Aβ-42 (Table 12). Associations between levels of 
CSF biomarkers and SNPs in the two other genes for growth factor receptor-bound protein-
associated binding protein 2 (GAB2; proposed to influence tau phosphorylation) and 
sortilin-related receptor (SORL1; an apoE receptor proposed to bind Aβ) were not found, 
perhaps because of power limitations of the study.
Using six imaging measures reflective of AD pathology as QTs, Biffi et al [193] searched 
for associations between these and SNPs in a range of established and candidate genes for 
AD risk. They first sought to confirm associations of APOE, PICALM, CLU, and CR1 with 
AD, and found that although APOE had a strong association with diagnosis, of the 
remaining identified risk alleles, only CR1 was associated with AD in the ADNI cohort, 
possibly reflecting sample size limitations for case–control studies. Two novel loci, CNTN5 
and BIN1, were also found to have significant association with AD (Table 12). When the 
relationship of APOE ε4, CR1, CNTN5, and BIN1 with imaging measures was examined, it 
appeared that APOE ε4 was associated with virtually all brain regions, whereas the other 
loci had a more limited pattern of association, consistent with APOE ε4 being the primary 
AD genetic risk factor and other loci making more modest contributions to the disease.
While the APOE ε 4 allele remains the major risk allele for AD, the question of its influence 
on other alleles remains to be clarified. Murphy et al [302] investigated the effect of APOE 
status on 2 alleles of the cholesteryl ester transfer protein (CETP) and their relationship with 
brain atrophy in the ADNI control, MCI and AD patients. Using atrophy of the 
hippocampus, entorhinal cortex and parahippocampal gyrus as a QT, they found that the V 
and A alleles of I405V and C629A, which decrease CETP activity and therefore increase 
high density lipoproteins, had differential effects depending on APOE status. In carriers of 
the APOE ε 4 allele, the V and A alleles were associated with less atrophy whereas results 
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were reversed in non-carriers, suggesting that CETP polymorphisms may influence 
neurodegenerative disease susceptibility in an APOE-dependent manner.
Given that glucose metabolism reflects cognition, the effect of genetic risk factors for AD 
that influence brain atrophy and subsequently cognition may be reflected in altered cerebral 
metabolism. Xu et al [303] investigated the influence of one genetic factor, the V66M 
polymorphism of brain-derived neurotrophic factor (BDNF), essential for neuron survival, 
on brain glucose metabolism and identified patterns of changed metabolism in carriers of the 
V66M polymorphism compared to non-carriers in the ADNI cohort. The regions affected by 
this polymorphism changed with disease severity, with MCI carriers exhibiting alterations in 
regions affected in both cognitively normal carriers (parahippocampal gyrus and temporal 
cortex) and those with AD (bilateral insula), providing further support for polymorphisms in 
BDNF as a genetic risk factor for AD. In a further study, Honea et al [522] tested 
associations between SNPs in the BNDFI gene and established cognitive and imaging AD 
phenotypes. In a pooled sample of 645 ADNI participants, no SNPs in this gene were 
associated with AD diagnosis. However, additional SNPs, other than the SNP containing the 
V66M polymorphism, were associated with baseline ADAS-cog scores and with 
hippocampal atrophy over 2 years. Additional SNPs were also associated with cognitive 
decline and whole brain atrophy over 2 years in cognitively normal patients. These results 
suggest that while BDNF genetic variation is not specifically associated with AD, it does 
play a role in memory-related performance and brain morphometry in aging individuals.
The fat mass and obesity associated (FTO) gene, an obesity genetic risk factor, has been 
associated with AD. Reitz et al [523] identified SNPs within introns 1 and 2 and within exon 
2 of the FTO gene that were significantly associated with AD in several data sets including 
ADNI. Moreover, the expression of FTO was lower in AD cases compared with that in 
controls.
Delta opioid receptors have been implicated in neurodegeneration. Roussotte et al [524] 
investigated associations between a common variant of the opioid receptor gene (OPRD1), 
rs 678849, and regional brain volumes in the ADNI cohort. The minor C allele at this locus 
(which alters Aβ processing by changing receptor structure) was associated with smaller 
volumes in frontal, temporal, and occipital brain regions and had a trend toward association 
with CSF biomarkers in the healthy elderly.
5.3. GWAS of quantitative phenotypes
In the first ADNI GWAS using the ADNI AD cases and control subjects, Potkin et al [184] 
confirmed the association of APOE with AD and identified a novel AD risk gene, 
TOMM40, encoding a regulatory subunit of a protein translocase in the outer mitochondrial 
membrane, as being significantly associated with AD. A further GWAS using VBM-derived 
estimates of hippocampal volume as a QT identified 21 loci with significant association with 
hippocampal volume including, in addition to APOE ε4, genes involved in hippocampal 
development (EFNA5), ubiquination (MAGI2, CAND1), apoptosis (PRUNE2, CAND1), 
necrosis (ARSB), and dementia (MAGI2, ARBS) (Table 12). The involvement of TOMM40 
in numerous brain regions of AD patients was confirmed by Shen et al [194]. This study 
used a novel whole brain set of ROIs from both VBM and FreeSurfer parcellation as QTs in 
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a GWAS. Of the three SNPs additionally identified as significantly associated with brain 
volumetric changes, only one, proximal to the NXPH1 gene encoding neurexophilin (known 
to promote adhesion between dendrites and axons), had a bilateral pattern of association and 
was chosen for further study (Table 12). AD patients homozygous for the T allele at this 
locus displayed reduced GM most significantly in hallmark regions of AD atrophy, such as 
the hippocampus. This study illustrates the potential power of imaging genetics to identify 
novel candidate genes that warrant further investigation as AD candidates.
While Shen et al [194] used ROIs covering the brain, Stein et al [195] further extended the 
dimensionality of imaging genetics studies by carrying out a voxelwise GWAS, which 
explored associations between hundreds of thousands of SNPs and each of the nearly 32,000 
voxels of the entire brain. Although no SNP was found significant at the stringent criteria 
used in the study, a number of SNPs of interest were identified in or near genes known to 
have functions relating to brain structure, such as monoamine uptake in neurons (CAPDS2), 
psychiatric illness (CSMD2 and CAPDS2), and neurite growth (SHB and ARP1) (Table 12). 
In a second GWAS of a targeted region of TBM-derived structural brain degeneration on 
MRI, Stein et al [196] identified an SNP located in the gene encoding N-methyl-D-aspartate 
receptor NR2B subunit (GRIN2B) that was significantly associated with lower volumes in 
the temporal lobe bilaterally. Risk alleles at this locus were more prevalent in AD patients of 
the AD cohort than in healthy elderly control subjects and were additionally associated with 
decreased MMSE scores (Table 12).
Furney et al [197] also used targeted imaging measures (entorhinal cortex thickness and 
volume, hippocampal volume, whole brain volume, and ventricular volume) as QTs in a 
large GWAS involving two cohorts (AddNeuroMed and ADNI). In addition to confirming a 
role of PICALM as a susceptibility gene for AD and as related to entorhinal thickness, they 
identified two other loci, ZNF292 and ARPP-21, as potential candidate genes based on 
associations of flanking SNPs with entorhinal cortex thickness and volume (Table 12). 
Kohannim et al [427] used the Lasso method of reducing dimensionality of multivariate 
GWAS to identify 22 genes associated with temporal lobe volumes in ADNI cohort. These 
included the previously identified GRIN2B and NRXN3 and a number of novel candidate 
genes. Of these, the greatest effect size was reported with MAC-ROD2 (macro-domain-
containing 2), a gene expressed in the brain, which has been previously associated with 
schizophrenia and MRI-defined brain infarcts.
Most imaging GWAS reports have addressed baseline ADNI data; however, genetic variants 
predicting rate of progression are of great interest. Saykin et al [6] reported an initial 
longitudinal analysis of hippocampal volume and GM density using baseline and 12-month 
scans. In a candidate gene analysis [198], five AD genes from the AlzGene database 
(alzgene.org) were found to have significant SNPs associated with hippocampal volume or 
GM density changes, after accounting for APOE, baseline diagnosis, and other factors 
(NEDD9, SORL1, DAPK1, IL1B, and SORCS1). Next, a longitudinal GWAS was 
performed on hippocampal volume and GM density, using the MRI measures reported in the 
paper by Risacher et al [115]. A number of interesting potential candidate genes were 
identified by this GWAS. In addition to APOE and TOMM40, an SNP (rs12449237) located 
at 16q22.1 between CDH8 (cadherin 8, type II) and LOC390735 was strongly associated 
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with change in hippocampal volume. CDH8 codes for a calcium-dependent cell adhesion 
protein related to synaptic integrity (neuronal adhesion and axonal growth and guidance). 
Although the cadherin protein has been implicated in AD and is known to interact with 
presenilin, this was the first indication that genetic variation in CDH8 may be associated 
with rate of neurodegenerative changes in the hippocampus. Several other markers did not 
reach genomewide significance but also showed association signals worthy of follow-up (for 
volume change: SLC6A13; for GM density change: MAD2L2, LOC728574, QPCT, and 
GRB2).
In a QT GWAS of CSF biomarker levels instead of imaging variables, Kim et al [149] 
examined levels of Aβ-42, t-tau, and p-tau181p and the ratios of p-tau181p/Aβ-42 and t-tau/
Aβ-42 in the ADNI cohort. They found five SNPs that reached genomewide significance for 
associations with one or more biomarkers, including the known candidates (APOE and 
TOMM40) as well as one hypothetical gene (LOC10012950) that partially overlaps APOE. 
Most interestingly, several SNPs in the vicinity of the novel gene EPC2 (enhancer of 
polycomb homolog 2) were associated with t-tau levels. EPC2 is involved in chromatin 
remodeling and has not been previously associated with AD, yet this gene may be causally 
associated with mental retardation in a microdeletion syndrome. Along with EPC2, SNPs 
near CCDC134, ABCG2, SREBF2, and NFATC4 approached significance (P < 105) in their 
association with CSF biomarkers and can be considered potential candidate genes for future 
studies (Table 12). Han et al [199] also used levels of CSF biomarkers as QTs in a GWAS of 
the ADNI cohort. They found that increasing APOE ε4 allele dose was associated with 
lowered Aβ-42 and elevated t-tau and p-tau181p levels. After adjusting for age and APOE 
genotype, several SNPs were found to be significantly associated with increased Aβ-42 
levels in normal subjects, the most strongly associated being within or proximal to the 
TOMM40, NCAM2, and CYP19A1 genes (Table 12). NCAM2 encodes neural adhesion 
molecule 2, a poorly characterized protein implicated in neuronal adhesion and fasciculation 
of neurons, whereas CYP19A1 encodes cytochrome P450 aromatase, an enzyme that 
catalyzes the conversion of androgens to estrogens.
Cruchaga et al [525] used t-tau and p-tau181 as quantitative phenotypes in a large GWAS (n 
= 1269 from four cohorts including ADNI) and identified three novel loci, one between 
GEMC1 and OSTN, one within GLIS4, and one within the TREM gene cluster. In an 
independent data set, the SNP between GEMC1 and OSTN was associated with CSF tau/
ptau181 levels as well as tangle pathology and the rate of cognitive decline. The introduction 
of Florbetapir amyloid imaging in ADNI-GO and ADNI-2 has provided another quantitative 
phenotype for GWAS studies. Using these data, Ramanan et al [526] conducted a GWAS 
that identified, in addition to APOE, an SNP upstream of BCHE that was independently 
associated with Aβ levels. Together, the two loci accounted for 15% of the variance in 
cortical Aβ levels (APOE, 10.7% and BCHE, 4.3%). BCHE (butyrylcholinesterase) is an 
AD risk gene that has been found in senile plaques. Genetic variation at this locus may 
increase enzymatic activity, decreasing acetylcholine levels and disrupting synaptic 
functioning. This result is of particular interest as acetylcholinesterase inhibitors are 
currently first-line symptomatic therapies for AD.
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In addition to risk for AD itself, age at onset (AAO) of the disease has an estimated 
heritability of 42%, some of it accounted for by APOE. Kamboh et al [307] conducted a 
GWAS of AAO data from 3 cohorts including ADNI to identify additional loci involved in 
AAO. They confirmed the involvement of APOE and neighboring loci (TOMM40 and 
APOC1) but no other SNPs reached significance. However, SNPs in 11 loci approached 
significance and as they lie in or near genes expressed in the brain, the authors suggested 
that they may be worthy candidates for further investigation.
GWAS appear to be a powerful tool for detecting associations between genes and 
phenotypes, but they are limited by the large sample sizes (typically thousands) required to 
gain sufficient statistical power to find these links and may also fail to detect connectivities 
between genetic loci by considering all SNPs separately. Imaging GWAS are also 
particularly extremely computationally intensive. In 2011–2012, various studies have 
focused on approaches to overcome these difficulties [305]. Schott et al [306] reported a 
method to increase the power of GWAS by defining cases and controls more accurately to 
reflect the presence of AD pathology rather than on the basis of clinical diagnosis. To this 
end, they divided the ADNI cohort into CSF positive and CSF negative groups based on 
previously established cut-points for Aβ42 and ptau181 and examined minor allele 
frequencies for 7 SNPs in previously identified AD risk genes. They found significant 
associations between the CSF negative group and SNPs in CR1, PICALM, TOMM40 and 
APOE using only slightly more than 300 subjects, an order of magnitude fewer than 
generally required to detect associations in GWAS. An alternative approach to reducing 
sample sizes and to leveraging information from potentially linked genes, was taken by 
Swaminathan et al [307] who used SNPs in 15 amyloid pathway associated genes and PiB 
uptake in 4 regions affected by AD to study genetic associations in 103 ADNI AD patients. 
This approach identified a minor allele (A) of an SNP in the DHCR24 gene that confers a 
protective effect and in a subsequent whole brain analysis, they found they found a higher 
mean PiB uptake for the major allele in frontal regions. Hu et al [308] also used a pathway 
approach, investigating multiple SNPs in canonical AD pathways, and identified SNPs in the 
Gleevec pathway, a cancer drug shown to modulate APP cleavage by γ-secretase, as being 
involved in AD. This targeted pathway-based approach may be more effective in identifying 
genes involved in AD pathology than traditional GWAS. The issue of reducing 
dimensionality was tackled by Hibar et al [305], who proposed that condensing the number 
of SNPs (around 400,000) to genes (slightly over 18,000) would avoid having to restrict 
phenotypes to a priori defined ROIs to enable a practical computational burden. They used 
principal components regression to test for gene association at each voxel and identify the 
most significant gene on a voxel basis. Although no genes identified remained significant 
after correction for multiple comparisons, many top genes, including GAB2, an established 
AD risk gene, had been previously identified as being associated with brain diseases, 
suggesting that this multivariate gene-based approach holds promise for future 
investigations.
The vGeneWAS approach of Hibar et al [527] refined the “brute force” approach of 
voxelwise GWAS by operating at the gene level. In 2012–2013, the GWAS SNP approach 
has been further refined to reduce computational burden and the high rate of false positives 
in the search for the full complement of genetic susceptibility genes for AD. Pathway and 
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network analyses have been used to narrow the selection of variants to be tested to a 
biologically relevant pathway. Thus, a biochemical understanding of pathologic mechanisms 
in combination with genetic approaches may together discover functional relationships that 
cannot be seen at the level of individual SNPs or genes. Similarly, pathways of interest have 
been selected that constrain the search space for such computationally demanding 
approaches as gene-gene or SNP-SNP interactions. A summary of brain-genome association 
strategies is shown in Fig. 45. Interaction analyses have been used to help identify epistatic 
relationships that may explain some of the “missing heritability” of AD. Next generation 
sequencing (whole genome or whole exome sequencing) and the combined use of 
proteomics data and genetics data represent further significant developments.
Several studies have used different quantitative traits to target a particular set of biochemical 
pathways putatively involved in AD pathogenesis. Koran et al [528] examined interactions 
of SNPs within genes identified as being on the AD pathway by the Kyoto Encyclopedia of 
Genes and Genomes (KEGG). Using a discovery set and two independent validation data 
sets from the ADNI cohort and amyloid deposition measured by Florbetapir uptake as a 
variable phenotype, they identified an interaction between the RYR3 and CACNA1C genes 
in which a minor allele in genes corresponded to a higher amyloid load than one or no minor 
alleles. Both genes are involved in calcium homeostasis, a process that is recognized as 
important in amyloid formation and deposition. RYR3 encodes ryanodine receptor-3, which 
regulates intracellular calcium homeostasis, while CACNA1C encodes a calcium channel 
subunit. Together, they accounted for between 4% and 9% of variance in amyloid load in the 
three data sets. In a similar approach, Meda et al [529] used 12-month hippocampal and 
entorhinal cortex atrophy rates as quantitative traits and used a priori knowledge to target 
biological pathways known to be associated with atrophy in these regions. They identified 
109 SNP-SNP interactions in 78 genes that were significantly associated with right 
hippocampal atrophy and 125 SNP-SNP interactions in 102 genes significantly associated 
with right entorhinal cortex atrophy (Fig. 46). These were located in three KEGG pathways 
for hippocampal interactions including calcium signaling, axon guidance, and ErbB 
signaling, and 14 pathways for entorhinal cortex atrophy including calcium signaling, axon 
guidance, long-term depression and potentiation, and neuroactive ligand-receptor 
interaction. The analysis confirmed the involvement of some genes as well as identifying 
novel candidate genes for further investigation and suggested that different biogenetic 
mechanisms may mediate atrophy in different brain regions. A psychometrically determined 
memory score was used as a phenotype to enrich pathways involved in memory impairment 
in a study by Ramanan et al [428]. Using GWA data from ADNI participants, they enriched 
27 pathways that included not only processes well understood to be involved in memory 
such as long-term potentiation and neurotransmitter receptor-mediated calcium signaling but 
also pathways involved in cell adhesion and differentiation. Expression in some of these 
identified pathways was coordinated; a large gene set was regulated by the SP1 transcription 
factor (Fig. 47). The newly identified enriched pathways may provide targets future studies 
of memory impairment. These studies demonstrate that a pathway-based approach to 
analyzing GWA data has great promise in untangling the relationships between genes in 
these complex phenotypes.
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Recent technological advances in proteomics have made it feasible to use protein analytes as 
diagnostic, prognostic, or treatment biomarkers for disease. The identification of important 
functional genetic variants that affect levels of protein analytes known to be associated with 
disease is an important step in the development of these biomarkers. Thus, Kim et al [530] 
integrated ADNI GWAS array data with baseline multiplex panel proteomics data to 
investigate the effects of SNPs within genes on the corresponding plasma protein level for 
140 gene-protein association pairs. They detected 112 significant associations within this 
cohort, of which 50 were replicated in an independent cohort. The top replicated 
associations included two SNPs in CHFH1 (complement factor H-related protein 1), along 
with gene-protein associations for interleukin-6 receptor, pulmonary and activation-regulated 
chemokine, chemokine CC-4, and apolipoprotein A4. Each SNP accounted for between 14% 
and 16% of the total variation in plasma protein levels, emphasizing the large role of genetic 
variation in proteomics.
An alternative to a pathway approach was reported by Benitez et al [531] who restricted 
their search for new risk loci to the known risk genes, APP, PSEN1, PSEN2, GRN, APOE, 
and MAPT. Using extreme levels of CSF Aβ, t-tau, and p-tau as quantitative traits, they 
confirmed one known pathogenic mutation in PSEN1 (p.A426P) and found a number of 
high-risk and novel variants in these genes. A new PSEN1 variant, p.E318G, was associated 
with high levels of CSF t-tau and p-tau and carriers of this variant who were also carriers of 
APOE ε 4 had a twofold increased risk of AD over APOE ε 4 carriers alone. Moreover, in 
APOE ε 4 carriers, the p.E318G variant was associated with more Aβ plaques and faster 
cognitive decline. These results suggest that p.E314G in PSEN1 interacts with the APOE ε 4 
allele to raise the risk of AD via increased amyloid deposition.
Although GWAS have been successful in identifying novel risk variants for AD, the 
observed effects of these are relatively small and substantial heritability has yet to be 
accounted for. One explanation for this is that the genetic makeup of AD is complex and 
involves epistatic relationships that go beyond single genes. Hohman et al [532] examined 
epistatic relationships between four top candidates SNPs: PICALM, BIN1, CR1, and CLU, 
using amyloid burden measured by Florbetapir uptake as a quantitative endophenotype. 
They reported a novel interaction between PICALM and BIN1 in that the minor allele of 
BIN1 was associated with higher levels of amyloid deposition but only in noncarriers of the 
protective minor allele of PICALM. The interaction suggests that variation in the genes may 
together modulate amyloid deposition by as yet unknown mechanisms. Glycogen synthase 
kinase 3 (GSK-3) has been posited to regulate both tau-phosphorylation and Aβ production, 
and overactivity of this kinase influences cognitive impairment, neuroinflammatory 
response, and the pathologic cascade of AD. Hohman et al [533] again searched for epistatic 
relationships, this time between GSK-3 and kinases involved in Aβ pathology using 
Florbetapir binding as a quantitative trait. They found three interactions involving a GSK-3β 
SNP and SNPs within APP and APBB2, each accounting for over 1% of the variance in 
amyloid deposition. GSK3β may therefore modify risk for amyloid deposition and increase 
amyloid burden together with APP-related genes. Clearly, the examination of epistatic 
relationships between carefully selected gene pairs is a promising approach that leverages 
both genetic and biochemical knowledge to fit more pieces into the complex puzzles of AD 
pathology and genetics.
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Brain phenotypic measures are only partially explained by genetic variation as represented 
by SNPs identified in GWAS studies. Bryant et al [534] mapped the proportion of 
phenotypic variance of multiple regions throughout the brain that are caused by genetic 
variation using genome-wide complex trait analysis. They reported that 85% variability in 
intracranial volume and 57% of the variability in cerebrospinal fluid volume was explained 
by considering the complete set of SNPs (512,905). In contrast, genetic variability for white 
and gray matter was close to zero. Within regional volumes, high genetic variability was 
found in several medial cortical regions, subcortical nuclei, and perceptual cortical pathways 
including the entorhinal cortex, caudate, and insula.
Next generation sequencing of either the whole genome or, more feasibly, the whole exome, 
is a logical next step in genetic analysis. Nho et al [535] reported the first application of 
whole exome sequencing to identification of risk alleles for LOAD. They selected MCI 
participants who were also APOE ε 3/ ε 3 homozygotes with an extreme change in 
hippocampal volume over 2 years. Two single nucleotide variants in CARD10 and PARP1 
accounted for the greatest group difference. Further quantitative trait analysis in the 
remaining ADNI ε 3/ ε 3 group revealed that genetic variation in both CARD10 and PARP1 
was associated with greater hippocampal atrophy. PARP1 was further found to be associated 
with baseline hippocampal volume in a meta-analysis of ε 3/ ε 3 subjects from five studies. 
CARD10 (caspase recruitment domain family, member 10) had not been previously 
associated with AD but is known to activate NFκB which is activated in the disease. PARP1 
(poly (ADP-ribose) polymerase-1) is involved in many cellular genetic processes, expressed 
in many regions of the brain, and has important role in long-term memory formation.
Shen et al (2012) [521] analyzed ADNI genetic associations using pathway and network 
enrichment and identified a number of pathways involved in cell adhesion, 
neurophysiological processes, immune response, and development in addition to 
neurogenesis, synaptic contact, angiogenesis, cell adhesion, and synaptogenesis process 
networks. This work highlighted pathways already identified in AD pathogenesis and also 
identified novel targets for future investigation.
5.4. Replication studies and meta-analyses
In 2011–2012, genetic data from the ADNI cohort have been used in a number of studies 
both confirming candidate AD risk genes, by attempting to replicate results in different 
cohorts, or by conducting meta-analyses of previously published work, and providing more 
detailed mapping of candidate genes. An independent confirmation of the involvement of 
CR1 in AD was reported by Antunez et al [309], who found a trend supporting association 
in a Spanish cohort of approximately 3500 and a stronger association in a meta-analysis of 
over 30,000 individuals. Further confirmation for CR1 as an AD risk gene came from Hu et 
al [308] who conducted a GWAS on combined cohorts including ADNI. They also 
replicated the BIN locus by testing top SNPs from the GWAS in an independent cohort, and 
used haplotype conditional analysis to show that multiple variants at the BIN locus had 
conditionally independent associations with AD. PICALM variants were also replicated, but 
their association with AD was attenuated by APOE status. Cruchaga et al [310] focused on 
replicating the association between APOE3-TOMM40 haplotypes and AD as well as age of 
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onset of the disease. They found it difficult to identify the genetic variant driving the 
association of the genes because of extensive linkage disequilibrium around TOMM40 and 
APOE and possibly an insufficient sample size. Consequently, they were not able to 
replicate results, identifying instead a polymorphism of TOMM40 associated with decreased 
risk of AD. An additional study by Antunez et al [311] independently identified the MSA4A 
gene cluster as being associated with AD after a meta-analysis of 4 public GWAS sets 
including ADNI, and a new Spanish cohort. This gene cluster was previously identified by 
Naj et al [186], and the use of a combined total of over 10,000 cases and over 14,000 
controls in this study underscores the importance of combining cohorts to increase power to 
detect genetic associations that may have small effect sizes. Kauwe et al [312] investigated 
whether common variants of BIN1, CLU, CR1 and PICALM were associated with Aβ42 
and p-tau181. No associations between these SNPs and CSF biomarkers were found in two 
cohorts including ADNI, suggesting that these candidate genes may affect risk for AD via 
other mechanisms than a direct effect on AD pathology. CSF biomarkers were also used as a 
QT in a study by Alexopoulos et al [313], who investigated the association between SORL1 
(neuronal sortilin-related receptor with A-type repeats), likely involved in sorting of APP in 
the Golgi, and levels of Aβ42, ptau181 and t-tau. They found that Aβ42 was significantly 
associated with the A allele for SORL1 SNP233 in the AD group and marginally associated 
with Tallele of SNP24. Levels of some SNPs in SORL1 were modulated by the APOE ε 4 
allele.
ADNI data continue to play a vital role as a subset of meta-analyses of GWAS results which 
have been necessary to gain sufficient statistical power to identify risk variants. For example, 
Rhinn et al [536] investigated regulatory mechanisms affecting AD and AD risk using 
differential co-expression analysis and identified candidate genes predicted to mediate 
transcriptional changes in APOE ε 4 carriers including modifiers of APP processing and 
endocytic trafficking. A meta-analysis of GWAS including ADNI data was then used to 
confirm that common genetic variants in two genes of interest, FYN and RNF219, affected 
amyloid deposition and age of disease onset in APOE ε 4 carriers. Likewise, five of nine 
previously identified AD risk loci (PICALM, BIN1, ABAC7, MS4A4/MS4A6E, and 
EPHA1) were confirmed in a GWAS by Kamboh et al [537] using a University of Pittsburgh 
cohort. When the top 1% most significant SNPs from this GWAS were then analyzed in a 
meta-analysis including the ADNI cohort, the authors found that the most significant SNP, 
located in PPP1R3B (protein phosphatase 1, regulatory subunit 1B), carried an OR for AD 
risk of 2.43. A replication study by Peterson et al [538] confirmed the association of another 
protein phosphatase gene, PPP3R1, as well as MAPT with CSF tau levels. The high-risk 
allele in MAPT was also associated with a 30% faster change in CDR-SB scores, and 
patients with the high-risk alleles at both loci progressed to AD six times faster than those 
with the low-risk alleles. A meta-analysis of five GWAS studies and subsequent replication 
of results in an independent sample by Martinez-Murcia et al [398] identified a marker in the 
NRXN3 gene with a consistent protective effect in men. These results support a role for 
neurexins, synaptic cell adhesion molecules processed by presenilin, in LOAD.
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5.5. Genomic copy number analysis
One method of genetic analysis not extensively used in the field of AD research is that of 
copy number variation analysis. Copy number variants (CNVs) are sequence alterations 
involving differences in gene copy numbers usually cause by deletions or duplications of 
genomic sequences. Swaminathan et al [314] used this technique to analyze the ADNI 
cohort and compared CNV calls generated in AD and MCI cases to those in controls using 
whole genome and candidate gene association approaches. While no excess CNV burden 
was observed in cases versus controls, a number of genes already implicated in AD were 
identified (CHRFAM7A, NRXN1), in addition to some novel loci (CSMD1, HNRNPCL1, 
SLC35F2, ERBB4) (Table 12). Of these candidate genes, three (CHRFAM7A, NRXN1, 
ERBB4) were replicated in an analysis of a different cohort by the same group [315]. This 
analysis also identified other loci previously identified as possible AD candidate genes 
(ATXN1, HLA-DPB1, RELN, DOPEY2, GSTT1) in addition to a novel candidate gene, 
IMMP2L which codes for a mitochondrial enzyme and may play a role in AD susceptibility 
through influencing oxidative damage (Table 12). A follow-up paper by the same group 
[539] confirmed in a separate cohort that the CHRFAM7A, RELN, and DOPEY2 genes 
were associated with AD and identified a novel gene, HLA-DRA (major histocompatibility 
complex, class II DR alpha). A subsequent meta-analysis that included the ADNI cohort 
found that the CHRFAM7A gene was significantly associated with MCI/AD risk (OR = 
3.986; 95% CI: 1.490–10.667). The gene has a putative function in synaptic transmission 
and cholinergic anti-inflammatory response.
Guffanti et al [540] used intensity variation in SNP microarrays to study differences in 
CNVs between control and AD/MCI patients and identified a number of CNV regions that 
included heterozygous deletions over-represented in MCI and AD patients. Genome 
resequencing identified genes putatively affected by these deletions, and functional pathway 
analysis revealed that these genes were involved in processes such as cell-cell adhesion, 
axon guidance, differentiation, and neuronal morphogenesis. The authors hypothesized that, 
although rare, these CNV regions may confer an increased susceptibility to cognitive decline 
by acting in combination with additional genetic or epigenetic mechanisms.
5.6. Other genetic studies using ADNI data
Like other fields discussed in this review, studies have recently emerged that utilize ADNI 
genetic and/or imaging data for uses not directly related to AD research. Stein et al [316] 
conducted a GWAS investigating genetic influences in caudate volume, a structure involved 
in many disorders including depression and schizophrenia as well as in AD. While no SNPs 
reached genome-wide significance, loci involved in dopaminergic neuron development and 
with links to schizophrenia were identified suggesting that MRI phenotypes may be 
powerful phenotypes when searching for genetic associations. The ADNI cohort was also 
used in 2 GWAS, one identifying SNPs associated with variability in the surface of the 
visual cortex [317] and the other determining that circadian clock SNPs are not associated 
with the breakdown of sleep-wake consolidation observed in AD [318]. Hibar et al [541] 
used ADNI genetic data to perform a GWAS to discover common genetic variants associated 
with lentiform nucleus volume, implicated in disorders such as Parkinson’s disease, ADHD, 
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and schizophrenia. They identified variants within the flavin-containing monooxygenase 
gene cluster.
5.7. Summary and conclusions of genetic risk factor studies
Genetic studies of the ADNI cohort have confirmed that the APOE ε4 allele is the major 
genetic risk factor for late-onset AD and that it is associated with atrophy in widespread 
areas of the brain. Case–control GWAS that have included ADNI data have also confirmed 
CLU, CRI, and PICALM as AD risk loci and identified a number of other candidate genes. 
QT GWAS using ADNI phenotypes such as Aβ-42 and tau or imaging measures of brain 
atrophy have detected genes implicated in the modification or modulation of Aβ or tau 
proteins, mitochondrial oxidative pathways, iron metabolism, neural adhesion and growth, 
synaptic plasticity, epigenetic processes, and memory function. A particular contribution of 
ADNI imaging genetic studies has been to develop methods to expand the dimensionality of 
GWAS studies to include all regions or voxels of an imaging scan, significantly expanding 
the potential of the field of imaging genetics to pinpoint specific brain regions influenced by 
different loci. Although candidate genes await confirmation by independent studies, they 
promise to unveil biological mechanisms underlying AD pathology.
Publications of genetic findings using ADNI data have continued to increase in 2011 and 
2012. From only 1 paper published in 2009 [184] and 19 in 2010 
[6,103,128,141,146,184,188,189,191–193,303,194–196,199,208–210], 2011 saw 20 new 
publications [105,139,149,186,187,194,197,305,308–311,314,316,318–323] and the first 
three-quarters of 2012 saw 32 new publications [262–264,302,304,306,307,315,317,324–
346]. This significant expansion in number has been matched by an equally impressive 
expansion in scope. While new candidate risk loci continue to be reported, the focus of many 
studies has been to replicate previous work, sometimes using meta-analysis of combined 
cohorts, to independently confirm candidate genes. These studies have demonstrated that the 
increased power resulting from the larger sample sizes is critical to success in this endeavor. 
Other approaches to increasing power to identify candidate genetic loci have been reported, 
such as targeting SNPs in selected pathways rather than using a genome-wide approach or 
using genes instead of SNPs in a genome wide search, and defining controls and cases on 
the basis of pathological rather than clinical criteria. The analysis of copy number variations 
in AD has been reported and appears to be an important additional tool for untangling the 
contributions of AD susceptibility loci to the disease. Finally, ADNI genetics data have been 
used in fields outside of Alzheimer’s research, demonstrating a pleasing contribution of the 
project to the greater scientific community. The ultimate goal of genetics research in AD is 
to identify novel candidates as targets for the development of disease-modifying agents. 
ADNI genetics data have now been used in the identification of 13 novel AD susceptibility 
genes in addition to APOE, 10 of which are not in linkage disequilibrium with APOE: BIN1, 
CD2AP, CLU, CR1, EPHA1, FTO, GRIN2B, MAGI2, MS4A4A, and PICALM. In 2012–
2013, rapid progress toward this goal has been made notably by the use of more targeted 
approaches that reflect an increasing understanding of the biochemistry of AD. The selection 
of suspected pathologic pathways or a particular set of genes has helped to narrow the search 
for risk alleles. Interaction studies of epistatic relationships have revealed additional 
heritability factors, and the first studies using ADNI whole exome sequencing and 
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proteomics data have been reported. Through these and other approaches, ADNI has 
continued to make substantial contributions to untangling the genetic basis of AD and has 
thereby deepened our understanding of the biological pathways involved in pathogenesis.
6. Studies of normal control subjects
With the realization that AD pathology most likely begins to accumulate years in advance of 
any detectable cognitive effect, a major issue has been determining the proportion of 
apparently normal control subjects who harbor preclinical AD. As more sensitive 
biomarkers have been developed, studies have emerged with the goals of ascertaining the 
utility of these biomarkers in healthy elderly subjects and determining the earliest stage at 
which incipient AD pathology can be detected. This clearly has implications for 
development of AD therapies: if AD pathology can be reliably detected at such an early 
stage, then would existing or novel AD-modifying treatments be more effective when used 
before clinical symptoms become evident? In tandem with these studies, ADNI’s cohort of 
well-characterized normal control subjects has been used to investigate processes occurring 
in the brain during healthy aging when there are no clinically detectable underlying 
pathologies. These two thrusts are often interwoven within the same study, as it becomes 
more obvious that healthy elderly subjects, although cognitively normal, are in fact a 
heterogeneous group when examined by other means.
6.1. MRI studies
The effect of developmental brain changes on neurocognitive late-life functions was 
investigated by Tamnes et al [542] who compared longitudinal volume changes in a 
developing cohort (8–22 years) with cognitively normal ADNI participants. Developmental 
reductions in GM volume proceeded in a generally posterior to anterior gradient and were 
generally greater than the cortex then subcortical structures. Late developing cortices were 
more vulnerable to atrophy in aging, with the exception of the medial temporal lobe. This 
study provides new insights into the relationships between brain changes during 
development and in normal aging. Insights into normal aging and into strategies for 
preventing age- or disease-related cognitive decline were gained by Harrison et al [543] who 
studied a group of “superagers”: people over 80 years who perform at a level equivalent to 
20 to 30 years younger in tests of episodic memory and at age level for other cognitive tests. 
Cortical volume and thickness in super-agers with superior memory function were greater 
than those of their age-matched peers and equivalent to those of middle-aged controls. This 
is contrary to the dictum of normal cognitive aging involving slow global atrophy, and future 
studies may identify other factors that may contribute to unusually successful cognitive 
aging.
The question of whether atrophy observed in normal aging is due primarily to normal aging 
processes or to the development of underlying pathologies is the subject of much debate. 
Fjell et al [200] presented the first detailed longitudinal study of brain atrophy in healthy 
elderly subjects aimed at understanding age-related changes in cognitive function. When 
volume changes in multiple ROIs and across the entire cortex were compared in healthy 
elderly subjects and AD patients, these authors found that the healthy elderly subjects had an 
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atrophy rate of about 0.5% per year and that volume loss was widely distributed across the 
brain and included both regions typical of AD-associated atrophy and areas not typically 
associated with AD, such as the inferior, superior, and middle frontal cortices. The rate of 
change accelerated with age, especially in those regions associated with AD, possibly 
because of the existence of preclinical AD pathology superimposed on normal aging 
processes. The authors believe, however, that the majority of volumetric changes observed in 
healthy aging are not related to those caused by degenerative diseases. Davatzikos et al [119] 
used the SPARE-AD index (see section 4.4.2.1. for further description) to examine the 
degree of AD pathology in healthy elderly subjects and its association with cognitive decline 
in ADNI and another cohort with longitudinal data available. They found that SPARE-AD 
scores increased with age, as did the rate of change of the SPARE-AD score. When healthy 
elderly subjects were divided into groups of high versus low SPARE-AD score, the majority 
had negative scores. However, a small group with positive scores had significantly lower 
MMSE scores at baseline, suggesting that a subset of cognitively normal elderly subjects 
harbored underlying AD preclinical pathology.
In response to a paper by Burgmans et al [201] suggesting that underlying preclinical 
disorders may lead to the overestimation of GM atrophy in normal aging studies, Fjell et al 
[202] conducted a meta-analysis of a number of cross-sectional studies. They found that 
atrophy correlated with age in virtually all ROIs studied, even at younger ages, suggesting a 
linear trajectory of brain atrophy over time. When 2-year follow-up cognitive data of healthy 
elderly subjects from the ADNI cohort were used to exclude participants with any indication 
of cognitive decline, significant atrophy in all ROIs was still found in the remaining “super-
stable” cohort. These results support the view that brain atrophy is part of normal aging and 
not necessarily caused by underlying neuropathological processes. To detect unusually fast 
atrophy in cognitively normal healthy elderly subjects, Franke et al [92] developed a model 
of healthy aging by estimating age from MRI scans of normal brain anatomy. Their method 
(described in more detail in section 3.7) accurately estimated the age of healthy subjects (r = 
0.92 between real and calculated ages). Using the same method, they also estimated ages of 
patients with early AD and found that the predicted ages were an average of 10 years higher 
than the actual ages, implying that the pattern of AD atrophy does accelerate relative to 
healthy elderly control subjects.
Murphy et al [203] used an automated method to examine volume changes in 14 cortical and 
subcortical regions over 6 months in an effort to determine whether atrophy was detectable 
over the short period in healthy elderly subjects and whether this atrophy was related to 2-
year declines in memory-specific neuropsychological tests. They found that volume changes 
in these regions could be measured and that they were predictive of future clinical decline. 
The most significant associations were found in the MTL, suggesting that this atrophy could 
represent the earliest stages of AD and that MRI may be a useful tool in complementing 
neuropsychological tests in the early detection of those at risk for subsequent cognitive 
decline.
Furthermore, cognitively normal individuals who were amyloid positive had greater thinning 
of the medial portion of the orbital frontal cortex than amyloid negative patients, and those 
who were tau-positive were distinguished from tau-negative individuals by greater thinning 
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of the entorhinal cortex. These results suggest that in asymptomatic individuals, Aβ and tau 
pathology affects GM thinning in select neocortical regions that potentially influence 
hippocampal atrophy at a later stage of the disease [163].
6.2. Studies of CSF biomarkers and amyloid deposition (11C-PiB PET)
In a manner similar to the examination of MRI markers of AD pathology, there has been 
interest in assessing the utility of CSF biomarkers in healthy elderly subjects on the basis 
that an “earlier biomarker horizon” [204] would have great clinical significance. 
Nettiksimmons et al [204] examined healthy elderly subjects in the ADNI cohort and found 
three clusters of participants when 11 biomarker and imaging measures were subjected to 
unsupervised cluster analysis. The first, compact cluster had the most “normal” CSF and 
MRI measures, whereas the measures of the third, more dispersed group more closely 
resembled those of MCI patients included in the study for comparison (the second cluster 
was placed in an intermediate position). The third cluster had a significantly higher 
proportion of APOE ε4 carriers and scored worse on tests of cognition (ADAS-cog, AVLT), 
suggesting that this group may harbor the earliest manifestations of AD symptoms. These 
results provide support for the notion that cognitively normal elderly subjects are in fact a 
heterogeneous group, a portion of which may progress to MCI in the future. The second 
cluster of normal controls found by Nettiksimmons et al [204] lacked the CSF biomarker 
signature for AD but had atrophy in multiple brain regions, approaching levels observed in 
MCI patients. A further study by the same group [544] examined whether vascular damage 
could account for these differences. They found that this subgroup had a higher mean 
frequency of WMHs in the periventricular area and higher BMI, triglycerides, blood 
glucose, and Haschinki scores. There was no difference in the APOE ε 4 allele frequency of 
this cluster compared with the first “normal” cluster, but it had a worse trajectory in 
longitudinal cognitive tests (AVLT, FAQ). The results support the involvement of a vascular 
component in cerebral atrophy observed in a subset of normal controls.
In a study of the relationship between levels of CSF biomarkers and 1-year atrophy in 15 
subcortical and 33 cortical ROIs in healthy elderly subjects, Fjell et al [205] reached similar 
conclusions. They found that levels of CSF biomarkers, especially Aβ-42, correlated with 
atrophy in many of the regions tested and that atrophy was not restricted to regions most 
typically associated with AD. When Aβ-42 concentration was plotted against the percentage 
of annual change in ROIs, there was an inflection point at approximately 175 pg/mL, below 
which participants had larger brain volume changes over a year, suggesting that Aβ-42 may 
play a role in changes in brain volume observed in healthy elderly subjects below a certain 
threshold level. De Meyer et al [159] found that when a biomarker “signature” for AD using 
levels of Aβ-42, t-tau, and p-tau181p was tested in healthy elderly subjects, there was a 
bimodal distribution of Aβ-42 levels with a separation point at 188 pg/mL. Although it was 
unknown whether those participants with low levels of Aβ-42 in these two studies would 
develop AD pathology, they once again highlighted the heterogeneity of the cognitively 
normal healthy elderly group.
In the current model of AD pathogenesis, it is well established that deposition of amyloid 
plaques is an early event that, in conjunction with subsequent tau pathology, causes neuronal 
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damage typically beginning in the hippocampus and resulting in the first clinical 
manifestations of the disease in the form of episodic memory deficits. Mormino et al [206] 
investigated the relationship between Aβ deposition, as measured by 11C-PiB PET uptake, 
hippocampal atrophy, and episodic memory loss in cognitively normal healthy elderly 
subjects. They found an inverse relationship between 11C-PiB uptake and hippocampal 
volume and that episodic memory loss was predicted by hippocampal volume, but not 
by 11C-PiB uptake. The results suggest that low levels of CSF Aβ-42 (high levels of brain 
accumulation) in healthy elderly subjects may reflect early stages of AD pathogenesis and 
may subsequently mediate dementia through an effect on hippocampal volume and the 
resulting declines in episodic memory. These findings warrant further investigation. Aβ 
deposition may require abnormal p-tau181 to induce neuronal and synaptic damage. Desikan 
et al [545] found that CSF Aβ-42 was significantly associated with longitudinal change in 
cognition (CDR-SB, ADAS-cog) only in the presence of elevated p-tau181 in cognitively 
normal subjects. There was no significant association between abnormal levels of Aβ-42 
alone and cognitive decline over 3 years. Results suggest that early intervention trials should 
take into account both increased p-tau181 and decreased Aβ-42 as individuals with this 
profile are likely to have a different rate of clinical progression from that of individuals with 
decreased Aβ-42 alone.
6.3. Genetic studies of normal control subjects
Although the APOE ε4 allele has been clearly identified as an AD risk allele, the question of 
whether a second variant in the APOE gene, the ε2 allele, confers a protective effect has 
been less well studied. Evidence for the protective effect of the APOE ε2 allele came from a 
study by Hua et al [120], who found reduced CSF volume in the ventricular system of 
healthy elderly subjects who had the highest frequency of this allele compared with MCI and 
AD patients. Chiang et al [207] sought to determine the effect of APOE ε2 allele on 
hippocampal volume and levels of CSF biomarkers in healthy elderly subjects. They found 
that carriers of the APOE ε2 genotype, constituting approximately 5%of the population, had 
lower rates of hippocampal atrophy and higher Aβ-42 and lower t-tau and p-tau181p levels 
compared with the more common (~70% of population) APOE ε3/ε3 homozygotes, 
suggesting that lower rates of atrophy could be related to decreased underlying AD 
pathology and may explain the lower rates of AD among carriers of this allele. A similar 
finding was reported by Fan et al [208], who examined the relationship between cortical 
thickness at multiple regions across the brain and APOE genotype in healthy elderly subjects 
who were grouped as ε2 carriers, ε3 homozygotes, and ε4 carriers. After adjusting for 
multiple comparisons, they found greater thickness in the superior temporal cortex in ε2 
carriers compared with ε3 homozygotes, and in the dorsolateral prefrontal cortex in ε2 
compared with ε4 carriers. Moreover, CSF concentrations of Aβ-42, t-tau, and p-tau181p 
were significantly different in all groups (Fig. 24), although no differences were found in the 
MMSE between groups. The results of these two studies provided support for the differential 
effect of APOE alleles on brain structure and on CSF biomarkers.
In addition to risk factors like age and APOE genotype, increased BMI has been associated 
with frontal, temporal, and subcortical atrophy and may increase susceptibility to AD. 
Recent studies identified a novel obesity genetic risk factor, a variant of the fat mass and 
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obesity associated (FTO) gene, carried by almost one-half of Western Europeans. Ho et al 
[209] examined the effect of the FTO risk allele on brain volumes in healthy elderly subjects 
and compared its effects on brain structure with that of increased BMI. They found that 
carriers of the FTO risk allele had an 8% to 12% deficit in a subset of areas affected by BMI, 
predominantly in the frontal and occipital lobes, compared with noncarriers, suggesting that 
the FTO risk allele contributes to, but does not fully account for, the effect of increasing 
BMI on brain atrophy. Bertam and Heekeren [198] discussed the findings of the study and 
the need for corroborating the results to determine the influence of genetics on normal brain 
structure and function.
The idea that common variance in brain structure may be primarily controlled not by 
polymorphisms resulting in altered protein structure, but by changes in regulatory elements 
found support in a study by Rimol et al [210]. Using the ADNI cohort, they found that two 
SNPs located in nonexonic regions of genes for primary microencephaly were correlated 
with reduced cortical surface in males only, regardless of disease status, and suggested that 
these polymorphisms may affect gene regulation and result in gross abnormalities in brain 
structure observed in this disease. More data on the role of common genetic sequence 
variations in accounting for commonly occurring brain structure variations came from a 
study by the same group [211] on associations between a common haplotype of the MECP2 
gene and brain structure. Mutations in MECP2, encoding methyl-CpG binding protein 2, 
cause microencephalopathy and are associated with other severe neurodevelopmental 
disorders, but Joyner et al [211] found that common sequence variations in this region 
correlated with reduced cortical surface area in males only of the ADNI cohort. As MECP2 
is thought to transcriptionally activate or repress thousands of genes, studies of the influence 
of such common sequence variations may reveal profound insights into brain structure and 
development.
Hypothesizing that multiple brain pathologies may share common pathways such as 
inflammation, protein misfolding and mitochondrial dynamics, De Jager et al [326] searched 
for genetic variants affected the rate of age-related cognitive decline. In addition to 
identifying the APOE locus, they found an SNP close to PDE7A and MTFR1, genes 
potentially involved in inflammation and oxidative injury, respectively.
6.4. Summary and conclusions of papers focusing on normal control subjects
Heterogeneity of cognitively normal healthy elderly subjects seems to be well supported by 
these studies, with a number suggesting the existence of a subset of cognitively normal 
elderly subjects that bears the hallmarks of early AD pathogenesis in terms of changes in 
brain volume and levels of CSF biomarkers. The extent to which these changes are separate 
from those of normal aging remains to be fully elucidated. Fjell et al [202] concluded, “We 
need more knowledge about which factors mediate brain atrophy in healthy elderly and what 
consequences the changes have for cognitive function.” Likewise, several intriguing studies 
have pointed to the role of genetics in healthy aging, and suggest a protective effect of the 
APOE ε2 allele and increased susceptibility to brain atrophy and perhaps AD conferred by a 
risk allele at the novel FTO locus. Clearly, studies of the healthy elderly control subjects are 
revealing information not only about the processes of healthy aging but also the initial 
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development of preclinical AD pathology. In 2011–2012 there has been a further shift 
toward considering cognitively normal elders as a heterogeneous population, some of whom 
harbor the earliest pathological manifestations of AD and are therefore part of the disease 
continuum. Many papers studying this group have therefore been included in other more 
relevant sections of this review.
7. Worldwide ADNI
Since the inception of ADNI in North America in 2004, there has been worldwide interest in 
creating programs that are at least partially modeled on the ADNI platform, and that use 
protocols developed by ADNI for at least part of their studies. Combined, the initiatives 
represent a concerted effort toward globalization of this concept. Society may well reap the 
rewards of having not just a well-characterized North American cohort for the development 
of AD biomarkers but also similarly characterized cohorts globally that may represent 
diverse ethnic groups, important for determining the applicability of ADNI findings to the 
world population. Like ADNI, these initiatives from Europe, Japan, and Australia are 
predicated on the sharing of data, and infrastructure is beginning to be developed to allow 
full transparency of global results. Future ADNIs are expected to begin in Argentina and 
China and have recently begun in Korea and Taiwan. All worldwide ADNIs share common 
goals of increasing understanding of AD onset and progression, both cognitively and 
physically, establishing globally recognized standards for diagnosis, and ultimately 
developing methods to allow more efficient clinical trials.
7.1. European ADNI
Frisoni [212] provides an overview of all programs, either completed or underway, in 
Europe that are in some way related to ADNI. The ADNI platform was first introduced into 
Europe in the form of a small cross-sectional pilot study, E-ADNI, which aimed to assess the 
feasibility of importing ADNI procedures to a European multicenter multicountry setting 
[213]. E-ADNI was initiated under the auspices of the Alzheimer’s Association through the 
generosity of the HEDCO Foundation and enrolled 49 control, MCI, and AD participants 
over seven sites in seven countries. The pilot study used all ADNI protocols, with the 
exception of PET imaging, the feasibility of which had been previously demonstrated, and 
MRI sequences for the detection of cerebral small vessel damage, a slightly different 
emphasis of the study. Buerger et al [214] conducted a multicenter feasibility study within 
E-ADNI and found that the use of fresh, rather than frozen, biological samples increased 
diagnostic accuracy. Overall, the study demonstrated that apart from age and education, the 
enrolled cohort was similar to the ADNI cohort in MRI and CSF measures and that 
implementation of the ADNI platform in Europe was feasible [213].
Other data collection programs in Europe include (1) AddNeuroMed, a public–private 
initiative with a cohort of 700 control, MCI, and AD subjects across Europe that used ADNI 
protocols for structural MRI; (2) Pharma-cog, which overlaps to the greatest extent with 
ADNI and which aims to predict cognitive properties of new drug candidates for 
neurodegenerative diseases; (3) Swedish ADNI, a small-scale initiative funded by the 
Alzheimer’s Association that used ADNI protocol and which has merged into the larger 
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Swedish BrainPower initiative; and (4) Italian ADNI, a larger project with 480 patients 
enrolled. These initiatives vary in the size and composition of enrolled cohorts, the length of 
study, and the frequency and type of data collection. However, they all have the use of 
standardized ADNI protocols in common for at least some of their data collection [212].
Two additional European programs funded by the Alzheimer’s Association focused on 
harmonization of measurements of both CSF biomarkers [215] and hippocampal volume 
[216], aiming to create worldwide protocols for standardized hippocampal segmentation and 
measurement of CSF biomarker concentrations to allow the direct comparison of results 
generated globally. Westman et al [347] investigated whether, based on shared MRI data 
acquisition methodologies, it was possible to combine data from Add-NeuroNet and ADNI 
to produce a combined cohort more representative of the general public that could be 
analyzed for classification and disease prediction purposes. They demonstrated that the 2 
cohorts showed similar patterns of atrophy and that data from the 2 programs produced 
similar classification accuracies and concluded that the combination of large data sets such 
as these was feasible and could improve overall knowledge of the disease.
Finally, initiatives inspired by ADNI to build infrastructure including a central repository of 
all data, like that developed at LONI, have been implemented in Europe. NeuGRID is being 
developed at the European equivalent of LONI, and outGRID aims to synergize neuGRID, 
LONI, and the Canadian repository CBRAIN and to develop full interoperability. CATI 
(Centre pour l’Acquisition et le Traitement de l’Image) is the French repository for data sets 
within that country.
ADNI-related programs and initiatives in Europe are summarized in Table 13.
7.2. AIBL study: The Australian ADNI
Often termed the “Australian ADNI,” the AIBL has similar goals to ADNI, namely, to better 
understand disease pathogenesis and to develop tests for an earlier diagnosis of AD, and, to 
this end, uses ADNI protocols for its imaging studies [217]. Some methodological 
differences between the two studies include the omission of FDG-PET metabolic 
investigations and the comparison of amyloid pathology using 11C-PiB PET and Aβ-42 
levels in blood plasma instead of from CSF on the basis that obtaining blood plasma is both 
less expensive and less invasive than lumbar punctures. Perhaps the greatest difference 
between AIBL and ADNI lies in the approach AIBL is taking to investigating lifestyle 
factors involved in AD. By collecting extensive neuropsychological and lifestyle data, the 
study aims to understand which health and lifestyle factors protect or contribute to AD. Like 
ADNI, however, all data are made available through LONI and are funded by the 
Alzheimer’s Association. Ellis et al [217] reported that one recent finding from the study 
found that hippocampal atrophy was regionally associated with 11C-PiB retention only in the 
inferior lobe, leading to a new hypothesis of how Aβ accumulation could disrupt 
connections between the hippocampus through accumulation in this area (Bourgeat et al., 
Beta-amyloid burden in the temporal neocortex is related to elderly subjects without 
dementia. Neurology 2010:74:121–7; see Appendix).
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Rowe et al [218] reported on the progress of the neuroimaging arm of the AIBL in 
characterizing a cohort of 177 healthy elderly subjects, 57 MCI patients, and 53 AD patients. 
The patient groups had increasing numbers of APOE ε4 carriers, increased hippocampal 
atrophy, and increased cognitive impairment with disease progression. The distribution 
of 11C-PiB binding in control subjects did not follow a normal distribution, and cluster 
analysis determined a separation point between low and high 11C-PiB binding groups at a 
neocortical standardized uptake value threshold of 1.5. This bimodal distribution in normal 
healthy elderly subjects again echoes the idea of heterogeneity within this group and the 
existence of a subset of patients with the first manifestations of AD pathogenesis well in 
advance of any effects on cognition. 11C-PiB binding may therefore play a role in populating 
and monitoring clinical trials of antiamyloid therapies. Rowe et al [218] also used 11C-PiB 
PET imaging for diagnosis and found that 11C-PiB scans discriminated between AD and 
control subjects with an accuracy of 73%, a sensitivity of 98%, and a specificity of 63%, 
comparable with results obtained using hippocampal volume (accuracy = 73%, specificity = 
80%, sensitivity = 78%).
7.3. Japanese ADNI
The need for a Japanese ADNI (J-ADNI) was realized in 2006 when ADNI was beginning 
in North America and at the end of the Japanese study J-COSMIC (Japan Cooperative 
SPECT Study on Assessment of Mild Impairment of Cognitive Function) [219,221]. 
Iwatsubo [220] reported that J-ADNI was needed not only to meet requirements for global 
clinical trials of AD drugs about to begin in Japan and to develop the necessary 
infrastructure for these trials, but was also motivated by the desire of Japanese researchers to 
improve their clinical science through international collaboration. A special issue of Rinsho 
Shinkeigaku near the inception of J-ADNI in 2007 reported on ADNI and the need for the 
establishment of a Japanese version [221], the goals of early detection of AD and biomarker 
development [222], the methods used by ADNI and adopted by J-ADNI for achieving these 
goals [219], and the use of ADNI approaches for detecting MCI in neuropathological studies 
[223]. Funding for J-ADNI was sought and received from both the public and private sector, 
including Japanese and international companies, to a total of approximately Ұ300 million 
per year [220]. The study began in 2008 and aimed to recruit 300 amnestic MCI patients, 
150 patients with early AD, and 150 healthy elderly control subjects from 30 centers across 
Japan by the end of 2010; participants would then be followed until 2013 using a research 
protocol designed to maximize compatibility with ADNI [220,224]. Compatibility with 
ADNI protocols was designed to allow sharing and direct comparison of data and as a way 
to contribute to global standardization of protocols. Arai et al [224] reported that initial 
results from ADNI supporting the use of biomarkers in clinical trials contributed to a 
paradigm shift in Japanese geriatric medicine from defining AD solely by cognitive 
measures to considering the information available from biomarkers.
7.4. Worldwide ADNI future directions
The establishment of Worldwide ADNI, an umbrella organization of global ADNI efforts, is 
coordinated by the Alzheimer’s Association and is a direct result of ADNI. Information on 
the countries that have established or plan to establish ADNI sties in their countries can be 
found at http://www.alz.org/research/funding/partnerships/WW-ADNI_overview.asp. (Fig. 
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25). Information on the countries that have established or plan to establish ADNI sties in 
their countries can be found at http://www.alz.org/research/funding/partnerships/WW-
ADNI_overview.asp. Using standardized protocols developed by ADNI, these programs 
collectively aim to help define the rate of progression of MCI and AD, and to develop 
improved methods for identifying the appropriate patient populations to participate in 
clinical trials. It is anticipated that data generated by these global initiatives will ultimately 
be shared through a common infrastructure with international researchers. It is clear that 
ADNI has had and will continue to have a profound and far-reaching impact on the 
development of methods for the prediction and monitoring of the onset and progression of 
AD and in gaining a worldwide picture of the physical changes that lead to AD.
8. Other papers using ADNI data
In addition to generating numerous papers related to its primary goals, ADNI is becoming a 
source of data for other fields of study in which a well-characterized cohort is desirable. 
Papers published from these studies may have some connection to AD, or may be 
completely unrelated.
Cuingnet et al [348] presented an improved method for the detection of regional changes in 
apparent diffusion coefficients (ADCs) that are indicative of irreversible ischemic damage in 
stroke victims. MR images of ADNI participants were used to test the method, based on a 
SVM in which spatial consistency is enforced by Laplacian regularization and then followed 
by statistical analysis to detect group differences in brain images, they found that the method 
was able to detect ADC changes that were not detected by standard univariate approaches.
Hypertension is a risk factor for AD and is associated with brain atrophy. Jennings et al 
[349] used longitudinal MR scans of ADNI controls as a normotensive control group in an 
investigation of whether hypertensive medication remediated the reduction in grey matter 
volume observed in hypertensive individuals over a year. They found that successful 
treatment of hypertension did not prevent brain atrophy in regions especially vulnerable to 
negative modification by hypertension. Another risk factor for AD is depression. Arnold et 
al [546] used the plasma sample collection of ADNI to identify a number of biochemical 
markers from a multianalyte biochemical panel that were associated with the number of 
depressive symptoms endorsed by participants.
Bakken et al [319] used ADNI MRI and genetic data to investigate the relationship between 
skull and brain morphology and European geography. They found a significant gradient of 
skull shape, predominantly in the frontotemporal cortical areas that extends across Europe in 
a NW-SE direction, supporting previous studies of European gene flow. This represents an 
intriguing contribution of ADNI to unlocking the mysteries of historical population 
movements.
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Generation of soluble β-amyloid (Aβ) fragments from amyloid precursor protein. 
Reproduced with permission from Ref [7].
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Model for Alzheimer’s disease (AD) progression. Reproduced with permission from Ref 
[14].
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Alzheimer’s Disease Neuroimaging Initiative (ADNI) structure and organization.
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AD drug development. Black arrows show the phases of drug development; the brick-
colored arrows show the ADNI biomarkers that could be used in that stage. Reproduced with 
permission from Ref [37].
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Roles of biomarkers in AD drug development. Abbreviations: AD-MET, absorption, 
distribution, metabolism, excretion, toxicity; BBB, blood–brain barrier; POP, proof of 
principle. Reproduced with permission from Ref [37].
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Steps of multiatlas segmentation. (I) nonrigid registration used to register all atlases to 
patient data, (II) classifier fusion using majority voting for producing class labels for all 
voxels, and (III) postprocessing of multiatlas segmentation result by various algorithms, 
taking into account intensity distributions of different structures. Reproduced with 
permission from Ref [61].
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Group differences in average thickness (mm) for left hemisphere. Top row: NC vs. SMCI; 
middle row: normal controls (NC) vs. MMCI; bottom row: NC vs. AD. Left mesial views, 
right lateral views. The scale ranges from < −0.3 (yellow) to > +0.3 (cyan) mm thickness. 
Areas on the red-yellow spectrum indicate regions of thinning with disease: approximate 
color scale in mm is −0.05 to −0.15 dark red, −0.20 bright red, −0.25 orange, and < −0.30 
yellow. For thicker regions: +0.05 to +0.15 blue. Any differences smaller than ± 0.05 mm 
are gray. Reproduced with permission from Ref [109].
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Annual atrophy rates as a function of degree of clinical impairment. Clinical impairment 
measured using baseline clinical dementia rating-sum of boxes (CDR-SB) scores. Mean 
atrophy rates are represented as a percent change in neocortical volume and mapped onto the 
lateral (left), ventral (middle), and medial (right) pial surface of the left hemisphere. These 
data demonstrate that atrophy rates are most prominent in posterior brain regions early in the 
course of disease, spreading to anterior regions as the level of impairment increases, with 
relative sparing of sensorimotor regions. Reproduced with permission from Ref [111].
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Distribution of atrophy scores used to classify subjects with MCI. MCI atrophy score was 
derived from LONI data archive trained on data from all control subjects and subjects with 
AD. Discriminant model assumed equal prior group probabilities. Individuals were 
classified as having control phenotype if their scores were above −0.33. Cutoff score was 
chosen to maximize overall accuracy of classifying control subjects and subjects with AD on 
whom this model was trained. Average atrophy score for subjects with MCI was −0.50. 
Atrophy score is not normally distributed (Kolmogorov–Smirnov test = 0.73, df = 175, P =.
025) but shows evidence of bimodal distribution. Reproduced with permission from Ref 
[117].
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Individual trajectories of hippocampal volume change. Thick black lines indicate the mean 
trajectory change of each group. Reproduced with permission from Ref [121].
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Group differences in regional shape deformations. Abbreviations: Am, amygdala; Hp, 
hippocampus; V, ventricles; iLV, inferior lateral ventricles; Cd, caudate; Pu, putamen; Pa, 
globus pallidus; Th, thalamus. Reproduced with permission from Ref [122].
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Cumulative distribution function (CDF) plots for voxelwise correlation of progressive 
temporal lobe tissue loss in MCI, AD, and pooled groups. (A) Correlations with various 
biomarker indices, including Aβ-42 (AB142), tau protein (TAU), phosphorylated-tau 181 
(PTAU), tau/Aβ-42 ratio (TAUAB), and p-tau/Aβ-42 ratio (PTAUAB), and (B) correlations 
with various clinical measures. Reproduced with permission from Ref [113].
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Apolipoprotein E (APOE) gene effects on regional brain volumes. Maps show the mean 
percent differences in regional brain volumes for four different group comparisons. Percent 
differences are displayed on models of the regions implicated: (A) ventricular cerebrospinal 
fluid (CSF), (B) sulcal CSF, (C) hippocampi, and (D) temporal lobes; dotted lines show the 
boundary of the hippocampus. Reproduced with permission from Ref [112].
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Association of regional brain tissue volumes with body mass index. These represent the 
estimated degree of tissue excess or deficit at each voxel, as a percentage, for every unit 
increase in body mass index, after statistically controlling for the effects of age, sex, and 
education on brain structure. Images are in radiological convention (left side of the brain 
shown on the right) and are displayed on a specially constructed average brain template 
created from the subjects within each cohort (mean deformation template). Reproduced with 
permission from Ref [133].
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The episodic memory network. Along with the hippocampal formation, the cortical areas 
shown here are part of the episodic memory network. Shown here are pial cortical 
representations of selected parcellations in the left hemisphere. From left to right: medial, 
ventral, and lateral views. Reproduced with permission from Ref [136].
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Correlations between biomarker levels, structural abnormalities, and cognitive performance 
in APOE ε4 carriers and noncarriers. Smoothed biomarker (A and B) or STAND (C) z score 
curves plotted as a function of cognitive performance (Mini-Mental State Examination, 
MMSE). Abbreviation: STAND, Structural Abnormality Index. Reproduced with permission 
from Ref [128].
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Biomarker trajectories through disease progression. For each biomarker, individual z scores 
are plotted against ADAS-cog (cognitive subscale of the Alzheimer’s Disease Assessment 
Scale) scores, and the fitted sigmoid curve is displayed. Full circles denote healthy control 
subjects, full squares MCI patients converted to AD, empty circles early AD, and full 
triangles late AD patients. Sigmoid fitting was better than linear fitting for tau, Aβ-42, and 
hippocampus (for the latter: sigmoid nonsignificantly better than linear); linear fitting was 
better for [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET). Reproduced 
with permission from Ref [153].
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Separation of control, MCI, and AD subjects using a CSFAβ-42/t-tau mixed model 
signature. A combined CSFAβ-42/t-tau mixed model was applied to the subject groups. 
Densities of each signature are represented with confidence ellipses, and signature 
membership of the subject based on the mixture is indicated with the corresponding color 
(signature 1 is the AD signature [red]; signature 2 is the healthy signature [green]). 
Reproduced with permission from Ref [159].
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Association between temporal lobe atrophy and conversion to AD. Subjects who converted 
from MCI to AD over a period of 1 year after their first scan were coded as “1”; 
nonconverters were coded as “0.” A negative correlation suggests that temporal lobe 
degeneration predicts future conversion to AD. Reproduced with permission from Ref [112].
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Effect size of imaging biomarkers for MCI converters versus MCI nonconverters. Effect 
sizes (Cohen d) of the comparison between MCI stable (MCI nonconverter) and MCI 
converter groups evaluated for selected imaging biomarkers. Reproduced with permission 
from Ref [114].
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Significance maps of correlation between ventricular shape and cognitive decline. 
Significance maps correlate baseline ventricular shape with subsequent decline, over the 
following year, in three commonly used clinical scores. Reproduced with permission from 
Ref [126].
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Maps of associations with MMSE scores at baseline and 1 year later, MCI-to-AD 
conversion, and CSF concentrations of tau. Three-dimensional maps show areas of 
significant associations between local volumetric atrophy in the caudate and MMSE scores 
at baseline and after a 1-year follow-up interval, with P values color-coded at each surface 
voxel. Reproduced with permission from Ref [130].
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Pittsburgh compound B-positron emission tomography (PiB-PET) and magnetic resonance 
imaging (MRI) comparisons of MCI converters versus MCI nonconverters. Left: MCI 
progressor. Top: positive PiB-PET. Bottom: MRI illustrating atrophic hippocampi and 
ventricular enlargement. Right: MCI nonprogressor. Top: negative PiB-PET with nonspecific 
white matter retention but no cortical retention. Bottom: MRI illustrating normal 
hippocampi and no ventricular enlargement. Reproduced with permission from Ref [152].
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Mean biomarker levels (t-tau, p-tau, and Aβ-42) for the APOE genotype groups. The APOE 
ε2 carriers are represented in black, the ε3 homozygotes in gray, and the ε4 carriers in 
white. The CSF Aβ-42 levels show a significant stepwise trend downward, from APOE ε2 
carriers to ε3 homozygotes to ε4 carriers, whereas the t-tau and the p-tau levels show the 
opposite trend. Reproduced with permission from Ref [208].
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Worldwide ADNI sites. Abbreviations: NA-ADNI, North American ADNI; Arg-ADNI, 
Argentinean ADNI; E-ADNI, European ADNI; C-ADNI, Chinese ADNI; K-ADNI, Korean 
ADNI; J-ADNI, Japanese ADNI; T-ADNI, Taiwanese ADNI; A-ADNI, Australian ADNI.
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Disease State Index values of a patient with subtle indication of AD (total DSI value = 0.56). 
The name of the test and DSI value is shown next to each node. Larger nodes discriminate 
better between healthy and diseased patients (visualization of relevance). ‘Hot,’ i.e., red, 
nodes highlights patient data that fits AD profile (visualization of DSI). Here, ADAS and 
MRI contribute most to the AD DSI, indicated by the largest node size. MRI variables, 
especially hippocampal volume, whose computation is depicted on the right hand side, push 
the total DSI value towards AD population. Reproduced with permission from Ref [252].
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Simulated power for studies in MCI and MCI with amyloid dysregulation (MCI-Aβ) versus 
total sample size, n. Lines represent LOESS smooths. Abbreviation: PH, proportional 
hazard. Reproduced with permission from Ref [266].
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Model illustrating the independent effect of cognitive reserve on the relationship between 
biomarkers of pathology and cognition in subjects with (A) low, (B), average and (C) high 
cognitive reserve. In (A) and (C), the levels of Aβ are indicated by a square and the levels of 
atrophy are indicated by a circle at the point where cognitively normal subjects progress to 
MCI. This illustrates that at an equivalent clinical diagnostic threshold, subjects with high 
cognitive reserve have greater biomarker abnormalities than those with low cognitive 
reserve. Reproduced with permission from Ref [278].
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Box plots and superimposed data points showing the distribution of AD biomarkers by 
baseline diagnosis and visit. The dotted horizontal line extending across all box plots 
represents the cut point delineating normal from abnormal for each biomarker. Reproduced 
with permission from Ref [282].
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(A) Expression of cortical signature of Alzheimer’s disease is associated with future 
cogntive decline. (B) Expression of cortical signature of Alzheimer’s disease is associated 
with AD-like spinal fluid. Reproduced with permission from Ref [139].
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Box plot of baseline PET AD scores for diagnostic groups. AD patients and MCI patients 
progressing to AD have significantly higher scores than stable subjects (arrows in top insert, 
P < .05 in Tukey multiple comparisons). Abbreviation: C, control. Reproduced with 
permission from Ref [291].
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A probabilistic hypercube. This can be interpreted as a geometrical representation of the 
output of a seat of classifiers, each one estimated with different types of data. The set of AD-
PS scores corresponding to a given individual define a position inside the hypercube. The 
position of three individuals is illustrated. From Casanova et al [411]. Abbreviations: ADNI, 
Alzheimer’s Disease Neuroimaging Initiative; AD, Alzheimer’s Disease; CN, cognitively 
normal; GM, gray matter; WM, white matter.
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Estimated trajectories of Aβ-42 (A) and p-tau181 (B) based on ADNI longitudinal data. The 
estimated time to reach the AD cut point threshold is indicated based on a model that 
includes all subjects (blue) or subjects with abnormal baseline values or changes during 
follow-up (red). From Toledo et al [434].
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Suboptimal targeting of ADAS-cog. The distribution of person measurements (upper pink 
histogram) and the distribution of item locations of the 11 ADAS-cog components (lower 
blue histogram) are presented. From Hobart et al [474].
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The effect of APOE ε 4 status on the β-amyloid PET standard uptake value ratio (SUVR) in 
four cortical regions across diagnostic categories. (−) APOE ε 4 negative; (+) APOE ε 4 
positive. From Murphy et al [482]. Abbreviations: EMCI, early mild cognitive impairment; 
LMCI, late mild cognitive impairment; AD, Alzheimer’s disease.
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(A) Estimated biomarker dynamics as a function of the ADPS score. (B) 90% Confidence 
intervals for the inflection point of each biomarker. From Jedynak et al [484]. Abbreviations: 
MMSE, Mini-Mental State Examination; CDR-SB, clinical dementia rating-sum of boxes; 
MCI, mild cognitive impairment; AD, Alzheimer’s disease.
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The effect of accounting missing data on classification. In addition to the feature selection of 
an incomplete Multi-Source Feature (iMSF) learning method, the incomplete Source Feature 
Section (iSFS) model accounts for missing data. From Xiang et al [416]. Abbreviations: 
AUC, area under the curve; AD, Alzheimer’s disease; NC, normal control; MCI, mild 
cognitive impairment.
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Flow charts showing the categorization of ADNI subjects with AD using the strict NIA-AA 
criteria (A) and Mayo-modified NIA-AA criteria (B). Abbreviations: AD, Alzheimer’s 
disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; FDG, fluorodeoxyglucose; 
MRI, magnetic resonance imaging; NIA-AA-C, National Institute on Aging-Alzheimer’s 
Association clinical diagnostic guidelines. From Lowe et al [354].
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Contribution of white matter hyperintensities (WMHs) to AD. Proportion of subjects with 
MCI who converted to Alzheimer’s disease (AD) during the follow-up period as a function 
of β-amyloid deposition (PiB) and WMHs. From Provenzano et al [441].
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The stability of different MRI features in predicting (A) ADAS-cog and (B) MMSE scores. 
MRI regions aligning with red in the stability vector most accurately predict cognitive 
scores. Several regions (e.g., cortical thickness averages of the left and right entorhinal, and 
left middle temporal, and hippocampal volume) predict ADAS-cog over 3 years, whereas 
most regions predict MMSE scores only over 6 to 12 months. From Zhou et al [407]. 
Abbreviations: MRI, magnetic resonance imaging; MMSE, Mini-Mental State Examination.
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Application of the AD-conv score in the ADNI population. (A) Box plot of MCI converters 
and nonconverters; (B) ROC curves for MCIc versus MCInc; (C) distribution of probabilities 
among the stratified groups according to the AD-conv score. From Arbizu et al [397].
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The effect of modeling disease onset time on hippocampal volume-time profiles. (A) 
Evolution of hippocampal volumes for each disease status. Disease onset times are shown 
with hippocampal volume (B) centered to the median of the normal population and (C) 
normalized for age and head size. From Delor et al [504]. Abbreviations: MCI, mild 
cognitive impairment; AD, Alzheimer’s disease.
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Prediction accuracies, sensitivities, and specificities for individual and combined 
neuroimaging modalities. From Trzepacz et al [510]. Abbreviations: MRI, magnetic 
resonance imaging; FDG, fluorodeoxyglucose; SUVR, standard uptake value ratio; PET, 
positron emission tomography.
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Enrichment strategies for the selection of MCI participants for clinical trials. Estimated 
N80s are indicated assuming a 24-month trial with scans every 6 months. From Holland et al 
[516]. Abbreviations: MCI, mild cognitive impairment; MRI, magnetic resonance imaging; 
CDR-SB, clinical dementia rating-sum of boxes.
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Genetic approaches used with ADNI data. From Shen et al [521]. Abbreviation: ROI, region 
of interest.
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Gene-gene interaction networks for (A) entorhinal atrophy and (B) hippocampal atrophy. 
Each circle is a gene that participated in a significant SNP-SNP interaction model. Circles 
colored orange are genes previously identified as a possible AD risk gene. From Meda et al 
[529].
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Involvement of genes of interest identified from pathways enriched in memory impairment 
in a transcriptional regulation network centered on SP1. From Ramanan et al [471].
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Table 1
Comparison of ADNI-1, ADNI-GO, and ADNI-2
Study characteristics ADNI-1 ADNI-GO ADNI-2
Primary goal Develop CSF/blood and 
imaging
  biomarkers as outcome 
measures
Act as bridging grant between
  ADNI-1 and ADNI-2, 
examine
  biomarkers in earlier stage of
  disease progression
Develop CSF/blood and imaging
  biomarkers as predictors of 
cognitive
  decline, and as outcome 
measures
Funding $40 million federal (NIA), 
$20
  million industry and 
foundation,
  $7 million industry for
  supplemental studies
$24 million American 
Recovery
  Act funds (stimulus finds)
$40 million federal (NIA), $27 
million
  expected industry and 
foundation
Duration/start date 5 years/October 2004 2 years/September 2009 5 years/September 2011
Cohort 200 elderly control 
subjects200
  MCI400 AD
Existing ADNI-1 cohort plus:
  200 EMCI
Existing ADNI-1 and ADNI-GO 
cohort
  plus:150 elderly control 
subjects100
  EMCI150 MCI150 AD
Study techniques
MRI X X X
fMRI X X
FLAIR (microhemorrhage detection) X X
T2* GRE (microhemorrhage detection) X X
Vendor-specific protocols (1) resting
  state (task-free) fMRI to Phillips
  systems, (2) perfusion imaging
  (ASL) to Siemens, and (3) DTI
  to General Electric
X X
FDG-PET X X X
AV45 X X
Biosamples X X X
“Add-on” studies GWAS, PiB-PET, lumbar 
puncture
Abbreviations: ADNI, Alzheimer’s Disease Neuroimaging Initiative; ADNI-GO, Grand Opportunities grant; CSF, cerebrospinal fluid; NIA, 
National Institute on Aging; MCI, mild cognitive impairment; AD, Alzheimer’s disease; EMCI, early mild cognitive impairment; MRI, magnetic 
resonance imaging; fMRI, functional magnetic resonance imaging; FLAIR, fluid attentuated inversion recovery; T2* GRE, T2* gradient echo; 
ASL, arterial spin labeling; DTI, diffusion tensor imaging; FDG-PET, [18F]-fluorodeoxyglucose-positron emission tomography; GWAS, 
genomewide association studies; PiB-PET, Pittsburgh compound B-positron emission tomography.
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Table 2
Characteristics of an ideal biomarker
Characteristic Ideal
Sensitivity: % of patients correctly identified as having AD >80%–85%
Specificity: % of patients correctly identified as not
  having AD.
>80%
Positive predictive value: % of patients who are positive
  for biomarker and have definite AD pathology at autopsy
>80%
Negative predictive value: % of patients who, at autopsy,
  prove not to have the disease
>80%
NOTE. Adapted from Refs [7] and [10].
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Table 11
Comparison of outcome measure methods in clinical trials: sample size estimates per arm required to detect a 
25% reduction in atrophy with 80% power, 5% significance
Outcome measure Method tested Sample size AD Sample size MCI Reference
Hippocampus Two scans, 0–6 months 462 949 [121]
Three scans, 0–6–12 months 255 673
Three scans + Markov Chain + APOE ε4 86 341
Clinical ADAS-cog two tests, 0–6 months 745 4663
ADAS-cog three tests, 0–6–12 months 569 8354
MMSE two tests, 0–6 months 1280 6300
MMSE three tests, 0–6–12 months 780 3353
Hippocampal atrophy 12-(24)-month 67 (46) 206 (121) [64]
Hippocampal atrophy 12-month 78 285 [59]
Ventricular expansion 6-month change 342 1180 [175]
Clinical MMSE 7056 7712
ADAS-cog 1607 >20,000
MRI (Model T/Model D) Entorhinal 45/65 135/241 [176]
Inferior temporal 79/117 199/449
Fusiform 72/114 185/485
Mid temporal 83/122 229/501
Hippocampus 67/118 179/510
Inferior lateral ventricle 76/157 160/550
Whole brain 101/189 158/541
Ventricles 86/240 189/1141
Clinical (Model T/Model D) CDR-SB 226/236 490/551
ADAS-cog 324/283 1232/804
MMSE 482/494 1214/1304
Whole brain atrophy KN-BSI 81 NA [51]
Classic-BSI 120 NA
TBM 1.5-T MRI/3.0-T MRI 37/48 107/159 [47]
SIENA* 1.5-T MRI/3.0-T MRI 116/92 207/265
TBM sKL-MI S6L8† 48 88 [177]
Clinical ADAS-cog 619 6797
MMSE 1078 3275
CDR-SB 408 796
TBM Gray matter atrophy 43 86 [120]
Temporal lobe atrophy 43 82
CSF biomarkers Aβ–42 5,721,531 75,816
t-tau 81,292 19,098
t-tau/Aβ–42 66,293 533,091
PET ROI-avg‡ 4605 [154]
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Structural Image Evaluation, using Normalization, of Atrophy (SIENA). See text for more details.
†





Foster laboratory method, measures of glucose hypometabolism, log transformed.
¶
Reiman laboratory method, data-driven summaries applied to independent test set.
**
Fox laboratory method, ventricular boundary shift interval as a percentage of baseline brain volume.
††
Schuff laboratory method (FreeSurfer).
‡‡
Fox laboratory method, brain shift interval.
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Table 12
AD susceptibility and quantitative trait loci identified by genetic studies of ADNI cohort
Confirmed AD risk loci identified using ADNI data
Gene Protein Putative protein function Reference
  TOMM40 Translocase of outer mitochondrial membrane Protein transport across mitochondrial 
membrane
[184] [199]
  [194] [149] [152] 
[313]
  CLU Clusterin Clearance of A? [185]
  CR1 Complement component[3b/4b] receptor Clearance of A? [185] [193]
  PICALM Phosphatidylinositol-binding clathrin assembly
  protein
Synaptic vesicle cycling and/or affects APP
  processing via endocytic pathways
[185] [193] [197]
  BIN1 Myc box-dependent-interacting protein 1 Synaptic vesicle endocytosis [193]
  CD2AP CD2-associated protein Regulation of receptor-mediated 
endocytosis
[186]
  CD33 Siglec-3 Clathrin-independent endocytosis [186]
  MSA4 Membrane Spanning 4 Domains Subfamily A gene
  cluster
Cell surface protein – receptor? [187] [186]
  ABCA7 ATP-binding cassette sub-family A member 7 Membrane transporter highly expressed in 
brain
[187]
  EFHA1 EF-hand domain family member A1 Regulation of cell morphology and motility 
in
  epithelial tissues
[181]
Candidate AD risk loci identified using ADNI data
  ARSB Arylsulfatase b Oxidative necrosis, dementia [184]
  ATXN1 Ataxin-1 Upregulates A?
  CADPS2 Calcium-dependent secretion activator 2 Synaptic vesicle priming [195]
  CAND1 Cullin-associated and neddylation-associated 1 Ubiquination, apoptosis [184]
  CDH8 cadherin 8, type 2 calcium-dependent cell adhesion protein 
implicated
  in synaptic adhesion; interacts with 
presenilin
[6]
  CHRFAM7A Cholinergic receptor, nicotinic, alpha7/FAM 7A unknown [317]
  CNTN5 Contactin-5 Neurite growth [301]
  CSMD1 CUB and sushi domain-containing protein 1 Central nervous system regulator [314]
  CSMD2 CUB and sushi domain-containing protein 2 Oligodendroglioma suppressor ? [195]
  CYP19A1 Cytochrome P450, family 19, subunit a, polypeptide 1 Conversion of androgens to estrogens [199]
  DOPEY Dopey family member 2 Down syndrome candidate gene
  EFNA5 Ephrin-A5 Hippocampal development [184]
  EPC2 Enhancer of polycomb homolog 2 Formation of heterochromatin [149]
  EPHA4 EPH receptor A4 Synapse morphology [194]
  ERBB4 v-erb-a erythroblastic leukemia viral oncogene
  homolog 4
Brain tyrosine kinase
  GRINB N-methyl-D-aspartate glutamate receptor Learning, memory, excitotoxic cell death [196]
  GSTT1 Glutathione S-synthetase Oxidative stress
  HFE Hemochromatosis Increases redox-active iron and oxidative 
stress
[189]
  HLA-DPB1 Major histocompatibility complex, class II Immune system
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Confirmed AD risk loci identified using ADNI data
Gene Protein Putative protein function Reference
  LOC10012 Unknown function, overlaps with APOE Unknown [149]
  IMMPL2 Inner mitochondrial protein peptidase-like Mitochondrial function − oxidative stress
  MAGI2 Membrane associated guanylate kinase Ubiquination, dementia [184]
  NCAM2 Neural cell adhesion molecule 2 Neural adhesion, fasciculation of neurons [199]
  NRXN1 Neurexin 1 Synaptic contacts
  NXPH1 Neurexophilin 1 Dendrite-axon adhesion [194]
  PPP3CA Protein phosphatase B Affects tau phosphorylation [190]
  PPP3R1 Protein phosphatase B Affects tau phosphorylation [190]
  PPP3R1 Protein phosphatase B Affects tau phosphorylation [191]
  PRUNE2 Prune homolog 2 Apoptosis [184]
  RELN Reelin Neuronal migration
  TF Transferrin Increased redox-active iron + oxidative 
stress
[189]
  TP63 Tumor protein 63 Unknown [194]
  ZNF292 zinc finger protein 292 Expressed in brain [197]
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Table 13
European initiatives related to ADNI
Purpose Program name Funding agency Time frame Countries
Data collection Pilot E-ADNI Alzheimer’s Association 2006–2007 IT, FR, GE, NL, SW, 
DE
AddNeuroMed EC Ongoing, 40 months FI, PL, UK, IT, GR, FR
Pharma-Cog WorkPackage
  5 (E-ADNI)
EC IMI Ongoing 5 years SP, IT, GE, FR
Swedish ADNI Alzheimer’s Association 2007–2009 SW
Italian ADNI NHS 2009–2011 IT
SOP development International harmonization of
  CSF Aβ42, t-tau, and p-tau
Alzheimer’s Association 2009–2013 40 laboratories (EU, 
US, Japan,
  Australia, Brazil)
EADC-ADNI harmonization of
  hippocampal volume
Alzheimer’s Association
  Lily-Wyeth
2010–2012 24 centers in EU, US, 
Canada,
  Australia
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